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Abstract  
Background: 
Obesity is associated with elevated risk of premature death and a range of co- 
morbidities. It is multifactorial and heterogeneous in origin, and, stratification of this 
disease, depending on the range of associated pathogenicities could help identify 
mediators and in the design of targeted therapies. Recent research has focused on 
microRNA (miRs) as potential biomarkers of cardiovascular risk, as well as their role as 
causative agents in the obesity associated pathologies.  
Aims of the project were to: 
 Stratify obese subjects depending on systemic biomarkers of insulin resistance 
and inflammation. 
 Identify and validate specific miRs associated with these phenotypes. 
 Confirm and validate, in the whole transcriptome, targets for the specific miRs to 
assign functionality. 
Methods: 
Non-diabetic, morbidly obese subjects of Arab origin were studied. Blood and 
adipose tissue samples were obtained before and after weight loss, along with 
anthropometric data. Glucose and lipids levels were determined by conventional 
methods. Insulin and adipokine concentrations were assayed by commercially 
available 2-site ELISA (R & D Systems, Oxon, UK). The population was 
dichotomised according to their serum insulin levels: Metabolically Healthy Obese 
(MHO) insulin <6.5 miU/ml; Patholigcally Obese (PO) insulin >7.0 miU/ml. Total 
RNA, including miR, was extracted from peripheral blood cells, whole adipose 
tissue, the stromal vascular fraction and adipocytes of the abdominal subcutaneous 
and omental adipose tissues. miR expression  was  assessed using an inflammatory 
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pathway specific array (Qiagen), and by small RNA sequencing (Ion Torrent). 
mRNA expression was assessed by whole transcriptome analysis (Ion Proton) and 
validated by PCR based microarrays (SurePrint G3 Human Gene Expression). 
Results: 
PO, matched for age and BMI, had significantly higher serum insulin levels and HOMA 
index of IR, compared to MHO. They also had higher leptin, a marker of fat mass and 
adipocyte hypertrophy, and lower adiponectin, an endogenous insulin sensitizer. 
However, blood pressure, lipids and inflammatory markers, such as IL-6, MCP-1 and 
CRP were not significantly different between the groups. 
Three miRs were significantly down-regulated in the PO; miR-29, miR-144 and miR- 
374, and associated with inflammation, along with miR-122, miR-302, miR-200, which 
were associated with hyperinsulinaemia and insulin resistance. Many of their targets, 
especially those of miR-29, showed elevated expression in the PO. Following surgical 
weight loss there was a significant reduction in insulin which correlated with an increase 
in the levels of expression of nine miRs; miR-9, miR-200c, miR-141, miR-124, miR- 
376c, miR-302, while one was downregulated, miR-26b. 
Whole transcriptome analysis of mRNA in blood and adipose tissue revealed modulation 
of several genes in the cardiometabolic pathways in the PO compared to MHO, along 
with genes leading to increased fibrosis. 
Conclusions: 
Significant differences in the expression of specific miR species occured along with 
insulin resistance and inflammation in PO compared to MHO. The target genes of these 
miRs, especially miR-29, miR-144 and miR-122, suggested fibrosis, in the presence of 
IR and inflammation, as a major lesion in these patients. Functional studies to explore 
the role of these miRs in fibrosis may offer new insights on putative therapeutic targets 
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for this group of patients. 
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Introduction 
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1.1 Prevelance and definition of Obesity 
It was reported by the World Health Organisation (WHO) in 2008 that around 200 million men 
and 300 million women were obese. Projections for 2015 suggest that these figures will have 
nearly doubled to 700 million obese adults. The rise in human obesity is mainly due to 
increased energy intake and decreased energy expenditure, resulting in a significant increase 
in adipose tissue, the inappropriate accumulation of which is generally harmful to health. 
This obesity epidemic reflects a lot of changes including social, economic and life-style 
(International Obesity Taskforce, 2005). 
Obesity is defined predominantly as an increase of the total mass of adipose tissue, due to 
both hyperplasia and/or hypertrophy of adipocytes. It is associated with an elevated risk of 
premature death and a range of co-morbidities, including Type 2 diabetes mellitus (T2DM), 
cardiovascular disease and cancers (Hotamisligil, 2006). The effects of obesity on disease 
outcome are shown in Figure 1. 
Obesity is multifactorial in origin. Environmental and genetic factors have major roles to play 
in the development of obesity, which determine not just obesity but also the distribution of 
the body fat tissue and its accumulation (Wajchenberg, et al, 2000). Obesity is not a 
homogenous pathological phenotype; it is heterogeneous in terms of its causes and metabolic 
complications. The regional body fat distribution appears to be an important correlate of the 
metabolic complications that have been associated with obesity. Abdominal fat accumulation 
increases the risk of metabolic complications to a greater extent in men, than in women. 
Several studies have suggested molecular mechanisms that link abdominal obesity, T2DM 
and cardiovascular disease. Both total body fatness and body fat distribution have a 
significant genetic correlation, perhaps explaining why some obese individuals are more 
susceptible to metabolic complications than others. Insulin resistance, a major precursor 
and risk factor for all the obesity associated diseases, has been shown to be more 
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related to abdominal adipose tissue accumulation, especially in the visceral depots (Ohlson 
et al, 1997). 
1.2 Prevalence of Obesity in the Arabian Gulf and Qatar 
Since the discovery of oil in the Arabian Gulf region in the 1960s, the countries that 
make up the Gulf Cooperation Council including Qatar, Bahrain, Kuwait, Saudi Arabia, 
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Figure 1. Obesity associated co-morbidities 
(Hotamisligil, 2006). 
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United Arab Emirates and Oman have experienced continued growth in both population and 
wealth. There has been a concomitant increase in obesity, associated with nutritional health 
problems and related diseases. The Arabian Gulf has amongst the highest rates of 
hypertension and T2DM in the world. Alarmingly in Qatar it has increased by over 7 fold 
in just the last two decades, ranking sixth in terms of global obesity prevalence 
(www.iaso.org) as shown in Figure 2. According to a recent survey by the Public Health 
D0epartment of the Supreme Council of Health (SCH) in Qatar, 70% of the Arab population 
were overweight, of whom 40% were obese with early onset of the disease, and especially 
so amongst women (55%). 
Various factors have contributed to the world-wide obesity epidemic, including increased 
intake of food rich in carbohydrates and fat, in addition to a lifestyle characterised by 
diminished physical activity. Qatar is a clear example of such changes, as Arabs have 
altered their lifestyle from pearl hunters, living mostly on sea food into a fast-food 
consuming population with minimal physical activity as the country’s economy has 
become almost completely dependent on gas and oil in the past 5 decades. The government 
has started to increase health awareness in the community and to encourage national 
programmes which help to support a healthy life-style, increase physical activities and 
choice of a balanced diet. However, a greater understanding of the effects of these changes 
in lifestyle to physiological and pathological outcomes still requires investigation. 
1.3 Insulin Resistance (IR) 
IR may be described as the inability of a specified concentration of insulin to increase 
cellular glucose uptake and its utilization. This is a comparative measure, using as a 
reference a normal population. Insulin action is brought about by the binding of the 
hormone to its cell surface receptor followed by cellular signal transduction through a 
series of protein-protein interactions. Insulin plays a role in two major pathways, the first 
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involved in regulating intermediary metabolism and the other in controlling growth and 
mitoses. In T2DM the lesion appears to be in the first pathway regulating metabolism, 
0 while its role in the mitogenic pathways is normal. 
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According to World Health Organisation statistics updated in 2010.  (IASO website). 
 
Figure 2. The Prevalence of Obesity in Qatar 
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The mechanisms underlying the development of IR include genetic abnormalities of the 
insulin receptor and/or proteins of the insulin action cascade, fetal malnutrition, as well 
as increases in adiposity, especially in the visceral compartments. IR occurs as part of a 
cluster of cardiometabolic abnormalities referred to as the ‘Insulin Resistance Syndrome’ 
or ‘Metabolic Syndrome’ (MeS). Often this cluster of risk factors leads to the accelerated 
development of T2DM, atherosclerosis, hypertension or polycystic ovarian syndrome. 
(Saltiel et al, 2001; Lumeng et al, 2011). 
1.3.1. Adipose tissue 
There are three types of adipose tissue in humans, white (WAT), brown (BAT) and 
Brite/Beige adipose tissue. (Ishibashi and Seale, 2010). WAT is the predominant type of 
AT in humans and acts as a storage organ, storing energy as TAGs for utilization during 
periods of energy deficit. In addition its secretory signals mediate glucose homeostasis, 
immune and various other angiogenic and metabolic function (see section 1.3.2; 
Karastergiou and Mohamed-Ali, 2010). In contrast, BAT is a mainly thermogenic organ. It 
dissipates the chemical energy stored in TAGs as heat to preserve core temperature during 
hypothermia and, perhaps, to help maintain body weight (Rosen and Spiegelman, 2014). 
Recently another type of AT has been described with an intermediate phenotype known as 
‘Biege’ or ‘Brite’ AT. 
BAT: Brown adipocytes (BAT) is made up of multilocular adipocytes with a high density 
of mitochondria, as well as other cells such as endothelial and epithelial cells. It is highly 
vascularized, with elevated expression of uncoupling protein-1 (UCP-1) allowing for the 
uncoupling of fatty acid oxidation from ATP production to generate heat (Rosen and 
Spiegelman, 2014). In addition two other members of the UCP family, UCP2 and UCP3, 
have also been described in this tissue, the roles of which are still being investigated. In 
previous studies in rodents leptin was suggested to increase UCP-3 mRNA expression in 
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skeletal muscle, and increase UCP-2 mRNA expression in WAT. Pinkney and colleagues 
reported that UCP-2 gene expression in SC abdominal AT is inversely related to adiposity 
and its biochemical correlates which may offer a therapeutic target (Pinkney et al, 2000). 
Although BAT was initially considered to be present in humans only in infants and 
neonates, recent data has established that substantial depots of UCP-1 expressing BAT can 
be detected in the supraspinal, supraclavicular, pericardial, and neck regions of adult 
humans (Virtanen et al., 2009; see Figure 3).  
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Fat distribuion: Brown adipose tissue is abundant at birth and still present in adulthood but 
to a lesser extent (Biege AT).  Gesta et al, 2007. 
 
  
Figure 3. Tracking Obesity to Its Source. 
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In rodents the thermogenic process in brown adipocytes can be mimicked by the addition 
of fatty acids (Nedergaard et al 1979). This fatty acid-induced thermogenesis is also 
completely UCP1 dependent. Therefore, the activation of lipolysis, recorded as glycerol 
or fatty acid release, is induced by norepinephrine, and a sufficient trigger for initiation of 
thermogenesis in brown adipocytes (Nedergaard et al 1979). An interscapular BAT depot 
was recently discovered in humans, where it is thought to maintain normal body 
temperature in newborns (Sanchez-Gurmaches et al, 2012). It is believed that this tissue 
is significantly reduced in adulthood or completely lost in obesity (Lee et al, 2014; Ouellet 
et al, 2011).  
Most brown fat cells originate from precursor cells in the embryonic mesoderm that also 
give rise to skeletal muscle cells and a subpopulation of white adipocytes. These 
precursors transiently express Myf5 and Pax7, two genes that were previously thought to 
selectively mark skeletal myogenic cells in the mesoderm (Figure 4a). Consistent with a 
developmental relationship between brown fat and muscle, brown fat precursor cells 
express a muscle-like gene signature, and brown fat and muscle have related mitochondrial 
proteomes. (Sanchez-Gurmaches et al, 2012). 
The recent discovery that both brown and white adipocytes derive from vascular 
endothelial cells of the adipose organ brings strong new support to another origin for the 
brown adipocytes: the transdifferentiation theory (Tran et al, 2012; Gupta et al, 2012). 
This theory basically suggests that in special circumstances, such as chronic cold 
exposure, the white part of the organ might ‘help’ the brown part by forming new BAT 
like AT (Cinti, 2009a). Enviromental factors play an important role in this 
transdifferentiation, including cold, exercise and diets high in fat.  
Beige adipose tissue. The embryonic origin of beige adipocytes is even less clear. Beige 
and brown adipocytes may arise from distinct cell lineages, given that the former, at least 
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in the subcutaneous depot, do not consistently show Myf5 expression (Seale et al, 2008). 
An important question is whether beige adipocytes arise from white adipocytes through 
transdifferentiation or through the de novo differentiation and maturation of precursors. 
Initial data suggested that most beige adipocytes arise from pre-existing, nondividing cells 
that were presumed to be mature adipocytes (Himms-Hagen, 2000). However, more recent 
evidence from Cinti and others have provided substantial evidence in support of the idea 
that large unilocular white adipocytes transform into beige adipocytes in response to cold 
or β3-adrenergic agonists (Cinti, 2009a). These data suggest that cold, mediated by β-
adrenergic agonists, triggers the differentiation of Cd137+Tmem26+ (transmembrane 
protein 26) precursor cells into UCP1+ beige adipocytes and that these beige cells require 
constant stimulation to maintain their thermogenic programming (Figure 5). In the basal 
state beige adipocytes are most abundant in the inguinal WAT, which is a major 
subcutaneous depot in rodents. However, UCP1-expressing adipocytes were evident in 
most WAT depots in response to cold exposure (Vitali et al, 2012). In perigonadal 
(visceral) fat of male mice, beige adipocytes develop from a population of precursors that 
also differentiates into white adipocytes (Figure 4b). These bipotent precursors express 
platelet-derived growth factor receptor-α (Pdgfr-α) and are closely associated with blood 
vessels. After treatment of mice with β3-adrenergic agonists, these precursor cells 
proliferate, lose Pdgfr-α expression and differentiate into UCP1+ adipocytes. Conversely, 
a high-fat diet stimulates the differentiation of Pdgfr-α+ cells into white adipocytes (Lee 
et al 2012; Figure 4b). 
Both the PET (positron-emission tomography)–CT studies and tissue biopsy specimens 
indicate that healthy, normal weight adult humans have brown adipose tissue. However it 
is still unclear whether the deposits of UCP1-expressing adipocytes identified by 
fluorodeoxyglucose (FDG) PET in adult humans are analogous to beige or brown fat. 
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Reports of supraclavicular tissue (Sharp et al, 2012), the largest FDG-PET–positive depot 
in humans, show expression of selective markers of beige fat cells. By contrast, Jesperson 
et al. found that tissue and in vitro–differentiated adipocytes from this depot express both 
brown- and beige-specific markers. Thus, brown and beige adipocytes appear to express 
distinct and distinguishing gene signatures (Wu et al 2013; Sharp et al, 2012; Figure 5). 
A striking difference between the two cell types is that brown adipocytes express high 
levels of Ucp1 and other thermogenic genes under basal (unstimulated) conditions, 
whereas beige adipocytes express these genes only in response to activators such as 
agonists of the β-adrenergic receptor or peroxisome proliferator-activated receptor-γ 
(Ppar-γ). (Petrovic et al 2010 and Wu et al 2013). 
Several factors have been shown to regulate brown and beige adipocyte differentiation by 
modulating Prdm16 expression or activity, a key regulator of brown fat cell fate). In 
addition to the bone morphogenetic protein 7 (Bmp7), a signal that is essential for brown 
fat development, which increases the amounts of Prdm16 mRNA in brown and white fat 
precursor cells. Additionally, thiazolidinediones (TZDs), which agonize Ppar-γ, induce 
thermogenic gene expression in fat cells through effects on Prdm16 (Ohno et al, 2012). 
Interestingly, the muscle-enriched microRNA miR-133 directly targets and reduces the 
amounts of Prdm16 to block both brown and beige adipose development. Cold exposure 
suppresses miR-133 expression in fat cells, which leads to increased amounts of Prdm16 
and increased expression of downstream thermogenic target genes.  Reduction of miR-
133 in regenerating muscle causes the ectopic development of brown adipocytes and an 
associated increase in energy expenditure. (Trajkovski et al, 2012). 
Overall, low brown and brown-like fat activity in humans correlates with aging, obesity 
and reducing metabolic health (Ouellet et al., 2011), but the basis for the decline remain 
unclear. Functional marker genes or assays are needed to better categorize the different 
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human and mouse fat depots and cell types, with concomitant studies to determine the 
biology and therapeutic potential of both classic BAT and inducible beige fat. 
Understanding the molecular processes governing WAT browning is highly significant, 
as this may identify novel approaches for increasing energy expenditure and combating 
obesity and the metabolic syndrome. Efforts to date have focused primarily on the role of 
factors that act directly on beige preadipocytes, such as irisin and FGF21 (Bostrom et al., 
2012; Figure 5). However, there is mounting evidence that the central nervous system 
(CNS) control of WAT browning may also be important (Cannon et al., 1986). 
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a. The origin of BAT from Mycf5+ cells. And, b. the transformation of precursor cells 
in denovo to form Biege cells through regulation of Prdm 16. The upper line shows 
the bieging conversion from the SC precursor, while the lower one shows the intra-
abdominal preadipocytes conversion to WAT under the HFD or Biege fat under 
cold or β-adrenergic activators. 
 
             
            
 
 
 
 
 
 
 
 
 
The comparison between Bat and Biege: In human compared to mice, the enriched 
markers, Key transcription factors and activators.  
Figure 4. Adipose tissue hypertrophy and its local effects in obesity 
Figure 5. The relationship between the oxidative stress and IR 
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1.3.2 White Adipose Tissue (WAT) derived factors 
The close association of the MeS and obesity has led to it being postulated that adipose 
tissue-derived mediators act on various organs such as the endothelium, liver and skeletal 
muscle to produce detrimental effects. Initial research into the secretory connections 
between adipose tissue and MeS centered on free fatty acids (FFA) and more recently on 
other ‘hormones’ and cytokines such as leptin, TNFα, IL-6 and adiponectin (Mohamed- 
Ali et al, 1997; Van Gaal et al, 2006; Karastergiou and Mohamed-Ali, 2010). 
1.3.2.1 Free fatty acids (FFA) 
The altered balance of the cross talk between skeletal muscle, the liver and adipose 
tissue, with varying effects at the systemic level, leads to rising levels of FFA (also 
known as non-esterified fatty acids, NEFA) due to the lack of the lipolysis-inhibiting 
effect of insulin on adipose tissue, in addition to impaired control of gluconeogenesis and 
glucose uptake. This leads to release of glucose, amino and fatty acids into the 
circulation along with compensatory increases in insulin secretion by pancreatic β-cells 
to maintain euglycaemia (DeFronzo et al, 1991). This in turn predisposes to T2DM, as 
systemic glucose concentrations increase. 
Regional distribution of adipose tissue has a significant impact on the correlation of 
obesity to disturbances in glucose and lipid metabolism (Kahn et al, 2006). Previous 
studies have shown that excess fat in the upper compartments (thoracic, cardiac and 
abdomenal) of the body has a stronger correlation with increased mortality and higher 
risk for disorders such as T2DM, hypertension, hyperlipidaemia, and atherosclerosis, 
compared to that deposited in the lower parts (gluteal and femoral) (Brunzell, 1999; 
Phillips et al, 1996; Wajchenberg et al, 1994). 
Additionally the visceral adipose tissue is related to IR to a greater extent than 
subcutaneous adipose tissue. Visceral adipose tissue shows high lipolytic activity, 
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releasing FFAs into the portal and systemic circulation. This elevation of FFA levels in 
the liver leads to decreased hepatic insulin extraction by inhibiting insulin binding and 
degradation (Svedberg et al, 1990). Increase in FFA levels results in increased 
esterification of FFAs and reduced hepatic degradation of apolipoprotein B and greater 
secretion of small VLDL particles (Brunzell et al, 1999). Furthermore, FFAs induce IR 
in obesity and T2DM by the initial inhibition of glucose transport. FFAs, and cytokines 
such as tumour necrosis factor (TNF-α), all mainly derived from visceral adipose tissue, 
impair insulin action at target cells in liver and muscle, by causing a post-binding defect 
that blocks tyrosine kinase activity, uncoupling insulin signal transduction from cellular 
glucose uptake. In addition, the accumulation of triglyceride in muscle has been linked to 
impaired glucose disposal (Phillips et al, 1996). IR is followed by pancreatic β-cell 
compensation and hyperinsulinaemia, due to fuel and neurohormonal signals derived 
from fat, liver, intestine and brain (Cornier et al, 2008). Although some data suggests 
that the β-cell defect may come first, ie.the β-cells, perhaps due to a genetic lesion, 
releases increased and unwanted levels of insulin leading to the hyperinsulinaemia and 
this then causes IR as a way to protect the insulin responsive organs. 
Thus, chronic exposure to very high levels of exogenous FFAs increases basal insulin 
levels and impairs glucose-stimulated insulin secretion. The outcome is that endogenous 
FFAs enhance insulin secretion in obesity/IR syndromes, which accumulates to toxic 
levels and contribute to cell failure and the development of T2DM (Dobbins, 1998). IR 
induced by cytokines (IL-6, TNF-CRP and low levels of adiponectin), FFA and retinol-
bidning protein 4 (RBP-4), may induce oxidative stress and subsequent endothelial 
dysfunction (Wajchenberg, 2000). Fat accumulation, IR, hepatic inflammation and 
dyslipidaemia may all lead to premature atherosclerosis (Figure 3). 
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1.3.2.2 Adipokines 
Adipose tissue, in addition to adipocytes, that make up about 50% of its cellular 
composition,    also    contains    the stromal    vascular    fraction (SVF)    which includes 
preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells. 
Obesity is mediated via increased fat mass through hypertrophy of adipocytes, and to a 
lesser degree their hyperplasia (see Figure 4; Karastergiou and Mohamed-Ali, 2010). 
While the main role of the adipose organ is to store energy in the form of 
triacylglycerols,  the  tissue  also  acts   as   an   endocrine   and   immue organ secreting 
hormones and cytokines, including leptin, adiponectin, resistin,  ometin, visfatin, IL-6 
and TNFα. Through these factors the tissue can affect other organ systems of the body 
and lead to the development of obesity-associated MeS and IR. The various factors 
derived from adipose tissue have collectively been referred to as adipokines. Specially, 
hypertrophied adipocytes secrete pro-inflammatory adipokines, such as, leptin, IL-6, IL-
8, and MCP-1, that exacerbate macrophage infiltration and secretion of IL-1β and 
TNFα, leading to reduced IRS-1 and GLUT4 expression and promoting insulin 
resistance (Gustafson et al ., 2009). This is also associated with increased lipolysis and 
reduced adiponectin release (Karastergiou and Mohamed-Ali, 2010). 
Adiponectin is defined as an anti-inflammatory and anti-diabetic adipokine, 
predominantly secreted by adipocytes, whose low levels in obesity appear to be related 
to the IR (Adiels et al, 2007, Arita et al, 1999). Elevated concentrations of circulating 
adiponectin have been associated with a lower incidence of T2DM (Trujillo et al, 2005, 
Zhu et al, 2010, Li et al, 2009). Adiponectin was detected in human plasma and shown 
to be expressed specifically in adipose tissue. There was a significant inverse correlation 
between BMI and plasma adiponectin. In obese subjects circulating concentrations of 
adiponectin are reduced, and subsequently, hypoadiponectinemia is associated with IR 
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(Zhu et al, 2010). Activation of adiponectin receptors stimulates AMPK, which increases 
fatty acid oxidation and glucose uptake in muscle. Adiponectin also increases PPARα 
activity and reduces inflammation. Additionally, one mechanism by which adiponectin 
directly improves insulin sensitivity is that the globular C-terminal fragment reduces 
glucose levels by increasing fatty acid combustion in myocytes (Turer et al, 2012). 
Adiponectin exerts anti-atherogenic actions including a reduction in the expression of 
several adhesion molecules, increased endothelial nitric oxide production, which improves 
vasodilation, and reduced vascular smooth muscle proliferation (Kadowaki et al, 2005, 
Karastergiou et al, 2011). A very recent in vitro study identified a variety of factors 
overexpressed in obesity, which are potential mediators linking hypertrophic obesity 
to IR (Weyer et al, 2001). In turn, weight loss results in a hypercellular state with reduced 
adipocyte size and subsequent alterations in the secretary activity (Toledo et al, 2006). 
It was established that obesity results in elevations in circulating IL-6 (Mohamed-Ali et 
al, 1997, 2010, Khaodhiar et al, 2004, Vozarova et al, 2001). Leptin is a mainly fat cell 
derived factor, whose secretion is also dependent on fat cell size. There are sex 
differences in its release, whereby the circulating levels of leptin are higher in women 
than in men at all BMI values (Trayhurn et al, 1998), perhaps reflecting regulation by the 
sex steroids. (Mohamed-Ali et al, 1998). Obese individuals have elevated circulating 
levels of inflammatory markers, such as C-reactive protein, and of proinflammatory 
cytokines, like IL-6 and leptin. Leptin as a proinflammatory cytokine mediates several 
immune responses (Fain et al, 2000; Madani et al, 2009). Its expression and release has 
been shown to depend on adipocyte size in rodents and humans (Loffreda et al, 1998; 
Hamilton et al, 1995). There was a positive correlation between BMI and leptin secretion 
from subcutaneous and omental fat tissue. The subcutaneous fat depot is the major 
source of leptin, which starts to decline in the face of weight loss and starvation. TNFα 
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positively modulates leptin secretion (Guo et al, 2004). 
Recent studies have suggested that systemic oxidative stress has a strong correlation with 
BMI (Grundy et al, 2004; Keaney et al, 2003). It has been shown that inducers of 
oxidative stress could suppress mRNA expression and secretion of adiponectin, and 
increase levels of inflammatory adipokines (PAI-1, TNF-α, MCP-1). (Furukawa et al, 
2004), suggested that the adipose tissue is a major source of the high plasma ROS level. 
Hypoxia occurs when oxygen availability does not match the demand of the surrounding 
tissue, resulting in decreased oxygen tension, which is shown to impair insulin secretion 
and glucose transport, as well as affecting the vascular walls, resulting in hypertension 
and atherosclerosis. (Rudich et al, 1998, Matsuoka et al, 1997, Keaney et al, 2003), 
Hypoxia-inducible factor-1  (HIF-1) is a transcription factor that accumulates during 
hypoxia  and  increases  the  mRNA  expression  of  a  wide  variety  of  genes  for 
erythropoiesis, angiogenesis, and glycolysism. (Semenza et al, 2000).  Hypoxia results in 
the rapid accumulation of HIF-1 in the nucleus, where it homodimerizes and binds to the 
core DNA, leading to the transcriptional activation of VEGF and several other known 
target genes (Semenza et al, 2000). 
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Fat accumulation, insulin res is tance , liver-induced inflammation and dyslipidemia 
features may all lead to the premature atherosclerotic process. (Van Gaal et al, 2006). 
 
 
 
Figure 6. The changes in abdominal adipose tissue to insulin resistance 
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(Karastergiou and Mohamed-Ali, 2010). 
Figure 7. Adipose tissue hypertrophy and its local effects in obesity 
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In addition, hypoxia reduces uptake of FFAs by the adipose tissue through inhibition of 
various transcription factors PPARγ and C/EBP. Therefore, hypoxia is associated with an 
increased expression of the inflammatory genes such as HIF-1, and decreased expression 
of adiponectin. This process intiates adipose tissue fibrosis, with an associated increase 
in local inflammation. Lysyl oxidase (LOX) is a transcriptional target of HIF-1 and acts 
by cross-linking collagen I and III to form the fibrillar collagen fibers which complicates 
the inflammation and ends with IR (Halberg et al, 2009, see Figure 8). 
1.4 Heterogeneity of obesity pathology 
MeS is a complex disorder which includes increased visceral obesity, hyperglycaemia, 
dyslipidaemia and hypertension. The major risk factors for the development of the MeS 
are obesity, regional body fat distribution, physical inactivity and food composition 
(Grundy et al 2004). It has been found in some studies that visceral abdominal adipose 
tissue (AT) and muscle-associated AT are related to IR in older subjects, especially in 
those who are of normal weight. Thus, normal-weight individuals may still be at risk for 
the MeS and its complications (Groop et al, 1989). 
It is also equally apparent that some obese subjects appear to be free of MeS. The 
common definition used to identify the metabolically healthy obese (MHO) individuals 
is the absence of metabolic complications (e.g; inflammation, dys-lipidemia and 
hypertension) and/or preserved insulin sensitivity despite excessive body fatness. Several 
studies have identified MHO individuals based on insulin sensitivity using the gold- 
standard hyperinsulinemic–euglycemic clamp technique. However, this technique is 
invasive, expensive and time consuming. Therefore, other techniques like the HOMA 
index that has been combined with clinical criteria to identify MHO individuals (Stefan 
et al, 2008; Meigs et al, 2006; Wildman et al, 2008). 
There are studies that show an increase in insulin sensitivity (IS) after weight loss in the 
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pathologically obese (PO) individuals, as opposed to a slight worsening of IR in the 
MHO population, suggesting that specific differences must be taken into account with 
respect to treatment for these individuals (Kantartzis et al , 2011). Other studies showed 
an improvement in inflammatory markers and lipid profiles of MHO women after weight 
loss, proving diet restrictions to be more effective in MHO than PO women (Kantartzis 
et al, 2006). 
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Figure 8. The relationship between the oxidative stress and IR 
Adipose tissue expansion is accompanied by the production of adipokines increase the 
production of ROS both locally and from other tissues leading to fibrosis, inflammation 
and IR. (Halberg et al, 2009). 
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However, Karelis et al. showed that low calorie diet-induced weight loss in MHO women 
gave a more unfavourable IR profile than with PO individuals, who showed 
improvement after weight loss (Karelis et al, 2008). Bariatric surgery has become one of 
the most popular ways of managing sustained weight loss in obese patients in the 
developed world (Dent et al, 2010). The proof of its effectiveness at reducing T2DM 
incidence among morbidly obese populations is well known (Buchwald et al, 2009), as 
well as reducing overall obesity mortality in morbidly obese patients (Adams et al, 
2007). However its effectiveness at improving an MHO metabolic profile is much less 
known. Healthy metabolic profiles, even in the morbidly obese, have less benefit to gain 
from bariatric surgery than IR. Although other studies showed that MHO subgroup of 
morbidly obese patients had significant weight loss and improvement in cardiometabolic 
risk markers compared to before gastric banding (Sesti et al, 2011). 
Therefore, more research needs to be carried out in order to discern MHO from PO 
patients in a clinical context, and to decide on different therapeutic approaches for the 
two groups. Further studies are needed to investigate the molecular mechanisms that 
explain the increased protection that this interesting group of patients have to enable 
them to avoid developing metabolic abnormalities across various BMI and age ranges 
(Cummings  et al, 2012). 
1.4.1 Metabolically healthy (MHO) and Pathological Obesity (PO) 
Several studies have shown that MHO individuals present a favourable blood lipid profile 
as evidenced by lower triglycerides (TGs) and elevated high density lipoprotein (HDL) 
cholesterol levels Ferrannini and colleagues initally showed the need for 
characterisation of obese patients who were healthy (insulin sensitive) from the 
unhealthy insulin resistant, (Ferrannini et al, 1997). Ethnicity studies are also important 
given differences in the incidince of obesity complications in different populations. The 
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identification of the MHO individual in both the clinical and research set-up could have 
important implications for therapeutic decision making. Thus understanding the 
molecular differences that lead to the MHO and PO phenotypes is important (see Figure 
6).  
Impaired adipose tissue function may contribute to a proinflammatory, atherogenic and 
diabetogenic state, linked to the development of obesity-associated disorders (Karelis et 
al, 2008). 
1.4.2 Mediators of pathological heterogeneity 
1.4.2.1 Specific biomarkers 
The differences in the secretory profile of adipose tissue with respect to its expansion 
could suggest an inherent difference in the levels of specific circulating adipokines, such 
as resistin (associated with increased insulin resistance), adiponectin (known to be an 
insulin sensitizer) and TNF-α (associated with insulin resistance), all of which have been 
seen to be altered in the presence of insulin resistance in humans (Hivert et al, 2008). 
Since these and other adipokines, like IL-6, which all also have autocrine and paracrine 
effects on glucose metabolism, lipolysis and insulin sensitivity (Karastergiou and 
Mohamed-Ali, 2010) could be different between MHO and PO in their levels and effects 
on IR, there could be a fundamental difference in secretion levels of these adipokines 
that could also be used as a biomarker for the onset of insulin resistance and MeS , which 
makes quantification of these adipokines and their metabolic effects important. Ratios of 
adiponectin to HOMA-IR index have already been used as a predictive tool for MeS in 
humans (De Luis et al, 2011), and inflammatory adipokine levels have been determined 
and shown to decrease during weight loss, while anti-inflammatory adipokines such as 
adiponectin increase after the weight loss (Blüher et al, 2012). 
Small adipocytes have been linked to whole body insulin sensitivity especially with 
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increased abdominal adipocyte surface area being associated with an elevated risk of 
developing insulin resistance and T2DM (Weyer et al, 2000, Lundgren et al, 2007). 
As yet unknown interactions of genetic and/or environmental factors may cause 
dysfunction of adipose tissue by a sequence of adipocyte hypertrophy, followed by tissue 
hypoxia, perhaps as a consequence of reduced capillary density, adipocyte cell death and 
initiation of inflammatory processes (Lundgren et al, 2007; Pasarica et al, 2009). 
Adipokines   may   underlie   associations   with   insulin   resistance   and   endothelial 
dysfunction (Karastergiou and Mohamed-Ali, 2010).  Thus, in PO subjects elevated 
levels of proinflammatory adipokines may induce IR, and lead to suppression of 
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The figure shows the documentaed differences in insulin sensitivity, fat mass, lipids, and 
inflammation in the two patient groups (Primeau et al, 2011). 
Figure 9. Clinical differences between MHO and PO subjects 
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adiponectin, an endogenous insulin sensitizer. MHO subjects fail to show these 
changes. This could account for their lower risk of developing obesity-associated 
diseases. However, data for this hypothesis is varied and detailed comparisons of the 
adipose tissue of MHO and PO subjects have yet to be done. Furthermore, there are 
uncertainties about the appropriateness of such costly, and potentially risky, procedures 
such as bariatric surgery for weight reduction, in patients who might best be treated 
otherwise. Therefore the molecular mechanisms that give rise to the different obesity 
phenotypes need to be elucidated. 
1.4.2.2 Inhibition of Adipogenesis 
Two independent prospective studies showed that adipose hypertrophy is an independent 
risk factor for developing T2DM (Olga et al, 2012). Large adipocytes may be a marker 
for impaired adipogenesis, or also increased deposition of fibrosis within the tissue 
which renders it less elastic. Lower levels of adipogenesis-inhibiting genes such as 
preadipocyte-factor1 (pref-1) in MHO patients may enable normal adipogenesis in these 
patients, while conversely increased (pref-1) may lead to inhibition ofadipogenesis in PO 
adipose tissue (O'Connell et al, 2011). Other inhibitors of adipogenesis, such as Wnt 
signalling pathway, may also be candidates for further investigation. The hypothesis that 
MHO patients have smaller adipocytes had been confirmed in various depots of the 
adipose tissue and lower levels of (pref-1) (O'Connell et al, 2011). Also, an association 
between smaller adipocyte size and heightened local inflammation signalling has been 
observed (McLaughlin et al, 2007, McLaughlin et al, 2010). It was reported that omental 
adipose tissue has smaller adipocytes than the SC but conversely these small adipocytes 
are inflamed and insulin resistant. 
The inflammation impairs differentiation and/or maturation of pre-adipocytes into 
mature adipose cells; and the small adipose cells demonstrate biological activity similar 
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to inflammatory cells due to the dysfunction of adipose cell differentiation caused by 
inflammation (McLaughlin et al, 2010). 
In addition to the high capacity of the subcutaneous adipose tissue for adipocyte 
differentiation and lipid storage where hyperplasia is correlated with decreased the 
glucose and IR (Kursawe et al, 2010).  On the other hand, visceral adipose tissue 
accumulates macrophages that release inflammatory cytokines, which can impair insulin 
sensitivity upon this depot expansion or hypertrophy. 
Age may also be a determining factor, as recent data from Wildmann et al, demonstrated 
that the prevalence of metabolic normality decreases with age, as well as BMI 
(Wildmann et al, 2008). These differences may also reflect different criteria used to 
select patients for the two different groups, therefore making the need for a common 
definition of an MHO individual ever more important. 
1.4.2.3 Adipocyte cell size in obesity heterogeneity 
‘Benign obesity’ as reported by Stefan et al, demonstrated a higher degree of insulin 
sensitivity, lower levels of ectopic fat in liver and skeletal muscle, when compared with 
an insulin resistant obese group (Stefan et al, 2008). However, waist circumference and 
degree of visceral adiposity were similar between the two groups pointed at the 
importance of considering the ectopic liver fat more that the visceral fat (Stefan et al, 
2008). 
Adipocyte size was shown to vary inversely with adipocyte insulin sensitivity, where 
adipose tissue with enlarged cells, showed a diminished response to insulin. After weight 
loss and reduction in adipose cell size, insulin sensitivity of the adipose tissue of obese 
patients was restored to normal. (Salans et al, 1968). More recently, studies have shown 
functional differences in large and small adipocytes from the same subjects, including 
altered gene expression profiles (Hansen et al, 2010). Adipocyte size has been shown to 
46  
influence adipokine secretion, with increasing adipocyte Size (Skurk et al, 2007). It was 
shown that OM adipocytes of PO are larger in size than OM adipocytes in MHO where 
they are equal in size for SC in both groups (O’Connell et al, 2010). Suggesting the role 
of OM Adipocytes during inflammation where they become larger and release lots of 
adipokines, see Table 1. 
1.4.2.4 Visceral Adipose Tissue and Insulin resistance 
Insulin sensitivity in humans effectively decreases by 30-40% when body weight 
increases by >35-40% (DeFronzo et al, 1991) and the development of IR has 
beendirectly shown to occur in response to experimental overfeeding in normal weight 
individuals (Sims et al, 1987). Progressive exacerbation of insulin resistance to T2DM, 
following a prolonged state of hyperinsulinemia has also been reported (Kahn et al, 
2006). The size of the visceral adipose depot and adipocyte size in humans is linked to 
systemic insulin resistance, as well as increased expression of chemokines and cytokines 
by immune cells in the tissue (Hardy et al, 2011). 
A recent study also revealed a correlation between increased amounts of visceral fat, 
adipocyte hypertrophy, insulin resistance, and elevated expression of autophagy genes in 
human omental adipose tissue (Kovsan et al, 2011). Therefore, FFAs, cytokines, 
adipokines and ROS all secreted from visceral adipose tissue, impair insulin action in 
liver and muscle which leads to a blockage in tyrosine kinase activity interrupting the 
insulin signal transduction (Hardy et al, 2012). Therefore, the effects of insulin resistance 
results in the development of non-alcoholic fatty liver disease and dyslipidaemia (Abdul- 
Ghani et al, 2010). 
The greater omental release of fatty acids which have been shown to increase insulin 
resistance are thought to act through the activation of inhibitory protein kinases such as 
JNK,and Protein Kinase C which inhibit IRS-1 function in the insulin signalling pathway 
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as it is shown in Figure (DeFronzo et al, 2010). 
Furthermore, South Asians (Indian, Bangladeshi, and Pakistani) living in urban societies 
have a higher incidence of obesity complications, and greater abdominal fat deposition 
than other ethnic groups. Therefore, weight loss and maintenance are crucial in the 
prevention of non-insulin dependent diabetes mellitus (McKeigue, 1996). 
1.5 Mediators of adipogenesis and IR 
Adipogenesis is the conversion of preadipocytes to lipid engorged fat cells. The majority 
of genes with altered expression encode proteins involved in cell proliferation, 
metabolism, immune response, signal transduction, and angiogenesis. A major regulator 
of adipogenesis is PPARγ. It is a nuclear receptor and is highly tissue selective, being 
abundant mostly in adipose tissue. It plays an important role as an adipogenic master 
switch and marker of terminal differentiation through suppressing pro-inflammatory 
adipokines  by  interfering  with  NF-κB  and  AP-1  or  inducing  transcription  of  anti-
inflammatory genes. PPARγ activity associated with smaller adipocytes is related more 
to its metabolic effects. 
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Adipocyte size MHO PO 
Omental n=35 80.9 98.2 
Subcutaneous n=19 104.1 104.9 
Table 1. Adipocyte size in MHO and PO omental adipose tissue 
 
OM adipocytes of PO were larger in size than those of MHO, while adipocytes of the SC 
were similar in both groups. O’Connell et al, 2010. 
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The elevation of PPARγ promotes the differentiation of pre-adipocytes into mature 
adipocytes (McGregor and Choi, 2011). 
 
Studies have suggested that preadipocytes account for most of the cytokines/chemokines 
secretion seen in the adipose tissue stromal cells (Isakson et al, 2009). Preadipocytes are 
morphologically indistinguishable from fibroblasts. Their transcriptional regulation is 
determined by a sequential activation of transcription factors, where induction of PPARγ 
and CCAAT/enhancer binding protein (C/EBP), C/EBPα, along with inhibition of Wnt 
signalling, are important regulatory steps in determining commitment to adipogenesis 
(Rosen et al, 2006). Four variants of the PPARγ mRNA are known, the PPARγ1, 
PPARγ2, PPARγ3 and PPARγ4.  PPARγ  can  be  activated  naturally  by  fatty  acid 
derivatives,  these  acids  act  as  PPAR  agonists  that  transcript  the  genes  involved  in 
glucose and lipid homeostasis (Neschen et al, 2007). They include docosahexaenoic acid 
and eicosapentaenoic acid used in the prevention and treatment of cardiovascular and 
metabolic diseases (Bang et al, 1985). Also synthetic ligands such as thiazolidinediones 
(TZDs), for example rosiglitazone are widely used for the treatment of diabetes mellitus. 
The WNT signalling pathway has recently been the focus of much research in this area 
as an inhibitor of adipogenesis. Studies have shown that macrophage-induced TNFα can 
activate Wnt signalling during early stages of adipogenesis leading to inhibition of 
preadipocyte differentiation (Gustafson et al, 2006). Further studies have suggested that 
TNFα inhibits preadipocyte differentiation through MAPK activation with cross-talk 
with the Wnt signalling cascade. 
 
PPARγ regulates the expression of various genes involved in adipocyte differentiation, 
glucose uptake and lipid metabolism (Rosen et al, 2006). Interestingly, this effect was 
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found to be long-lasting in cultured cells, even after several generations (Isakson et al, 
2009). Multipotent mesenchymal stem cells can develop into lineage committed pre- 
adipocytes. PPAR and C/EBP transcription factors co-ordinate adipogenic gene 
expression during terminal differentiation into lipid storing mature adipocytes (McGregor 
and Choi, 2011). 
 
Numerous other genes have been implicated in mediating some of the changes associated 
with the pathologies of obesity. Omental adipose tissue of obese humans, with its closer 
relationship to MeS, exhibits an up-regulation of lipolysis repressor genes and a down- 
regulation of genes involved in lipolysis activation (Gómez-Ambrosi et al, 2004). 
Another gene of interest is that of NPY, a neurotransmitter, whose central functions include 
regulation of food intake and body weight, and acts peripherally as a vasoconstrictor as well 
as an anti-lipolytic agent. The increase of its expression in adipose tissue of obese 
individuals has been linked to the increased inhibition of lipolysis. 
 
1.6 miR 
MicroRNAs are small oligonucleotides, 21-25 in length that post-transcriptionally 
regulate gene expression by binding to the 3’-untranslated region (3’-UTR) of message 
encoding RNAs resulting in mRNA degradation or inhibition of translation (Esau et al, 
2004). The primary miR transcript is cut by the RNaseIII enzyme known as DROSHA in 
the nucleus to yield a 70–100 nucleotide product that forms a hairpin structure which is 
exported to the cytosol by exportin (Zeng, and Cullen, 2004). In the cytosol, these 
hairpin structures are cut by the endonuclease DICER to a double stranded product of 
20–25 bp. This double-stranded RNA is incorporated into the RNA-induced silencing 
complex (RISC) where the dominant miR is retained and used to direct RISC to the 
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target mRNA. 
Identical pairing of the entire miR with its target results in target degradation, whereas 
imperfect pairing beyond the first 7–9 bases at the 5 end of the miR blocks translation of 
the targeted mRNA but does not destroy it (Novina, and Sharp, 2004). To date, 2,042 
mature miRs have been identified in human cells (miRBase version 19; 
http://miRbase.org/), and each is predicted to regulate several target genes (Kozomara et 
al, 2011). 
Novel findings suggest that miRs may be stable and functional mediators a b l e  
to distinguish MHO from PO individuals. The discovery of microRNAs (miRs) by 
(Ambros et al, 1993) has introduced another level of intricacy in the regulation of the 
genome. A recent study by Laterza et al established the general principle that 
microRNAs may act as biomarkers of disease secreted into the systemic circulation upon 
tissue injury (Laterza et al, 2009). The team demonstrated how circulating miRs may 
serve as potential indicators of what is happening at the tissue level. Also, Kosaka et al 
reported how these circulatory miRs are released through secretory machinery and then 
transferred to the recipients where they can resume their functions (Kosaka et al, 2010). 
The origin of circulating miRs remains largely unknown, despite intense research. A 
number of studies have reported that miRs are actively secreted in microvesicles or 
exosomes from different cell types, which are a likely source of circulating miRs (Caby 
et al, 2005). In addition to microvesicles or exosomes, microparticles and lipoprotein 
complexes (such as high-density lipoprotein complexes) are other possible sources of 
circulating miRs (Olivieri et al, 2013). The exosomes are microvesicles that are present in 
biological fluids such as urine, saliva and blood (Michael et al, 2010). Within these 
exosomes are cellular gene products including miRs, mRNAs and proteins that can be 
transferred to recipient cells to carry out specific molecular functions (Mathivanan et al 
46  
2010). Such interactions allow exosomes to mediate cell-to-cell communication by 
facilitating the exchange of molecular components. 
 
1.6.1 Regulation of miRNA expression 
MiRNA expression profiles represent a promising new category of disease biomarkers. 
However, several endogenous and exogenous factors regulate their expression and need 
to be borne in mind. These include genetics factors such as ethinicity, sex, nuclear 
receptors, diet and dietary components as well as exercise. These factors are discussed in 
the following section. 
Population specific genetic variation can affect the prevalence and baseline expression of 
miRNAs in diverse populations. Consequently, miRNA genetic and expression level 
variation among ethnic groups may contribute, at least in part, to health disparities 
observed in multiple forms of cancer, specifically breast cancer, and may be an essential 
consideration when assessing the utility of miRNA as biomarkers in the clinic. Somatic 
mutations and dysregulation by miRNAs have been reported in cancer patients (Renata et 
al, 2014). Also common SNPs in the 3'UTR of GATA4 that alter miRNA gene regulation 
may be contributing to the pathogenesis of CHDs (Sabina et al 2013). 
NRs are ligand activated transcription factors that regulate gene transcription by binding 
to the promoter region or by interacting with other transcription factors. NRs can regulate 
miRNA expression either at the transcriptional level or through posttranscriptional 
maturation by interacting with miRNA processing factors. Growing evidence suggests that 
miRNAs can be regulated extensively at the levels of promoter transcription, methylation, 
miRNA processing, RNA editing, and miRNA-target interactions (Breving et al, 2010). 
Transcriptional regulation by nuclear receptors is the primary level of control for miRNA 
expression (Table 2). As shown in the Table 2 as an example, miR-122 is regulated by a 
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nuclear receptor, HNF4α, which binds to its promotor to regulate miR-122 target genes 
like Hfe, Hjv, CPEB, HCV, CAT-1, smarcd1/Baf60a. Another interesting miR is miR-29a 
which is regulated by FXR which binds to its promotor and is regulated by TGF-b, c-Myc, 
Hedgehog or NF-B to alter the expression of targets such as Ski, MCT1, PTEN and CDK6. 
The importance of gender has been highlighted in immunerelated diseases, many cancers, 
and coronary heart disease (CHD). Recent studies have begun identifying sex differences 
and specificity in miR responses to pathologic conditions, such as cerebral ischemia and 
radiation, and in cancers including hepatocellular and squamous cell carcinomas (Yeh et 
al, 2010; Ober et al, 2008; Voskuhl et al, 2011). A thorough analysis of the effects of sex 
steroid signaling on the transcriptome (Hah et al, 2011) identified 322 distinct pri-miRs, 
37% regulated by oestradiol. A microarray analysis of uterine tissue samples from 
ovariectomized female mice treated with oestradiol identified 39 miRs that were 
suppressed, surprisingly none were induced (Yamagata et al., 2009). 
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miRNA 
name 
NR             Endogenous ligands and 2 signals miR target 
Let 7 family ER;PPA
R;PR 
Induced by estradiol; PPARa and PR agonist regulate let-7c. K-ras; HMGA2; caspase-
3; c- Myc; PGRMC1 
miR-17-92 
cluster 
ER c-Myc, adiol, binds induced by estr to the miR-17-92 promoter; p53 
and STAT3 bind to the miR-17-92 promoter. 
Myc;E2F;HNF1;PTEN;
B IM;ER;AIB1;cyclin  D1 
miR-21 ER;AR STAT3, NF-B, CREB and CBP/p300, ER and AR bind to the miR-21 
promoter. 
Pdcd4;PTEN;PPARa; 
miR-221/222 ER;AR NF-B, c-JUN, ER and AR bind to the miR-221/222 promoter. P27kip1;PTEN;ERa;PU
M A miR-200 family ER;AR;P
R 
Upregulated by estradiol, androgen and progesterone. ZEB1; ZEB2; BMI1 
miR-146a ER;AR Repressed by estradiol, androgen and LPS; LPS induces NF-..:B 
binding to the miR-416a promoter. 
ROCK1; TRAF6; 
IRAK1; CD40L; 
STAT1BRCA1; miR-26a ER;AR Estradiol induces miR-26a, which reduces PR mRNA level EZH2;MTDH 
miR-101 AR ARE identified in the miR-101 promoter EZH2; MAGI-2; MKP-1; 
ATP5B; COX-2; MYCN 
miR-125b AR AR loading to the 5’ UTR region MUC1; PIGF; IGF-II; 
PUMA;E2F3FGFR2; 
P53; miR-122 HNF4a HNF4a binds to the miR-122 promoter. Hfe Hjv; CPEB; HCV; 
CAT-1; Smarcd1/Baf60a 
miR-29a FXR FXR-responsive element in the miR-29a promoter; regulated by TGF-
b, c- Myc, Hedgehog or NF-B. 
Ski; MCT1; PTEN; 
CDK6 
miR-210 RA
Ra/ 
RX
Ra 
RARa/RXRa heterodimers bind to the miR-210 promoter. FGFRL1; HOXA3; 
E2F3; RAD52 
miR-23a/ 24-2 RA
Ra/ 
RX
Ra 
RARa/RXRa heterodimers bind to the miR-23a/24-2 promoter. Runx2; XIAP; IL6R 
miR-9 TLX TLX binds to the downstream of miR-9 and miR-9 targets TLX mRNA 
to form a feedback loop. 
PDGFR-b; Nr2e1; 
FoxP1; Gsh2; NF-kB1 
miR-34a FXR;SH
P 
p53 binds to the miR-34a promoter; FXR interacts with p53 through 
SHP to regulate miR-34a 
FoxP1; Bcl-
2;CDK4;E2F3; N-
MYC;SIRT1;HMGA2 miR-433/127 SHP SHP inhibits ERRg which binds to the miR-433/127 promoters HDAC6;BCL6 
miR-206 SHP SHP represses ERRg leading to decreased YY1 which inhibits AP1 Notch3; HDAC4; KLF4; 
activation of the miR-
206 promoter Pax7 
Table 2. miRNAs regulated by NRs 
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1.6.1.1 Environmental mediators 
Epigenetics, including miR regulation, has revolutionized our understanding of how genes 
are switched on and off. A single miR can regulate several biological processes, as well 
as a group of miRs affecting the expression of a single gene. In addition, miRs themselves 
are regulated by various molecules such as sex steroid hormones or insulin. In addition 
dietary components (e.g.PUFA, cholesterol, Vitamin A) have been shown to alter the level 
of the miRs gene expression, The regulation of adipogenic genes by miRNA can be 
influenced by dietary fatty acids (FA) in mice (Parra et al, 2010). Meale and colleagues 
examined the effect of DHA-Gold, an algal meal high in n-3 FA docosahexaenoic acid 
(DHA), on the expression of 15 miRNA, and found that the expression of miR-142 
changed significantly when DHA-G was included in the diet (Meale et al, 2014). Previous 
reports (Jin et al., 2010; Romao et al., 2012), which examined a wide range of miRNA 
associated with adipogenesis also indicate that diet has a significant influence on the 
molecular regulation of adipogenesis. Furthermore, it has also been reported that many 
macro- and micronutrients, such as vitamins, amino acid, fatty acids, retinoic acid, and 
folate, can modulate miRNA expression (Drummond et al, 2009). As with diet, responses 
to exercise as a mediator of weight loss shows a high level of interindividual variability.  
Several studies have identified some circulating miRNAs associated with weight loss 
following dietary and physical activity interventions. MiRNAs showing differential 
expression after an acute bout of exercise also appear to differ from those that are altered 
as a result of long-term training.  
In addition circulating miRNAs can differ in their cellular origin, as shown in studies that 
evaluated monocytes (Radom-Aizik et al, 2014), neutrophils (Radom-Aizik et al, 2010), 
and whole blood (Tonevitsky et al, 2013). Cellular origin was a determinant of miRs 
species expressed and involved in regulating different mRNAs and thus their associated 
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biological pathways.  
1.6.1.2 Physiological/pathological regulation 
Changes in miR expression and activity have been reported in various pathological states. 
An overall decrease of miRNA expression has been observed in many types of cancer, 
though their functional significance remains largely unknown (Lu et al, 2005; Chen and 
Stallings, 2007; Ozen et al, 2008). In type 2 diabetes, CVD and MeS miRs may regulate 
the major mechanisms involved in these disorders, such as, inflammation, angiogenesis 
and hypoxia. 
1.6.1.3 Inflammation 
Disruption of miRNA biogenesis has a major impact on the overall immune system. 
Emerging studies indicate that some miRNAs, especially miR-21, miR-146a/b and miR-
155, play a key role in regulating inflammatory processes. Furthermore, the brain-specific 
miR-124 appears to abrogate inflammation by turning off activated microglial cells and 
macrophages (Ponomarev et al, 2010; Rink et al, Roy et al, 2010). Of relevance to tissue 
repair is the regulatory loop between cytokines and miRs: cytokines induced following 
injury are regulated by miRNAs and in turn regulate miRNA expression. 
1.6.1.4 Angiogenesis and Hypoxia response 
The significance of miRNAs in the regulation of mammalian vascular biology came from 
experimental studies involved in arresting miRNA biogenesis to deplete the miRNA pools 
of vascular tissues and cells (Sen et al, 2009). Dicer-dependent biogenesis of miRNA is 
required for blood vessel development during embryogenesis. Mice with endothelial cell-
specific deletion of Dicer, a key enzyme supporting biogenesis of miRNAs, display 
defective postnatal angiogenesis. Various aspects of angiogenesis, such as proliferation, 
migration, and morphogenesis of endothelial cells, appear to be regulated by specific 
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miRNAs in an endothelal specific manner. miRNA-126 is specific to endothelial cells and 
regulates vascular integrity and developmental angiogenesis. Manipulating angiomiRs in 
the setting of tissue repair may represent a new therapeutic approach that could be 
effective in promoting wound angiogenesis. 
Tissue injury is often associated with disruption of vascular supply to the injury site. Thus, 
the injured tissue often suffers from insufficient oxygen supply or hypoxia. Hypoxia 
induces specific miRNAs, collectively referred to as hypoxamirs (Chan et al, 2010). miR-
210 is a classical hypoxamir. Expression of hypoxia-inducible factor 1 (HIF-1) is also 
controlled by specific miRs. In turn, HIF-1 controls the expression of hypoxamirs that are 
induced in the injured tissue (Loscalzo et al, 2010). Hypoxamirs are also induced by HIF 
independent pathways. Although hypoxamirs generally favor angiogenesis their metabolic 
and cell cycle arrest functions need to be finely regulated, especially when 
consideringtissue repair in an ischemia. Silencing specific hypoxamirs may therefore 
represent an approach to facilitate tissue repair.  
1.7 Adipose micro RNA 
Over 2000 microRNAs have been identified. MiRs are abundant in adipocytes and 
adipose tissue and have been assigned various functions. In differentiated human 
adipocytes it has been shown that regulation of SirT1 by miR-132 leads to IL-8 and 
MCP-1 production through activation of NFkB (Strum et al, 2009). Recently using a 
global miR expression microarray in human subcutaneous fat samples from non-obese 
and obese women with and without type-2 diabetes (Ortega et al, 2010), it was shown 
that approximately 6% of miRs significantly differed between fat cells from lean and 
obese subjects, 9% were highly and significantly up- or down-regulated in mature 
adipocytes as compared to preadipocytes, while 2% of miRs were correlated with BMI, 
fasting glucose and triglycerides. They identified 1.4% of miRs significantly deregulated 
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in subcutaneous fat from obese subjects with and without T2DM and also many of the 
changes associated with miRs appeared to regulate adipocyte differentiation (Xie et al, 
2009; see Figure 7). MicroRNAs may play regulatory roles in many biological processes 
including adipocyte differentiation (see Figure 8) and insulin resistance. Additionally, 
miRs may also regulate functions in other insulin responsive tissues such as the liver and 
the skeletal muscle (Rottiers  et al, 2012). 
The liver is where the triglycerides and cholesterols are synthesised and transported to 
the blood through the lipoproteins such as Very Low Density Lipoprotein (VLDL), Low 
Density Lipoprotein (LDL), and High Density Lipoprotein (HDL). The excess 
accumulation of triglycerides and FFAs has a strong correlation with insulin resistance 
and MeS (Cornier,et al 2008). The role of miR-122 in lowering circulating cholesterol 
has been described by some studies (Elmen et al, 2008). In addition, other studies 
highlighted the role of miR33a and miR33b and the SREBP gene regulators in 
controlling cholesterol and lipid homeostasis (Gerin et al, 2010). MiR-375 is highly 
expressed in the pancreatic alpha and beta cells, implicated in their maintenance in mice. 
It may also be required for glucose homeostasis (Poy et al, 2009). Therefore the 
dysregulation of miRs may contribute to metabolic abnormalities, and this opens up the 
possibility that miRs may serve as therapeutic targets for cardiometabolic disorders. 
 
1.7.1 miR in obesity related diseases 
T2DM is characterized by a dysregulation of blood glucose levels and results from 
progressive peripheral insulin resistance in conjunction with pathologically altered 
pancreatic insulin secretion. Diabetes is diagnosed by repeated measurement of fasting 
glucose levels over 126 mg/dL (7 mmol/L), or over 200 mg/dL (11.1 mmol/L) following 
oral glucose challenge, and T2DM often presents in obese, inactive individuals. Men and 
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women with diabetes have an increased risk for cardiovascular disease (Kannel et al , 
1979), and the frequent comorbidity of T2DM with other cardiovascular risk factors, 
such as hypertension, dyslipidemia, and obesity, significantly increases the risk of heart 
failure in these patients (He et al, 2001). Therefore, diabetes is one of the most important 
risk factors for the development of cardiovascular diseases, and miRs involved in 
diabetic-related cardiovascular disorders have received much attention, especially in 
trying to elucidate how cardiovascular risk factors might affect miR signalling. (Han et al 
2012). Recently the miR-mediated regulation of the cardiomyocyte-relevant transcription 
factor GATA4 and pressure-induced cardiac hypertrophy was reported (Han et al 2012). 
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(McGregor & Choi, 2011). 
Figure 10. The regulation of target genes by MicroRNAs during adipogenesis 
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1.7.1.1 The role of miRs in IR and endothelial dysfunction 
Accumulated adiposity leads to increased oxidative stress in adipose tissue and increased 
production of ROS and inflammatory chemokines which then promotes insulin 
resistance. Collectively, these processes induce the progression of endothelial 
dysfunction (see Figure 8). Excess production of ROS and inflammatory adipokines 
eventually induce deregulation of inflammatory-associated miRs and vice versa in the 
endothelium. MiRs regulate insulin secretion and β-cell function and several miRs are 
differentially regulated in diabetes during endothelial dysfunction, diabetic heart disease, 
and diabetic retinopathy (Shantikumar et al, 2012). Another important aspect of miR 
function is the regulation of smooth muscle cells (SMCs). SMCs in the vessel wall 
contribute to vascular remodelling and activation of inflammatory cells. miRs involved 
in acute vascular injury and pulmonary vascular remodelling have recently been 
described (McDonald et al,2012). The identification of key miRs in vascular SMCs may 
result in novel therapeutic strategies. For example, miR-214 appears to play a role in 
regulating angiogenesis and has been identified as a potentially important target for pro- 
or anti-angiogenic therapies (Van Mil et al, 2012). 
The prolonged pathogenesis of atherosclerosis is marked by endothelial cell dysfunction, 
followed by infiltration of macrophages into the vessel wall and SMC proliferation, 
leading to occlusion of the arterial lumen. Hypertension and hyperlipidemia significantly 
contribute to the process of atherosclerotic plaque formation (Chobanian et al, 1996). 
Hypoxia results in the activation of miR-210 and miR-92a, which promote and inhibit 
angiogenesis, respectively. miR-126, an endothelial-cell-enriched miR encoded by an 
intron of the Egfl7 gene, modulates atherosclerosis and angiogenesis by regulating 
MAPK and PI(3)K signalling. Angiogenesis is also regulated by miR-218, which is 
encoded by an intron of the Slit genes. miR-143 and miR-145 are expressed in SMCs and 
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control blood pressure and vascular tone, and contribute to vascular remodelling. 
Therefore, gain and loss of function of smooth muscle–enriched miR-143/145 in vivo 
results in reduced smooth muscle cell proliferation and consequently prevents neointima 
formation in surgical models of vascular injury, suggesting that closely titrated levels of 
miR-143/145 are required for the pathological proliferative response to injury (see Figure 
8). MiR-21 is induced in SMCs after vascular injury, and promotes proliferation and 
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Blood vessel schematic showing the endothelial and smooth muscle layers, red blood 
cells and the proliferating SMCs of a neointimal lesion (Small and Olson, 2011). 
Figure 11. The expression of select miRs with their observed functional role 
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neointima formation. miR-451 regulates the proliferation and differentiation of erythroid 
cells (Small and Olson, 2011). 
Thus the discovery of circulating miRs has highlighted their potential as both endocrine 
signalling molecules and disease markers. Dysregulation of miRs may contribute to 
various vascular and metabolic abnormalities, further proof that miRs may potentially 
serve as therapeutic targets for ameliorating cardiometabolic disorders. 
1.7.2 Preventative miR therapies 
Through the understanding of the role miRs play in normal physiology and pathological 
conditions, researchers will be able to unlock a new class of therapeutic targets with the 
potential to significantly alter multiple aspects of their respective conditions. The role of 
miRs in the pathogenesis of the cardiovascular risk factors suggests that they might be 
interesting candidate drug targets. However their pluripotency needs to be considered 
when considering administration of miR-targeted therapies for long-term risk 
modification as this may have several potential adverse effects. The potential use of anti– 
let-7 therapy to counteract the diabetic state should take into consideration the long-term 
risk of developing cancer. There is a need for targeting β cell–enriched miRs to increase 
insulin secretion which could aid in glycemic control in diabetic patients. But the role of 
miRs remains to be tested in vivo in disease models. Overexpressed miRs could be 
inhibited by introducing complementary anti-miR oligonucleotides (antagomiRs), while 
those miRs that are under-expressed could have their activity restored by synthetic miR 
mimics. The manipulation of miR expression comprises of two main approaches: miR 
inhibition therapy and miR replacement therapy. Numerous studies have reported various 
miRs which showed deregulated expression during the manifestation of metabolic 
disorders prior to clinical cardiovascular diseases (Hulsmans et al, 2013). Among these, 
reduced expression of miR-126 in particular, could be detected years before the 
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appearance of diabetes and symptoms of related vascular diseases. These findings not 
only feature miRs as good markers for early diagnosis of cardiovascular events but also 
prompted several clinicians and scientists to assess the predictive value of other miRs in 
diabesity-induced vascular dysfunction. Early identification of cardiovascular events in 
obese and diabetic individuals raises the possibility for pharmacotherapy to delay 
progression and prevent future vascular complications. In addition, several studies have 
also demonstrated different methods of modulating miR expression and activity to treat 
vascular complications in obese/diabetic study models. With capacity to control gene 
expression and regulate various biological pathways, miRs are definitely intriguing 
targets for novel therapeutic interventions, distinct from that of the classical single-drug- 
target strategy and analogous to stratergies that advocated the use of nuclear receptors or 
transcription factors as drug targets. 
Moreover, the existence of stable miRs in the circulation has made them easily 
accessible for detection and thus serves as an effective platform for prevention, early 
diagnosis and treatment. 
Theraputic replacement can be done by using miR antagonists, such as anti-miRs, locked-
nucleic acids (LNA) or antagomiRs. These miR antagonists are oligonucleotides with 
sequences complementary to the endogenous miR.Several studies have reported on 
efficient antagonism of several miRs, using high-affinity 15 to 16 nucleotide LNA- 
modified DNA/PS oligonucleotides targeting the 5’ region of the mature miR. The best 
example is therapeutic targeting of miR-122 for treatment of hepatitis C virus infection 
using a high-affinity 15-mer LNA-modified antimiR-122. (Elmen et al, 2008, Hedtjarn et 
al, 2008). 
However, a detailed understanding still is required of the molecular mechanisms 
regulated by the miRs of interest in the specific pathological condition, before 
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proceeding into clinical applications. 
1.8 Obesity and Insulin sensitivity in Arabs 
Obesity constitutes a major health problem in Qatar. Increased obesity prevalence among 
Arabs has rendered a high proportion of this population IR. However, like in Caucasians, 
some obese individuals maintain IS. The characterization of IR and IS obesity may shed 
light on the mechanisms underlying the association between increased fat accumulation 
in obesity and impaired insulin sensitivity. Adipocytes play a central role in the 
development of obesity-associated MeS, mainly through promoting IR. Understanding 
the molecular mechanisms underlying the site-specific impaired adipogenesis associated 
with IR may offer novel ways to prevent the metabolic consequences of obesity and may 
constitute the basis for future treatment strategies. 
Preliminary data showed that systemic insulin levels increased with BMI. Fasting insulin 
levels appear to be a good surrogate to differentiate between MHO and PO (see 
Figure16), and both obesity phenotypes were present at every BMI criteria. 
1.8.1 Cardiometabolic risk factors and their mediators in subjects of Arab origin 
Lack of data on any of these parameters in non-caucasian subjects therefore need for 
studies: It is very recently that there is emerging data on the prevelance in Arab, gender, 
ethnicity and insulin differences. How the disese progress related to the diet and genetic 
predisposition are poorly reported. MIRs useful as mediators. Much of data suggested 
that Arabs have intermediate phenotypes in Arabs specific to this population between, 
South Asian and Caucasians. Mechanistic studies about the mediators that could be 
different from the previous reported studies in other ethnicities which required to be done 
in Arabs. 
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1.9 Summary 
Studies have shown that MHO have less fat accumulation in the liver, lower muscle fat 
infiltration and lower concentrations of hepatic enzymes compared to PO individuals 
(Diabetes care 2011). Their metabolic profiles are not significantly different from those 
of lean subjects, and longitudinal studies show them to have a lower incidence of T2DM 
and CHD, compared to PO subjects (Meigs et al, 2006). Furthermore, it was shown that 
all-cause mortality was higher in the PO subjects, but not MHO subjects, when compared 
with lean subjects. Therefore, recent interest has focused on trying to stratify obesity into 
groups with varying degrees of disease risk, understanding the mechanisms that underlie 
these differences and the most appropriate therapeutic strategies to adopt for treating 
these different phenotypes. It is not clear whether MHO individuals maintain IS 
throughout life or whether it only represents delayed onset of obesity-related IR. Little is 
also known about the effect of this heterogeneity in obesity on responsiveness to diet, 
exercise or surgery (Karelis et al, 2008). 
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In a pilot study carried out in 2009 in a non- diabetic Arab population 
(n=149), the prevalence of normoinsulinamia decreased with increasing 
obesity, while hyperinsulinaemia increased. However, even at normal BMI, 
hyperinsulinaemia was apparent in a subset, while conversely 
normoinsulinaemia prevailed in a subset of morbidly obese subjects. (Aspetar, 
unpublished, 2009). IS decreased when body weight increased past ideal levels 
by >35-40% leading to IR. 
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Figure 12. Insulin levels increase with BMI 
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1.10 The Aims of the project 
The aims of the projcect were, in subjects of Arab origin, to: 
 
1. Stratify obese subjects depending on systemic biomarkers of insulin sensitivity and 
inflammation. 
2. Identify and validate specific miRs that might be associated with these phenotypes. 
3. Confirm and validate, in the whole transcriptome, targets for the specific miRs and 
assign functionality. 
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Materials 
and 
Methods 
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2.1 Materials and Methods 
2.2 Patient recruitment 
Morbidly obese patients, of Arab origin, undergoing laparoscopic bariatric surgery (gastric 
bypass, gastric sleeve, or gastric band) were recruited from the pre-operative clinic (Al-
Emadi Hospital and Hamad Medical Corporation, Doha, Qatar). Morbid obesity was 
defined as BMI ≥ 40 kg.m-2 or BMI ≥ 35 kg.m-2 with significant co- morbidities. 
Patients with coronary artery disease, uncontrolled hypertension, malignancy or terminal 
illness, connective tissue disease or other inflammatory conditions likely to affect cytokine 
levels, immuno-compromised subjects and those with substance abuse or other causes for 
poor compliance were excluded. It was ensured that the duration of obesity in all patients 
was greater than 10 years. 
Effect of surgical weight loss was explored using a sub-set of patients, 3-6 months post- 
surgery, from the Al-Emadi Hospital cohort. 
Patients of Arab origin were compared to Caucasian patients recruited from an analogous 
clinic based at the Whittington Hospital (North London Obesity Surgery Service, 
Whittington Hospital, London, UK) 
The studies were approved by the Ethics Committees of Al-Shafallah, of Hamad Medical 
Corporation (HMC), Doha, Qatar and National Ethics Committees (UK). 
The studies included both males and females over the age of 18 years. Written informed 
consent was obtained from all participants. 
2.3 Anthropometric measurements 
Weight (kg) and height (m) were measured in pre-clinic assessment and BMI was calculated 
(kg.m
-2
). Blood pressure was measured using digital monitor (Halma, India). Patient 
information including demographic data (date of birth, gender, ethnicity), surgery type 
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(gastric bypass, gastric band, gastric sleeve), co-morbidities, current medication, weight 
loss history, smoking habits and alcohol consumption were recorded from hospital notes. 
2.4 Blood and Adipose tissue samples 
Blood samples (EDTA, NaF, no anti-coagulent, PAX RNA-later), following an overnight 
fast, were drawn from an ante-cubital vein on the day of the operation immediately after 
anaesthesia. Similar fasting samples were obtained in the sub-set cohort after surgical weight 
loss when attending routine post-surgery clinics. 
Samples were centrifuged (3000 rpm, 15 minutes, 25
o
C), and the plasma or serum was 
collected and stored at -80 
o
C until analysis. 
AT from the abdominal subcutaneous and intra-abdominal greater omental depots was 
obtained during the surgery (~5g each) and quickly transported in serum-free medium 
(Cellgro, Mediatech Manassas, VA) to the laboratory. Approximately 0.5g of the tissue were 
preserved in RNA-later solution (Life Technologies, Paisley UK) and stored at - 80°C for 
subsequent extraction. In addition 1-2 grams of tissue was digested by collagenase to 
separate the adipocytes from the stomal vascular fraction (SVF). 
The tissue and the fractionated components were used for organ cultures (Appendix 1), 
histology (Appendix 1), mRNA and miR gene expression studies as described below. 
2.4.1 Biochemical analysis 
Plasma glucose concentration was assayed with glucose oxidase reagent (Beckman, USA). 
Serum triglycerides, total, low density lipoprotein (LDL) and high density lipoprotein (HDL) 
cholesterol were assayed with commercial reagents (Roche Diagnostics, UK). 
Serum insulin levels were determined by ELISA (Mercodia, Uppsala, Sweden). 
Insulin resistance was calculated using the homeostatic model assessment where HOMA = 
(glucose in mmol/L x insulin in miU/ml)/22.5. 
After determination of fasting insulin and glucose levels patients were classified as MHO 
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based on the presence of the following criteria: 
 
• No metabolic disorders including T2DM, dyslipidaemia and hypertension 
• Systolic blood pressure at < 140 mmHg, diastolic blood pressure at <85mmHg 
• Absence of cardiovascular disease (diastolic blood pressure less than 85mmHg). 
• Fasting plasma glucose of <6.8 mmol/l and insulin <6.5 miU/ml. 
•  
2.4.2 Serum Adipokines levels 
All circulating adipokines were tested in the serum (adiponectin) or plasma and measured 
by 2-site ELISA (R&D Systems (UK), according to manufacturer’s instructions. 
Briefly, standards and samples were pipetted into the 96 wells of microplates pre-coated with 
antibody against the target protein. After incubation, target protein was bound to the antibody 
pre-coated on the bottom of the well. The unbound substance was then washed away, 
followed by adding a detecting enzyme-linked antibody specific for the target protein. 
After washing, to remove the unbound antibody-enzyme reagent, the substrate was added 
and colour development in proportion to the amount of target protein bound was observed. 
Colour development was stopped at set times as per manufacturer’s instructions and the 
intensity of the colour measured by the microplate reader (Tecan, U.S), as absorbance at 
450 nm, with correction at 540 nm. All assays had inter- and intra-assay coefficients of 
variation (CVs) less than 10%. 
2.4.3 Preparation of adipocytes and stromal vascular fraction 
Adipose tissue biopsies (1-2g) were washed with warm PBS containing 1% antibiotic 
solution then minced into small pieces. Then digested using freshly made collagenase 
solution (0.1% collagenase I/1% BSA in PBS). Adipocytes were separated from SVF after 
centrifugation at 400g for 10 min and mature adipocytes are collected for further analysis 
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(see Figure 10). Erythrocytes were removed by resuspension of stromal vascular cell pellets 
in lysis buffer (2.06 mg/ml Tris base, pH 7.2, 7.49 mg/ml NH4Cl) for 10 min. After 
centrifugation, the pellets were resuspended in HBSS containing 2%fetal bovine serum 
(FBS) and filtered through a 70uM and 40uM sieves. RNA extraction procedure was 
performed using a trizol RNA extraction procedure (Section 2.3.4.1). 
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The composition of stromal vascular fraction is described (from google images 
Alexey Bersenev. Stem cell assay, 2013: http://stemcellassays.com/2013/05/breaking-
fat-svf/). 
Figure 13. Preparation of adipocytes and stromal vascular fraction 
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2.4.4 Total RNA extraction 
2.4.4.1 Adipose tissue RNA 
Approximately 0.15 g of AT was ground in liquid N2 using a pestle and mortar. Tissue 
powder were collected and homogenized in TRIzol reagent (Invitrogen, Life Technologies, 
UK). Then chloroform was added and mixed thoroughly (0.2 ml chloroform per 1ml 
TRIzol). After centrifugation (3200 rpm, 15 minutes, 4 
o
C), the mixture was separated 
into a lower red phenol-chloroform phase, an interphase, and a colourless upper aqueous 
phase. The upper phase containing total RNA was transported into a new Eppendorf and an 
equal volume of 100% isopropanol was added and mixed gently.  The sample was 
incubated at -20
o
C for 1.5 hour.  After another round of centrifugation (3200 rpm, 15 
minutes, 4
o
C), the RNA pellet was visible at the bottom of the eppendorf. The pellet was 
washed twice in 75% ethanol (molecule biology grade, Sigma-Aldrich, UK) and nuclease-
free water (Invitrogen, Life Technologies, UK) and dissolved in 40 μl nuclease-free water. 
The purity and yield of total RNA were determined spectrophotometrically (NanoDrop- 1000 
Spectrophotometer, Thermo Scientific, USA). The concentration of RNA was measured as 
absorbance at 260 nm. The purity was determined by the ratios between 260 nm and 280 nm 
(260/280) and between 260 nm and 230 nm (260/230). 260/280 and 260/230 ratios within 
1.7-2.0 were accepted purity for RNA. 
Further assessment of purity was carried out using the Agilent Bioanalyser (Section 2.5). 
2.4.4.2 Peripheral blood cell RNA and miR extraction 
Total RNA and miR was extracted from peripheral blood cells (n= 58 samples) using two 
different commercially available kits (PAXgene Blood RNA and miR kits, Qiagen, UK. The 
extracted RNA species were assayed on the Agilent Bioanalyzer using the Pico 6000 and 
small RNA chip and ladder 50nt (Section 2.5). 
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2.5 Assessment of RNA quality 
2.5.1 Purity assessment using the Agilent Bioanalyser 
Further assessment of total RNA and miRNA quality and quantity was required for the 
comparison of the gene expression profile of total RNA by pathway specific arrays and 
validation of hits by next generation sequencing (NGS). For miR NGS, RNA exhibiting high 
yield and RNA integrity number (RIN) greater than 7 was used for miR enrichment and 
library preparation. The same samples were used for the pathway specific arrays. 
2.5.2 Total RNA quality assessment 
Total RNA from the SC and OM adipose tissue was extracted from 48 patients, however, only 
seventeen samples were selected depending on their quality/purity (RIN ≥7), as assessed 
by the analyzer (Figure 11). These samples were used for sequencing and the miR pathway 
specific array (Qiagen, UK). 
2.5.3 Small RNA quality assessment 
For small RNA sequencing the best samples (n=6 each of MHO and PO) were selected, 
enriched for miR and checked on the analyser (see Figure 12 and more figures showed the 
different concentration in the appendix 2). 
2.6 cDNA synthesis 
2.6.1 cDNA synthesis for RT-PCR 
For reverse transcription, 0.5μg of total RNA was incubated with recombinant Moloney 
Murine Leukaemia Virus Reverse Transcriptase (1.25 U/μL), deoxyNTP mixture (ATP, 
CTP, GTP, UTP at 500 μM each), oligo d(T)16 (2.5 μM), RNase inhibitor (0.4 U/μL), 
MgCl2 (5.5 mM) and reaction buffer (all Applied Biosystems, Paisley, UK) at 42
o
C for 60 
min. 
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The Agilent 2100 Bioanalyzer was used to check the quality of the different types of 
RNA: A: Intact total RNA. RIN=8.7 B: Partially degraded RNA. RIN=3.6. C: with the RNA 
Figure 14. Assessment of RNA quality 
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ladder (50-300bp). 
 
 
 
 
 
 
 
 
 
 
 Figure 15. Size selection of small RNA species 
The miR size required for further investigation was in the region of 10-40nt. Samples 
were selected depending on the percentage of miR within the small RNA fraction (sRNA). 
MiRNA 
region 
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2.6.2 miR cDNA synthesis 
miR cDNA synthesis (200ng per sample) was performed using the miScript Reverse 
Transcriptase Mix (Qiagen). cDNA samples were diluted with 200µl of RFW after the 
incubation (one hour at 36°C and 95°C for five minutes) and stored at -80
o
C. 
2.6.3 cDNA Synthesis for target analysis 
Samples from patients (n=3; SC and OM adipose tissues and PBCs) were used for the 
target arrays analysis. β-actin was used as the house-keeping gene. Depot specific 
differnces in the expression of the target genes were also investigated in SVF samples 
(SC/OM; n=6). For cDNA systhesis 1 µg of RNA, 2µl of gDNA Wipeout Buffer (7x), 
water to a volume of 14µl, along with 6µl of the PCR master mix that contained 1µl of 
Quantiscript Reverse Transcriptase, 4µl of Quantiscript RT Buffer (5x) and 1µl of RT 
primer mix. The mixture was incubated for 15 minutes at 42°C, followed by incubation 
for three minutes at 95°C. 
2.7 Real-time PCR and Miscript Arrays 
2.7.1 RT-PCR 
Transcripts encoding various genes were measured by real-time PCR on an Applied 
Biosystems ABI7500 machine, using ABI SYBR Green master mix (Applied Biosystems, 
USA). This technique was used to analyze expression of target genes in peripheral 
blood samples and adipose tissues (subcutaneous and omenta) from PO and MHO 
samples. Specific primers were obtained from Qiagen (UK). PCR reaction conditions 
were 50°C for 2 minutes, 95°C for 15 minutes, followed by 40 cycles of 94°C for 15 
seconds, 56°C for 30 seconds and 76°C for 30 seconds. The level of β-actin in each 
sample was used to normalize for the variability in RNA quantity or differences in the 
efficiency of the reverse transcriptase reaction. Data was presented as fold change (2
-
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∆∆CT) after normalisation. 
2.7.3 miR PCR Array 
100µl of the diluted cDNA samples was used to run the Pathway specific miScript miR 
PCR Array. This protocol enables real-time PCR profiling of mature miR using miScript 
miR PCR Arrays in combination with the miScript SYBR Green PCR Kit, which contains 
the miScript Universal Primer (reverse primer) and QuantiTect SYBR Green PCR 
Master Mix. 0.5–1 ng of cDNA was added per well of the plate. After the addition of 
the master mix, the plate was sealed, centrifuged and amplified. PCR reaction conditions 
were 95°C for 15 minutes, followed by 40 cycles of 94°C for 15 seconds, 55°C for 
30 seconds and 70°C for 30 seconds (ViaVII, Applied Biosystems, USA). 
Pathway specific PCR arrays (Qiagen) were used to assess the expression of 84 key miR 
genes involved in the metabolism, differentiation and maintenance of mature adipocytes 
using real time PCR (see Table 2). Endogenous reference RNA controls were used to 
normalize the amount of target miR which is known as relative quantification. 
Normalization corrects for factors that could otherwise lead to inaccurate quantification. 
These factors include variation in quantity of input RNA, possible RNA degradation or 
presence of inhibitors in the RNA samples, and differences in sample handling. 
Normalization also allows results from different experiments and samples to be 
compared directly. MiScript PCR house-keeping genes used a panel as described in the 
array (SNORD61, SNORD68, SNORD72, SNORD95, SNORD96A, snRNA, RNU6B 
and RNU6-2). Results were analyzed as described in Section2.16. 
 
2.8 Validation of the miR Array data 
Specific miRs were selected for further validation by q-PCR as they gave significant 
results on comparison between MHO and PO, or before and after weight loss or by their 
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correlation with inflammation and IR. MiR from both peripheral blood and SVF were 
used for these validations. The following miR was chosen: miR-122, miR-29b, let7c, 
let7g, miR-124, miR-302a, miR-302-b, miR-302-c, miR-9a, miR-9b and miR-9. 
Housekeeping genes were included for normalization (see section 2.7.2). The protocol of 
the RT-PCR was described in section 2.7.1. Results were analyzed using the Qiagen on- 
line programme (see Section 2.16). 
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2.9 Target arrays 
Commercially available target arrays for miR-29 (Qiagen, UK) were used to detect 
expression of 84 hsa-miR target genes (see Table 3 ). This panel of 84 genes includes 
currently known experimentally verified and bioinformatically predicted target genes 
regulated by hsa-miR. 
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Table 3. Inflammation associated miR array 
 
The array consisted of a panel of 84 inflammatory miRs. 
 
This array also includes target genes regulated by other miRs that have the same 
seed sequence as hsa-miR-29a-3p, including hsa-miR-29b-3p and hsa-miR-29c-3p. 
A set of controls present on each array enables data analysis using the ΔΔCT method 
of relative quantification as well as assessment of reverse transcription performance, 
genomic DNA contamination, and PCR performance. 
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2.9.1 Target array PCR 
102µl of cDNA (see section 2.5.3), 1350µl of 2X RT Syber Green mastermix and 
1248µl RFW was added to each well of the miR-29 target plate (Table 4). The plate 
was sealed, centrifuged and amplified for 95°C for 10 minutes, followed by 40 cycles 
of 95°C for 15 seconds, and 60°C for 1 minute. 
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Table 4. miR-29 target genes 
 
The array (Qiagen) detected 84 genes previously examined experimentally. See 
Appendix for full gene list. 
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2.9.2 Validation of genes from the Target arrays 
Three collagen genes that were seen in the miR 29 target arrays, and have also been 
reported both by predictive software and in functional studies of adipose tissue, were 
chosen for further validation studies: COL1A, COL3A and COL6A and β-actin (house 
keeping gene). cDNA synthesis and real time PCR were performed following the protocol 
as mentioned in section 2.6 and 2.7. 
RNA samples of whole SC and OM adipose tissue (n=14; 2 MHO, 5 PO) were used. 
2.10 Small RNA sequencing – PGM 
2.10.1 Library preparation 
Libraries were prepared to analyse miR, using magnetic bead–based clean up, for the 
detecting of transcripts and changes in miRNA gene expression (Ion Torrent, Life 
Technologies; see Figure 13). 
2.10.2 Sample selection 
Samples that passed the QC checks were enriched for miRs. The miR (%) was calculated 
according to the formula:  % miR = (mass of miR ÷ mass of total RNA) × 100. 
The RNA were enriched and assessed of quality using the bio analyzer, Figure 14. 
2.10.3 Enrichment of RNA samples 
The Nucleic Acid Binding Beads were gently mixed and 7μL added to each well of the 
processing plate with 120μL of the Binding Solution Concentrate and the contents mixed 
(10 times). Total RNA (0.5–20) μg was resuspended in 75μL NFW and 75μL of each 
RNA sample (30μL of RNA+45 of NFW) transfered to the prepared processing plate. 
Absolute ethanol (105μL) was added to each well, mixed (X 10) and incubated for 5 
minutes at room temperature off the magnetic stand. The supernatant was removed from 
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the beads without disturbing the beads and transferred to a new well in the plate. 30μL of 
NFW was added to the supernatant in a new sample well. 570μL of 100% ethanol was 
added to each well, 7μL Nucleic Acid Binding beads were added to the wells of the 
processing plate and mixed 10 times. The samples were incubated for 5 minutes at room 
temperature off the magnetic stand, and then the supernatant was aspirated and 
discarded. 150μL of Wash Solution Concentrate with ethanol were added to each sample, 
and the samples were incubated for 30 seconds, aspirated and discarded from the plate, 
followed by air drying and elution in 30μL of pre-warmed (80°C) NFW (one minute). 
30μL of the eluate was collected and stored at -80°C. One μL of the purified and 
enriched small RNA sample was run on the Agilent 2100 Bioanalyzer using the Small 
RNA Kit chip to assess the quality and quantity. 
 
 
 
Figure 16. Small RNA sequencing using the PGM. Libraries were prepared using magnetic 
bead–based clean up for the detection of miRs expression. 
 
 
 RNA 
 
Library 
prep 
S
a
 
 
 
   Data 
Analysis 
 
 
1
0
 
L
o
 
 
81  
 
        Figure 17. Quality control data of samples used for small RNA sequencing. 
Three samples were selected, along with their controls, and used for NGS (shown in 
box). 
MHO (83) DM (88) PO (89) 
Control 
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2.10.4 Hybridization and ligation 
The hybridization was performed by adding 5µl of hybridization master mix (2μL of Ion 
adaptor were mixed with 3µl of hybridization solution) to 3μL of the enriched miR (1- 
100ng) and incubating after mixing at 65°C for 10 minutes followed by 16°C for 5 
minutes. Next 12µl of the ligation master mix (10µl of 2X ligation buffer and 2µl of 
ligation Enzyme mix) was added to each of the 8µl hybridization reactions. The mixture 
was centrifuged and incubated at 16°C for 2-16 hours (8 hours was the minimum time 
used). The cDNA was prepared by reverse transcriptase kit by adding 2µl of NFR with 
4µl of 10X RT buffer, 2µl of 2.5 mM of NTP mix and 8µl of ion RT primer v2. The RT 
master mix and the ligation mix were pooled, vortexed gently and incubated for 10 
minutes at 70°C and snap cooled on ice. 4µl of 10X Superscript ш Enzyme mix was 
added to the ligated mix and left at 42°C for 30 minutes. The cDNA was purified using 
the magnetic beads clean up module. Seven µl of the beads was added to each well with 
140µl of the binding solution concentrate, mixed well (10 X) and 40µl of the cDNA 
transferred into each well. 120µl of 100% ethanol was added to each well and mixed ( 10 
X), incubated for five minutes at room temperature, followed by a another incubation on 
the magnetic stand for five minutes to separate the beads. The supernatant was 
transferred to a new well in the plate to which 72µl of NFW were added, mixed with 
78µl of 100% ethanol and 7µl of beads. 150µl of wash solution concentrate with ethanol 
was added into each well on the magnetic stand for 5 minutes. The supernatant was 
discarded and the residual ethanol removed followed by air drying on the magnetic stand 
for 2 minutes. The cDNA was eluted on the stand by adding 12µl of pre-warmed RFW 
for 10 minutes at 37°C and snap coolled on ice and collected to be amplified. Six µl of 
cDNA, 45µl of PCR mix (45µl of platinum PCR Super Mix High Fidelity) and 1µl of 
barcode specific primer were mixed and incubated at 94°C for 2 min, two cycles at 94°C 
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for 30 sec, 50°C for 30 sec and 68°C 30 sec, followed by 14 cycles at 94°C for 30 sec, 
62°C for 30 sec and 68°C for 30 sec. The final cycle was for 5 minutes at 68°C. The 
amplified cDNA was purified by the magnetic beads clean up module. The yield and size 
distribution was assessed by DNA High Sensitivity kit. The molar concentration (nM) of 
each of the barcoded cDNA libraries was measured and diluted, equal volume of each 
diluted samples in the library were mixed to prepare a pool of the barcoded libraries. The 
template dilution factor was determined by the use of the final molar concentration using 
the formula: 
(Library       concentration       in       nM)       X       (5x10
9
molecules/µl)/(8.3nM)       X 
(20µl)(210x10
6
molecules). 
It was recommended that the highest quality of libraries should not be less than 50% 
amplified DNA after selecting the region of interest of miR (10-40nt). The samples used 
here were close to this recommendation and found to be acceptable. 
MiR conc (10-40nt) on Small RNA chip 1 uL)/Total RNA con from Nano Chip NG/Ul 
(1 ul)*100. 
Four samples were pooled together in an equal volume of each library to get a final 
concentration of 14pM of each diluted library. Three samples with their control were 
pooled and loaded in the PGM. 
2.10.5 PGM runs summary of the small miR samples 
miR samples from 3 patients were sequenced, (1 MHO, 1 T2DM and 1 PO – Table 5). 
The same samples were used as a replicate for the second run (83-001, 88-002, 89-003). 
The report summaries are shown in Figures 15 and 16. 
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2.11 Whole transcriptome analysis 
2.11.1 Sample selection 
PBCs samples (n=100 patients) and adipose tissue samples (n=5 patients; two depots, SC 
and OM, from which the SVF and adipocytes were isolated; total n=20 samples) were 
checked for RNA quality/quantity. The final number of samples that fulfilled the 
necessary QC for sequencing were: 25 blood samples (7MHO, 15PO and 3Diabetics) 
and 16 tissue samples (2PO and 2MHO: 2 depots of SVF and adipocytes for each depot). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5. Sample selection for miRNA sequencing. 
 
Three samples were used for the sequencing of miR gene expression. 
Samples Condition Description 
001_R2 MHO metabolically healthy obesity 
002_R2 DM diabetes mellitus 
003_R2 PO pathological obesity 
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Three samples were used, barcoded: 001 MHO, 002 T2DM and 003 PO. 
Figure 18. First run summary report of the small RNA sequencing 
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    Three samples were used, barcoded: 001 MHO, 002 T2DM and 003 PO. 
Figure 19. Second run summary report of the small RNA sequencing 
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2.11.2 rRNA depletion 
ERCC (external control) was added to each sample prior to the process of ribosomal 
RNA (rRNA) depletion. The efficiency of rRNA depletion in RiboMinus™ RNA, RNA 
degradation, and RNA concentration were analyzed using Agilent 2100 Bioanalyzer with 
the Agilent RNA 6000 Pico Kit. The RiboMinus™ Eukaryote Kit for RNA-Seq provides 
a novel and efficient method to isolate RNA molecules of the transcriptome devoid 
of large rRNA species from total RNA for transcriptome analysis. One μg of RNA 
was added gently to 100 μL of Hybridization Buffer and 10μL of RiboMinus™ Probe 
(15 pmol/μL), vortexed gently and incubated at 70–75ºC for 5 minutes to denature the 
RNA. The tubes were transferred immediately to a 37ºC water bath/heat block for 30 
minutes to promote the sequence-specific hybridization. During the cooling step, the 
RiboMinus™ Magnetic Beads bottle was vortexed and 750μL of the beads were added 
to 1.5 ml tube and placed on a magnetic separator for 1 minute. The supernatant was 
aspirated and discarded. Then 750μL of sterile NFW was added to resuspend the beads 
and placed on a separator for another 1 minute. The supernatant was discarded and the 
last step was repeated once. The beads were resuspended in 750μL Hybridization Buffer 
and 250μL transferred to a new tube and kept at 37ºC for a later stage. The remaining 
500μL of the beads were placed on a magnetic seperator for one minute where the 
supernatant was aspirated and discarded. The beads were resuspended in 200μL of 
Hybridization Buffer at 37ºC. Briefly the tube of RNA/ RiboMinus™ Probe mixture 
(after cooling at 37ºC) was centrifuged to collect the sample to the bottom of the tube. 
The sample was transferred to the prepared ribominus beads and mixed well by pippeting 
and incubated at 37ºC for 15 minutes. The samples were centrifuged and separated on a 
magentic seperator to collect the supernatant, which contains the ribominus RNA. The 
smaller RNA (low input) was concentrated using the ribominus concentration module. 
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The ribominus RNA samples were transferred into clean tubes and concentrated using 
the ethanol precipitation, to which 10μL of glycogen (20 μg/μL) was added and mixed 
with 32μL of 3M sodium acetate and 800 μL of 100% ethanol. The samples were 
incubated at -80ºC for ≥30 minutes. The tubes were centrifuged for 15 minutes at 
≥12,000 × g at 4ºC. Carefully, the supernatant was discarded without disturbing the 
pellet, and 500μL of cold 70% ethanol was added twice with a centrifugation step in 
between for 5 minutes at ≥12,000 × g at 4ºC. Finally the supernatant was removed and 
the pellet was dried completely before adding 20μL of nuclease-free water. 
2.11.3 Fragmentation 
Eight µl of depleted RNA (100-500ng) was mixed with 1µl of 10X RNase III Reaction 
Buffer and 1µl of RNase III and incubated at 37°C for 10 minutes. Immediately after the 
incubation, 20µl of NFR was added and stored on ice. The fragmented RNA was purified 
following the magnetic bead clean up module: Five µl of beads, 90µl of binding solution 
concentrate, 30µl of fragmented RNA and 150µl of 100% ethanol were mixed (10 X) 
and incubated for 5 minutes at room temperature, followed by another incubation on the 
magnetic stand for 5 minutes to separate the beads. The supernatant was discarded and 
150µl of wash solution concentrate with ethanol was added into each well on the magnetic 
stand for 5 minutes. The supernatant was discarded and the residual ethanol removed 
and air dried on the magnetic stand for 2 minutes. The fragmented RNA was eluted on 
the stand by adding 12µl of pre-warmed RFW for 10 minutes at 70° C and snap 
cooled on ice. The frangented RNA was then assessed for the concentration and size 
distribution using the 1000 PICO chip on the bioanalyser (see Figure 17). A final total 
concentration of 50-100 ng is optimal. The whole sample was vacuum dried, reconstituted 
in 3µl of RNF and stored on -80°C. 
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2.11.4 The Hybridization-Ligation-cDNA 
The hybridisation was performed by adding 5µl of hybridization master mix, (2µl of Ion 
adaptor were mixed with 3µl of hybridization solution) with 3µl of the fragmented 
sample. The mixture was iincubated at 65°C for 10 minutes and 30°C for five minutes. 
Then 12µl of the ligation master mix (10µl of 2X ligation buffer and 2µl of ligation 
Enzyme mix) was added to each 8µl of hybridization reactions. The 20µl of the ligation 
mix was incubated at 30° C for one hour. cDNA was synthesized by adding 2µl of RFW 
with 4µl of 10X RT buffer, 2µl of 2.5 mM of NTP mix and 8µl of ion RT primer v2. The 
RT master mix was incubated with the ligation mix and vortexed gently and incubated 
for 10 minutes at 70° C and snap cooled on ice. 4µl of 10X Superscript III Enzyme mix 
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Average size (100-200). 
Figure 20. The size distribution of the fragmented and purified r-depleted RNA 
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was added to the ligated mix and incubated at 42°C for 30 minutes. The cDNA was 
purified using the magnetic beads clean up module. Five µl of beads and 72µl of the 
binding solution concentrate were added and mixed (10 X). 40µl of the RT mix and 56µl 
of 100% ethanol were added to each well, mixed (10 X) and incubated for five minutes 
at room temperature, followed by a another incubation on the magnetic stand for five 
minutes to separate the beads and the supernatant discarded. 150µl of wash solution 
concentrate with ethanol was added into each well on the magnetic stand for 5 minutes. 
The supernatant was discarded and the residual ethanol was removed followed by air 
drying on the magnetic stand for 2 minutes. cDNA was eluted on the stand by adding 
12µl of pre-warmed RFW for 10 minutes at 70°C and snap cooled on ice and collected to 
be amplified. Six µl of cDNA, 47µl of the PCR mix (45µl of platinum PCR Super Mix 
High Fidelity, 1µl of Ion5 PCR Primer v2 and 1µl of Ion3 PCR Primer V2) and 1µl of 
barcode specific primer was added to the platinum master mix and incubated for 94°C 
for 2 min, two cycles at 94°C for 30 sec, 50°C for 30 sec, 68°C for 30 sec and held for 5 
minutes at 68°C. The amplified cDNA was purified by the magnetic beads clean up 
module. The yield and size distribution was assessed by DNA High Sensitivity. The 
template dilution factor was determined by the use of the final molar concentration. The 
highest quality libraries was less than 50% amplified DNA, between 25-160bp. 
2.11.5 Assess the yield and size distribution of the amplified DNA 
The molar concentration (pM) was determined using the Agielent High Sensitivity DNA 
kit as in the Figure 18. The cDNA concentration in pM was used to calculate the final 
TDF required as per the protocol to get 11pM as a final concentration for each sample. 
TDF was used to calculate the direct dilution of the final library (2µl). 
The dilution= (the final library*TDF)-final library. 
Three samples were pooled (after diluting each of them according to the formula) by 
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adding 33.3µl of each to make the total volume of three of them to 100µl, which was 
used in the Ion Touch version3. 
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The region of interest in this sample was between 160-418bp which gave 23619pM. 
Figure 21. The area of interest was selected in a region 
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2.11.6 The Ion Touch version3 
The diluted library for each sample was prepared according to the calculation and equal 
volume of each sample was mixed together to reach upto 75µl final volume (25µl each 
of three samples were mixed together), vortexed, briefly centrifuged and stored on ice. 
At room temperature 2.5ml reaction mix was prepared with the following reagents: 
 160µl of NFW 
 1200µlof Ion PI Reagent Mix TL 
 720µl of Ion PI PCR Reagent B 
 120µl of Ion PI Enzyme Mix TL 
 100µl of Ion PI ion sphere Particles V3 
 100µl of the diluted library. 
The amplification solution (2400µl) was mixed at maximum speed for 5 seconds, 
centrifuged and 800µl inserted into the port of the reaction filter assembly three times 
then inverted to be inserted into the Ion one touch 2 instrument. The positive template 
(IPS) was recovered after the run and washed with NFW two times through 
centrifugation at 15500g for 8 minutes and resuspended in ISP resuspension solution. 
The IPS was enriched with the Ion one touch ES instrument for 30 minutes, where the 8 
well strip was filled with IPS in the first well, 130µl of the Dynabeads in the second, the 
three wells with the wash solution and the 7th well with the melting off solution which 
was composed of 280µl of Tween solution (supplied) mixed with 40µl of 1 M NaOH 
(prepared). By the end of the run, The IPS was collected in a 0.2ml tube closed, 
centrifuged 15500xg for 5 minutes, washed and resuspended in NFW to be stored at 4°C 
for up to three days or proceed to sequencing. 
The Ion PI control Ion sphere particles was vortexed and centrifuged before taking 5µl to 
be added directly to the IPS where it was mixed and centrifuged for 5 minutes at 
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15500xg. The supernatant was removed carefully leaving 10µl of liquid. 15µl of ion PI 
Annealing Buffer was added followed by 20µl of Ion PI sequencing Primer and making 
the final volume up to 45µl of adding the annealing buffer. It was incubated for 95°C for 
2 minutes and 37°C for 2 minutes. After cycling, 10µl of Ion PI loading buffer was 
added, vortexed and centrifuged (ready for loading). 
The run of the samples was set up following the protocol: (Ion PI sequencing 200 kit V3 
on the Proton): 
The Instrument was cleaned, and the process of initialization started when the reagent 
bottles were filled with required volume of all reagents supplied according to the protocol. 
All the bottles were attached including 3 bottles of wash buffer and 2 bottles for 
cleaning in addition to 4 dNTPs bottles. The chip was prepared and calibrated ready for 
loading the samples. Finally it was inserted into the proton and the run started. 
2.12 Validation of the NGS by SurePrint G3 Human Gene Expression Microarrays 
With the new Human Gene Expression v2 Microarray, long intergenic non-coding RNA 
(lincRNA) probes designed to the human catalog of lincRNAs from the Broad Institute, 
along with an update of mRNA content, sourced from RefSeq, Ensembl, UniGene, and 
GenBank databases provides a full coverage of the human transcriptome. 
Eight RNA samples from PBCs that were sequenced on the Proton were sent for the 
microarrays validation by Genotypic Technology Pvt. Ltd in India. All samples were 
checked for quality and quantity and the best four samples were used for scanning (See 
Table 6; 4 samples in duplicate and Figure 19 for workflow). 
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No. ID 260/280 260/230 RNA 
Conc. 
(ng/μl) 
Total 
yield 
(ng) 
RIN QC 
conc./yield 
2 PO-122 2.1 0.6 88.9 1510.7 5.0 Optimal 
3 MHO-102 2.0 0.6 107.6 3336.8 7.5 Optimal 
4 MHO-128 2.0 0.9 152.4 2591.4 8.8 Optimal 
6 PO-48 2.1 0.8 123.9 929.1 6.6 Optimal 
Table 6. The samples were used for validation after sequencing 
 
All samples were checked for quality and quantity and the best four samples were used 
for scanning (4 in duplicate). 
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2.12.1 RNA Labelling, Amplification and Hybridization 
The samples were labelled using Agilent Quick Amp Labeling Kit one color (Part 
number: 5190-0442). 500ng of total RNA was reverse transcribed using oligodT primer 
tagged to T7 promoter sequence. cDNA thus obtained was converted to double stranded 
cDNA in the same reaction. Further the cDNA was converted to cRNA in the in-vitro 
transcription step using T7 RNA polymerase enzyme and Cy3 dye was added into the 
reaction mix. During cRNA synthesis Cy3 dye was incorporated into the newly 
synthesized strands. cRNA obtained was cleaned up using RNeasy Mini Kit (Qiagen, 
Cat No: 74106). Concentration and amount of dye incorporated was determined using 
Nanodrop. Samples that pass the QC for specific activity were taken for hybridization. 
600ng of labeled cRNA were hybridized on the array using the Hi-RPM large 
Hybridization Kit (Part No: 5190-0404; Agilent) in Sure hybridization Chambers 
(Agilent) at 65º C for 16 hours. Hybridized slides were washed using Agilent Gene 
Expression Wash Buffers Set (Part No: 5188-5327). The hybridized, washed microarray 
slides were then scanned on a G2600D scanner (Agilent Technologies) Feature 
Extraction. Data extraction from Images was done using Feature Extraction software 
Version 11.5 of Agilent. 
2.12.2 Microarray Data Analysis 
Images were quantified using Feature Extraction Software (Version-11.5 Agilent). 
Feature extracted raw data was analyzed using GeneSpring GX Version 12.0 software 
from Agilent. Normalization of the data was done in GeneSpring GX using the 75th 
percentile shift (Percentile shift normalization is a global normalization, where the 
locations of all the spot intensities in an array are adjusted. [This normalization takes 
each column in an experiment independently, and computes the percentile of the 
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expression values for this array, across all spots (where n has a range from 0-100 and 
n=75 is the median). It subtracts this value from the expression value of each entity) and 
fold expression values were obtained with respect to Specific control 
Samples].Significant genes up and down regulated showing one fold (log base2) and 
above within the samples with respect to control sample were identified. Differential 
expression patterns were identified among the samples. Differentially regulated genes 
were clustered using hierarchical clustering based on Pearson coefficient correlation 
algorithm to identify significant gene expression patterns. Genes were classified based 
on functional category and pathways using GeneSpring GX and Genotypic 
Biointerpreter-Biological Analysis Software. (Biointerpreter is a user-friendly web-based 
Biological interpretation tool developed by Genotypic Technology Private Limited, 
Bangalore). 
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The procedure was carried out as below: 
 
                                                     Template total RNA 
 
 
 
 
 
 
 
 
 
 
 
                
                   
                    
           
Figure 22. Work flow of the sample preparation and array scan 
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2.13 Runs QC and summary for NGS 
See the appendix 2 for the summary reports. 
 
2.14 Data analysis 
Results were expressed as mean ± SD or median (interquartile range), unless otherwise 
stated. Normally distributed data were compared by Student’s paried or independent t- 
test or for skewed data by Wilcoxon or Mann-Whitney U test to describe statistical 
significance. Statistical significance was assumed at the level of p values <0.05. All data 
analyses were performed with the SPSS 14.0 software package. 
2.14.1 Analysis of RNA arrays 
RNA expression was calculated either as a ratio of the house-keeping gene threshold 
cycle value (Ct) or using the 2
-ΔΔCt 
method (Livak and Schmittgen, 2001). 
The microarry data were analysed by two separate methods: 
First method: The expression of a target gene (TG) relative to the EC, the comparative Ct 
(∆∆Ct) as per the following equation was calculated: 
∆∆Ct = (Ct Target gene)-(Ct EC) – (Ct Target gene)-(Ct EC) 
The ∆∆Ct values were converted to a linear form using the formula: E –∆∆Ct. All results 
with a p<0.05 were considered statistically significant. To correct for variables, such as 
the amount of starting template and enzymatic efficiencies, RQ-PCR data is routinely 
normalised using endogenous control genes (house-keeping genes) which are highly and 
stably expressed across a sample set. The appropriate choice of endogenous control is 
critical to ensure validity and accuracy of the results generated.The data was exported 
into an excel sheet through the sabioscience website for the data nalysis. 
The analysis was carried out using the online program form Qiagen: 
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(http://www.sabiosciences.com/miRna_pcr_product/HTML/MIHS-001Z.html). 
 
Second method: The normalization of the data was performed against the housekeeping 
genes, obtaining ΔCt values, and the miR expression values were calculated as 2^ (-ΔCt). 
For  each  miR  Fold  Change  (ΔΔCt)  =  2^  (-ΔCt)_PO  /  2^(-ΔCt)_MHO.    P-value 
(Student’s t-Test) was calculated. Selected significant PO vs. MHO differentially 
expressed miRs: absolute Fold Change ≥ 2 and p-value ≤ 0.05. 
2.14.2 Analysis of small RNA Seq 
miR-seq data was processed using RandA tool (Isakov etal, 2012). Sequencing reads 
were trimmed to clip the adapter sequence and then mapped by Burrows-Wheeler 
alignment algorithm (Li and Durbin, 2009) against adatabase derived from Rfam (Burge 
etal, 2012). Differential expression was tested by a negative binomial distribution model 
for variance estimation, using the Bioconductor package DESeq (Anders and Huber et al, 
2010). 
2.14.3 Analysis of whole transcriptome data 
Whole transcriptome sequencing data (RNA-seq) was analysed to find differentially 
expressed genes. Quality control of raw sequencing data, FASTQ files, was performed 
using FastQC tool (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The 
short sequencing reads that pass the quality check were mapped to the Homo sapiens 
reference genome GRCh37/hg19 using the TopHat2 algorithm (Kim et al, 2013). The 
reads were either aligned or unaligned in this process. The unaligned reads were then 
mapped with the Bowtie2 algorithm (Langmead et al, 2012). The output BAM files from 
these two alignment processes were then merged to generate final aligned BAM for 
further downstream analysis. Mapped reads were counted using countOverlaps function 
of Bioconductor package, to measure how many reads in the sample overlap with each 
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specific gene. Gene expression was analysed through the Bioconductor package EdgeR 
(Robinson et al, 2010). Read counts were normalized for different library size and to 
account for sample-specific effects using EdgeR TMM method. Differential expression 
was determined by negative binomial exact test and significant genes were selected with 
corrected p-Value (FDR) ≤ 0.05 and absolute log2 (Fold Change) ≥ 1. 
 
2.14.4 Gene enrichment analysis 
Ingenuity Pathways Analysis (IPA, http://www.ingenuity.com/) was used to perform gene 
enrichment analysis. Gene expression data was mapped into relevant pathways based 
on their  functional  annotat ion  and known molecular  interactions .  Statistical 
significance was evaluated with Fisher’s exact test adjusted for multiple comparisons by 
the Benjamini-Hochberg method. 
 
2.14.5 miR target analysis 
Differentially expressed microRNAs were analysed to find their experimentally validated 
target genes, using the databases Ingenuity Knowledge Base 
(http://www.ingenuity.com/), miRecords (Xiao et al, 2009), TarBase (Vergoulis et al, 
2012), and their predicted targets, using TargetScan (Benjamin et al, 2005). miR 
expression and gene expression results were integrated to verify if validated or predicted 
microRNA-targets were regulated coherently with the expression of their microRNA. 
For each regulated microRNA we selected those experimentally validated or predicted 
targets that resulted differentially expressed from RNAseq data. 
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Chapter 3 
Clinical 
Stratification 
of MHO and 
PO 
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3.1 Introduction 
The prevalence of obesity has increased globally and as a consequence so has the 
associated comorbidities, such as T2DM and hypertension. These diseases pose a 
significant risk of morbidity and mortality (Hotamisligil, 2006). While 60-80% of obese 
subjects rapidly develop metabolic diseases a proportion still remain relatively healthy, 
either because the progression to disease is slower in these individuals or they have 
developed pathways that renders them immune (Stefan et al, 2008 ). Understanding the 
mediators and mechanisms for this apparent protection is imperative. Some of the 
heterogeneity in susceptibility includes gender, ethnicity and physical fitness; all of 
which have a significant impact on the early predictors of cardiometabolic disease, such 
as insulin resistance and inflammation (Stefan et al, 2008, Meigs et al, 2006; Wildman et 
al, 2008). 
3.2 Gender 
Many studies have shown that there is a difference between males and females related 
not just to the incidence of obesity, but also to the pathological consequences of being 
obese. However, emerging data suggest that this gender difference disappears in the face 
of weight gain. There is a higher prevalence of obesity in females, implying that they 
carry more of its burden, including reduced life expectancy, greater risk of obesity- 
related disease, and increased medical costs. In pre-menapausal females sex hormones 
(e.g.oestrogen) are thought to provide protection from cardiometabolic diseases. But this 
protection disappears in obesity, making both males and females at least equally 
susceptible to comorbidities. Depending on ethnicities the heterogeneity between males 
and females in the prevalence of obesity can vary from 4 to 22% (Dobbs et al, 2014, 
Figure 20). The difference between males and females in a Qatari population is relatively 
small, and may be related to the ethnic admixture, compared to, for example Egypt, 
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which has a higher gender difference in the prevlance of obesity, perhaps reflecting 
homogeneity in ethnicity. 
The reasons for these differences in predisposition to obesity associated pathologies are 
still under investigation. However, gender differences in body composition and regional 
fat deposition may be a factor. Women have a higher percentage of body fat and more 
often develop peripheral adiposity, whereas men accumulate abdominal fat. This male 
pattern of fat deposition is also seen in a proportion of overweight women. Also men, 
and post-menapausal women, tend towards more visceral fat which releases greater levels 
of FFAs and proinflammatory adipokines (Wajchenberg, 2000). It may be that these 
factors, via the portal circulation, reach the liver to induce hepatic IR and a more 
atherogenic lipid profile. Among patients with T2DM, 40% of men and upto 70% of 
women display abdominal obesity, perhaps pointing to a closer association between 
T2DM and central in women than in men (Krotkiewski et al, 1983). Females also have 
higher systemic leptin and adiponectin, perhaps reflecting both greater body fat and 
regulation by the sex hormones. 
3.1.1 Adiponectin and leptin 
Adiponectin is a hormone synthesized almost exclusively in adipose tissue and increases 
insulin sensitivity of the liver and skeletal muscle. Its synthesis is stimulated by insulin 
and PPARγ agonists, and inhibited by β-adrenergic stimulation, cytokines and androgens. 
Adiponectin levels decrease with IR and obesity, which may explain why they are 
higher in women as well in non-diabetic subjects. Low levels are a marker of IR, whereas 
high levels have been associated with reduced risk of T2DM and cardiovascular disease. 
Leptin is an adipokine that acts as a satiety factor and is involved in the regulation of 
food intake. Normal human obesity appears to be a ‘leptin resistant’ state, perhaps 
reflecting reduced signaling through leptin receptors. Leptin levels are higher in women 
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than in men, reflecting greater total percent fat mass. It is positively correlated with free 
estrogen in post-menopausal women, and with free testosterone in men. Increased leptin 
levels are associated with cardiovascular disease in men, while they may be protective in 
women. 
3.2 Ethnicity 
Ethinicity may also be a cause for the heterogeneity in the consequence of obesity. Some 
ethnicities, such as South Asians and Arabs, appear especially susceptible to obesity 
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While the prevalence was higher in women than men globally, the gender disparity 
varies significantly between countries. (Dobbs et al, 2014). 
Figure 23. The prevalence of obesity in the Arab countries 
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associated T2DM and the reasons for this warrant further study. 
3.3 Sedentary lifestyle and surgical weight loss 
Sedentory lifestyle plays a critical role in the development of metabolic disease, leading 
to chronic inflammation and MeS. Few studies have compared the efficacy of exercise 
interventions, or the benefits of various types of exercise, in men versus women. It 
appears that intensive exercise appeared to prevent T2DM in both men and women; 
however weight loss retarded the development of T2DM more effectively in men. 
However, among patients with T2DM, women were found to be more successful at 
losing weight after initiation of glucose-lowering therapy. Thus, exercise is important to 
reduce morbidity and mortality in patients with T2DM regardless of sex. 
Surgery results in greater sustained improvement in weight loss and weight associated 
comorbidities compared with non-surgical interventions, be it diet, exercise and/or 
pharmacotherapy. Some surgical procedures may result in greater weight loss and 
improvements in comorbidities than others, but outcomes were similar between RYGB 
and sleeve gastrectomy, and both of these procedures had better outcomes than 
adjustable gastric banding. These are the main procedures carried out in Qatar. However, 
adverse effects and reoperation rates were generally poorly reported and also the long- 
term effects of surgery yet unclear. 
3.4 Diagnosis of MeS 
It is obvious that the MeS is a cluster of risk factors for T2DM and cardiovascular 
disease that occurs together to a greater extent than by chance alone. However, the 
description and definition of MeS for diagnosis varies somewhat depending on what 
criteria is used. WHO, in 1999, stipulated that MeS patients should have one of 3 of the 
following: T2DM, IGT or IR, as well as, at least 2 of these: hypertension, obesity, raised 
TG/low HDL or microalbuminuria. EGIR, also in 1999, stipulated that MeS should not 
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include IGT or T2DM but have IR and 2 of the following: central obesity, raised TG/low 
HDL, hypertension or fasting plasma glucose greater than 6.1 mmol/l. More recently, in 
2001, ATP III defined MeS as having 3 or more of the following: Central obesity, raised 
TG, low HDL, hypertension and fasting plasma glucose greater than 6.1mmol/l. 
All three clasifications included obesity, suggesting that in obesity there can be those 
who were insulin sensitive and others insulin resistant. Both the WHO and EGIR need 
measures of IR but the problem is that there is no standard measurement for insulin. 
More recently hyperleptinemia and inflammation have also been included as additional 
measures of MeS, as they are occur as part of the cluster of risk factors. 
Also many of these measures have been mainly described in Caucasian populations and 
norms for all these measures in other ethnicities are still being generated. As both obesity 
and the associated diseases have a greater prevalence in non-Caucasian populations 
having robust biomarkers in these populations is important both for diagnosis and for 
treatment. 
3.5 Aims of the study were to 
1. Stratify morbidly obese Arab subjects depending on systemic biomarkers of insulin 
sensitivity and inflammation. 
2. Investigate the markers of insulin sensitivity and inflammation in obesity-matched 
Arabs and Caucasians, in the absence of type 2 diabetes. 
3. Investigate the effect of the surgical weight loss in insulin sensitive and insulin 
resistant morbidly obese Arabs. 
3.6 Methods 
The methods have been described in detail in section 2.3.1. Briefly, randomly selected 
morbidly obese patients awaiting bariatric surgery were recruited in Doha, Qatar (Hamad 
Hospital and al-Emadi hospitals) and London, UK (Whittington Hospital). The study was 
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approved by national ethics committees and all patients gave written informed consent. 
Anthropometric measurements were recorded (age, weight, height systolic and diastolic 
blood pressure). 
Fasting blood samples were used to determine glucose (hexokinase), lipids (Total 
Cholesterol, LDL and HDL: Roche) and insulin (ELISA, Mercodia). Adipokines (leptin, 
adiponectin, interleukin-6 and and MCP1) were assayed by ELISA (R&D Systems, 
Oxon, UK). 
 
Two separate calculations were to generate indicies of insulin resistance: 
HOMA1IR – Insulin (mU/L)* FBG (mmol/L) /22.5 
HOMA2IR - HOMA calculator v2.2.3. This index was also used for obtaining measures 
of β-cell function and insulin sensitivity. 
Criteria for MeS: HOMA1IR > 2.7 and HOMA2IR > 1.8. 
Startification criteria for MHO and PO. 
Subjects were considered MHO if free of T2DM, dyslipidaemia, and cardiovascular 
disease, and exhibited systolic blood pressure less than 140 mmHg, diastolic blood 
pressure less than 85mmHg, fasting plasma glucose less than 6.8 mmol/l and insulin less 
than 6.5 miU/ml. 
Based on these criteria, obese subjects of were dichotomised into MHO and PO 
accordingly. 
Data were entered in SPSS version 22.0 for statistical analysis. Parametric tests were 
used for normally distributed data and non-parametric analysis for skewed data. 
3.7 Results 
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3.7.1 Gender differences in cardiometabolic risk in Arabs 
The population was relatively young (Table 7A). Despite being BMI and age matched, 
the males had higher SBP and DBP, were relatively hyperglycaemic, with 
hyperinsulinaemia and insulin resistance, compared to females. The females had higher 
leptin that probably reflects greater fat mass, despite having similar BMI. 
The data was reanalyzed after excluding those with fasting blood glucose greater than 
6.1mmol/L (Table 7B). Despite being matched for BMI, age and glucose, both SBP and 
DBP was higher in males, along with slightly lower HDL-cholesteol. However the males 
also still remained hyperinsulinaemic and insulin resistant compared to females. Leptin 
still remained higher in the females. 
3.7.2 Differences in cardiometabolic risk in Arab MHO and PO 
There were differences between PO and MHO after they were all matched for glycemia 
(glucose less than 6.1mmol/l; Table 8) and gender (Table 9). When males and females 
were analysed together (Table 8 ) the PO had higher TG, IL-6, glucose, insulin and 
HOMA-IR, compared to the MHO. However, leptin was lower in PO compared to MHO. 
In order to exclude gender as a counfounding factor, the analysis repeated in females 
only, and this confirmed higher TG, insulin and HOMA-IR and a reduced letpin in PO 
subjects compared to MHO (Table 9). 
3.7.3 Effect of ethnicity on cardiometabolic risk factors 
The objectives of the study were to investigate markers of insulin resistance and MeS in 
obesity-matched Arabs and Caucasians, in the absence of diabetes. Basic characteristics 
of the two populations were shown in Table 1 0 . Despite the Arab cohort being 
significantly younger they were hyperglycemic and hyperinsulemic compared to the 
Caucasians. This population also had elevated β-cell function and insulin resistance, 
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while insulin sensitivity was lower. However there was no significant difference in blood 
pressure. Total-, LDL- and HDL-cholesterol were higher, but triglycerides lower, in 
Arabs. Leptin, a marker of adipose tissue mass, was elevated in Arabs. Furthermore the 
proinflammatory adipokines (MCP-1, IL-6) were higher and the anti-inflammatory 
adipokines (adiponectin) lower in this population (Table 10). 
3.7.3.1 Correlations 
Fasting Blood Glucose (FBG) significantly correlated with age (p=0.02), DBP (p=0.01) 
and with HOMA-IR with p-value < 0.01 among Arabs, while a negative correlation was 
found with %B (Betacell Function %) and %S (Insulin sensitivity %). TG also correlated 
with fasting blood sugar (p=0.04) and with adipokines, leptin (p<0.001). 
On the other hand FBG among the Caucasian cohort correlated with insulin (p=0.06), 
HOMA-IR (p=0.01) and IL-6 (p=0.02) and negatively with %B (p<0.001), %S (p=0.01) 
and MCP1 (p=0.03).  As expected, insulin correlated with HOMA, %B and IR (p<0.01) 
and negatively correlated with %S (p<0.01) in both cohorts. It also correlated with DBP 
among Arabs (p=0.017) and with FBG (p=0.058) among Caucasians. 
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Characteristics Males Females p-value 
N 24 58  
Age (years) 32.0 ± 8.1 33.8 ± 9.6 0.40 
BMI (kg.m
-2
) 45.5 ± 5.6 45.2 ± 14.3 0.90 
SBP (mmHg) 132.0 ± 13.2 121.5 ± 14.1 0.001 
DBP (mmHg) 78.1 ± 14.7 71.6 ± 9.8 0.05 
Cholesterol (mmol/L) 4.6 ± 1.2 4.5 ± 1.0 0.96 
LDL (mmol/L) 2.9 ± 0.9 2.9 ± 0.7 0.57 
HDLC (mmol/L) 1.1 ± 0.3 1.3 ± 0.3 0.21 
Triglyceride (mmol/L) 1.4 (0.9-1.8) 1.2 (0.8-1.5) 0.22 
Interleukin-6 (pg/ml) 3.3 (1.9 – 6.0) 3.8 (2.2 - 5.7) 0.54 
MCP1 (pg/ml) 216.63(122.9-301.5) 220.0 (179.0-297.0) 0.55 
Leptin (ng/ml) 49.4 (33.7-70.5) 72.9 (52.0-96.5) 0.001 
Adiponectin (μg/ml) 2.5 (2.4-3.9) 3.1 (2.4-4.8) 0.65 
Plasma Glucose (mmol/L) 7.2 ± 3.2 5.8 ± 1.4 0.05 
Insulin  (mU/L) 17.9 (10.1-26.5) 11.6 (7.4-18.3) 0.04 
HOMA 5.4 (2.9-7.7) 2.9 (1.6-4.6) 0.003 
 
Table 7A. Gender differences in cardiometabolic risk factors in the whole cohort 
 
Data shown as mean ± SD or median (interquartile range). Comparisons were performed 
using t test or Wilcoxon test as appropriate. Significance was defined as P≤ 0.05. 
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Characteristics Males Females p-value 
N 11 44  
Age (years) 29 ± 7.5 32 ± 9.4 0.27 
BMI (kg.m
-2
) 45.7 ± 6.5 42.9 ± 6.9 0.23 
SBP (mmHg) 137.0 ± 11.4 122.0 ± 14.5 0.001 
DBP (mmHg) 79.8 ± 15.7 70.4 ± 8.4 0.001 
Cholesterol (mmol/L) 4.9 ± 0.8 4.6 ± 0.8 0.35 
LDL (mmol/L) 2.9 ± 1.1 2.8 ± 0.7 0.66 
HDLC (mmol/L) 1.1 ± 0.2 1.3 ± 0.3 0.07 
Triglyceride (mmol/L) 1.4 (0.9-1.8) 1.0 (0.7-1.5) 0.11 
Interleukin-6 (pg/ml) 3.3 (2.3-6.5) 3.7 (2.1-5.3) 0.76 
MCP1 (pg/ml) 261.4 (135.4-308.8) 220.0 (183.0-295.5) 0.83 
Leptin (ng/ml) 49.0 (38.6-81.1) 74.0 (52.7-96.8) 0.06 
Adiponectin (μg/ml) 2.5 (2.4-5.3) 3.7 (2.4-5.0) 0.92 
Fasting Plasma Glucose 
(mmol/L) 
 
5.2 ± 0.6 
 
5.1 ± 0.7 
 
0.92 
Insulin  (mU/L) 16.9 (13.2-28.1) 11.2 (7.4-16.2) 0.01 
HOMA 3.9 (3.0-6.5) 2.6 (1.5-3.8) 0.008 
 
Table 7B. Gender differences in cardiometabolic risk factors- matched for glycemia 
 
All glucose less than 6.1mmol/l. Data presented as mean ± SD or median (interquartile 
range). Comparisons were performed using t test or Wilcoxon test as appropriate. 
Significance was defined as P≤ 0.05. 
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Characteristics MHO PO p-value 
N 24 30  
Age (years) 32.8 ± 9.9 31.1 ± 8.6 0.50 
BMI (kg.m
-2
) 42.5 ± 6.1 44.2 ± 7.5 0.38 
SBP (mmHg) 123.8 ± 14.4 126.0 ± 15.8 0.61 
DBP (mmHg) 70.2 ± 7.7 74.0 ± 12.6 0.17 
Cholesterol (mmol/L) 4.6 ± 0.7 4.7 ± 0.9 0.83 
LDL (mmol/L) 2.8 ± 0.7 2.9 ± 0.9 0.69 
HDLC (mmol/L) 1.3 ± 0.3 1.2 ± 0.3 0.32 
Triglyceride (mmol/L) 0.99 (0.75-1.3) 1.4 (0.87-1.8) 0.02 
Interleukin-6 (pg/ml) 3.1 (1.78-5.0) 3.7 (2.6-6.0) 0.06 
 
MCP1 (pg/ml) 
198.0 (149.5- 
275.0) 
 
250.2 (185.8-303.7) 
 
0.16 
Leptin (ng/ml) 80.9 (54.7-98.4) 54.0 (46.8-81.1) 0.04 
Adiponectin (μg/ml) 3.8 (2.5-5) 2.8 (2.4-4.97) 0.83 
Plasma Glucose (mmol/L) 4.8 ± 0.6 5.4 ± 0.7 0.001 
Insulin  (mU/L) 7.4 (6.5-10.0) 15.8 (13.5-27.2) 0.001 
HOMA 1.6 (1.2-2.2) 4.0 (3.1-6.4) 0.001 
 
Table 8. Characteristics of Arab MHO and PO subjects 
 
All matched for glucose less than 6.1 mmol/L. Data presented as mean ± SD or median 
(interquartile range). Comparisons were performed using t test or Wilcoxon test as 
appropriate. Significance was defined as P≤ 0.05). 
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Characteristics MHO PO p-value 
N 22 22  
Age (years) 33.5 ± 10.1 31.1 ± 8.8 0.50 
BMI (kg.m 
-2
) 42.8 ± 6.2 43.0 ± 7.8 0.92 
SBP (mmHg) 122.8 ± 14.5 121.0 ± 149.0 0.75 
DBP (mmHg) 69.5 ± 7.6 71.4  ± 9.2 0.45 
Cholesterol (mmol/L) 4.6 ± 0.7 4.6 ± 1.0 0.75 
LDL (mmol/L) 2.8 ± 0.7 2.8 ± 0.8 0.90 
HDLC (mmol/L) 1.3 ± 0.3 1.2 ± 0.4 0.54 
Triglyceride (mmol/L) 1.0 (0.7-1.3) 1.5 (0.7-1.8) 0.03 
Interleukin-6 (pg/ml) 3.7 (1.6-5.0) 3.7 (2.3-5.9) 0.20 
MCP1 (pg/ml) 210.0 (165.0-288.0) 236.0 (183.6-299.0) 0.47 
Leptin (ng/ml) 86.0 (68.0-99.0) 64.0 (49.4-81.5) 0.02 
Adiponectin (μg/ml) 3.7 (2.2-5.5) 3.4 (2.3-4.8) 0.97 
Plasma Glucose (mmol/L) 4.8 ± 0.6 5.4 ± 0.7 0.002 
Insulin  (mU/L) 7.4 (6.1-9.3) 16.0 (13.5-23.1) 0.001 
HOMA 1.56 (1.16-2.1) 3.7 (3.0-5.7) 0.001 
 
Table 9. Characteristics of female Arab MHO and PO subjects 
 
All females and matched for glucose less than 6.1 mmol/L. Data presented as mean ± SD 
or median (interquartile range). Comparisons were performed using t test or Wilcoxon 
test as appropriate. Significance was defined as P≤ 0.05.). 
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Characteristics 
N 
Arabs 
79 
Caucasians 
75 
p-value 
Age (years) 33.0 (9.2) 41.4 (10.6) <0.001 
BMI (kg/m
2
) 45.2 (12.5) 43.7 (9.3) 0.41 
Systolic BP (mmHg) 124.0 (14.0) 129.0 (18.0) 0.15 
Diastolic BP(mmHg) 74.0 (11.0) 76.0 (11.0) 0.14 
Plasma Glucose (mmol/L) 5.9 (1.4) 5.3 (0.9) 0.001 
Insulin (mU/L) 13.2 (7.5-20.2) 7.3 (5.2-12.7) <0.001 
HOMA-1IR 3.1 (2.0-5.9) 1.7 (1.2-2.9) <0.001 
Betacell Function (%) 111 (75-153) 89 (64-128) 0.04 
Insulin sensitivity (%) 57 (37-104) 105 (63-147) <0.001 
HOMA-2IR 1.7 (1.0-2.7) 1.0 (0.7-1.6) 0.001 
Total-Chol (mmol/L) 4.6 (1.1) 4.2 (1.1) 0.04 
LDL-Chol (mmol/L) 2.9 (0.8) 2.5 (1.1) 0.02 
HDL-Chol (mmol/L) 1.2 (0.3) 1.0 (0.3) <0.001 
Triglycerides (mmol/L) 1.3 (0.9-1.6) 1.4 (1.0-1.9) 0.02 
Interleukin-6 (pg/ml) 3.8 (2.1-5.8) 2.3 (1.5-4.1) 0.001 
MCP-1 (pg/ml) 220.6 (174.7-300.0) 132.7 (90.8-143.4) <0.001 
Leptin (ng/mL) 66.8 (49.8-90.8) 34.9 (21.4-67.9) <0.001 
Adiponectin (µg/mL) 2.9 (2.4-4.5) 4.3 (2.2-8.2) 0.06 
Table 10. Comparison of basic characteristics of the Arab and Caucasian cohorts 
Data are shown as mean (±SD) or median (interquartile range). 
Insulin and TG significantly correlated in both cohorts (p=0.01 for Arabs and p<0.01 
among Caucasians). There was a correlation between HOMA and TG in both cohorts: 
(p=0.01 among Arabs and p<0.01 in Caucasians). 
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In Arabs b-cell function correlated positively with FBG, insulin, HOMA-IR (p<0.01) and 
leptin (p=0.03), and negatively with age (p<0.01). 
Among the Caucasian cohort, %B negatively correlated with FBG (p<0.01), %S 
(p<0.01), HDLC (p=0.03) and adiponectin (p<0.01). While a positive correlation of %B 
was apparent with insulin, HOMA-IR, TG (p<0.01) and MCP1 (p=0.01). 
 
Insulin sensitivity negatively correlated with FBG, insulin, %B, HOMA-IR and TG 
(p<0.01) among Arabs and Caucasians while only Arabs showed negative correlation 
with DBP. The Caucasian cohort also revealed a correlation with Adiponectin (p<0.01). 
 
In only the Arabs HOMA-IR showed significant correlation with SBP (p=0.04), DBP 
(p<0.01) and IL-6 (p=0.07). 
 
Using either criteria of Metabolic Syndrome (MeS) (HOMA1-IR > 2.70 and HOMA- 
2IR> 1.8) the prevalence of MeS in Arabs was higher compared to Caucasians. Sixty two 
percent (62%) of the Arab study population (n=51) exhibited MeS according to 
HOMA1-IR while 51% (n=42) did so by HOMA-2IR. Twenty nine percent (29%) of the 
Caucasian patients (n=23) had MeS by HOMA1-IR and 21% (n=17) using HOMA-2IR. 
These data suggest a greater prevalence of MeS in the study population, which may 
preceed the development of cardiovascular disease leading to an earlier age of onset in 
the Arab population (Table 11). 
3.7.4 Comparison of effects of surgical weight loss in MHO and PO groups 
Three months after surgery there was a significant reduction in BMI, as expected, and 
this was associated with reduction in insulin, HOMA and leptin (Figure 21 and Figure 
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22). There was no change in total-, LDL- and HDL-cholesterol, whereas triglycerides 
were reduced after the weight loss. The inflammatory biomarkers CRP and IL-6 were 
also unchanged (Figure 22). 
 
 
 
 
 
 
 
 
 
Arabs MeS out of 82 Caucasians MeS out of 79 
 
 
 
 
N MeS (%) N MeS (%) 
 
 
 
HOMA-1IR 51 62.2 23  29.0 
 
 
 
HOMA-2IR 42 51.2 17  21.5 
 
 
 
 
Table 11. MeS in Arabs and Caucasians 
Arabs had significantly higher MeS (%) using either meseaurements IR: HOMA-1IR or 
HOMA-2IR. 
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Three months after surgery there was no change in fasting blood glucose (FBG), but 
significant reduction in insulin and HOMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight loss led to lower leptin but no change in plasma triacylglycerides (TAG), 
adiponectin or inflammatory biomarkers (IL-6). 
Figure 24. Glucose and insulin parameters after weight loss 
Figure 25. Adipokines after weight loss 
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3.8 Discussion 
Effect of gender. Morbidly obese Arab males had significantly higher systolic and 
diastolic higher blood pressure, compared to females. Furthermore they were also more 
hyperinsulinaemic and insulin resistant. As both the men and women in this population 
were relatively young a possible explanation for the greater BP and IR in the men may 
be attributed to greater levels of smoking and perhaps alcohol consumption. Only leptin, 
perhaps indicating greater fat mass, was higher in the females. 
 
Differences in insulin sensitivity. MHO showed, as expected, lower levels of insulin 
and HOMA-IR, as well as triglycerides compared to PO. They also had lower fasting 
plasma glucose. In order to determine whether increased FPG may be driving these 
associations, analysis was repeated after matching for hyperglycemia, which confirmed 
prior observation of increased TG, insulin and HOMA-IR independent of FPG. Surprisigly 
the PO groups had lower leptin.  Leptin may be a marker for hypertrophied adipocytes 
and in Caucasian populations this has been reported to be elevated in the PO (Makki et 
al, 2013). A possible explanation for low levels of leptin in the PO may be that these 
individuals have elevated SNS activation which directly inhibits adipose leptin 
production (Pinkney et al, 1998). 
 
Effect of Ethinicity. In non-diabetic Arabs, compared to Caucasians, insulin resistance 
and inflammation appeared to be predominant lesions. Despite both populations being 
equally obese the Arabs had greater prevalence of risk factors for MeS, with fewer 
having a metabolically healthy phenotype. The young age at which Arab subjects were 
showing signs of MeS may be due to earlier onset of obesity, perhaps the reason for 
greater disease susceptibility, perhaps a consequence of sedentary life-style and 
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unhealthy diet. 
 
Effect of weight loss. Three months after surgery, both MHO and PO subjects showed 
significant reduction in BMI, which was accompanied by lower systemic insulin, 
HOMA-IR and leptin. 
 
These findings have driven the plan of the project to look at other factors, e.g, miRs, 
which may be important regulators of pathways leading to inflammation and insulin 
resistance. MiRs are remarkably stable, reproducible, and tissue specific among 
individuals. Several studies suggested the potential use of the blood miRs as biomarkers 
for the obesity, cardiovascular diseases, atherosclerosis, and T2DM. 
Therefore, a better understanding of the function of miRs may provide new insights into 
the molecular basis of human pathologies, and act as novel biomarkers for disease 
diagnosis and therapy. In the next chapter samples generated in the MHO and PO patients 
were used to investigate circulating miR signatures as possible biomarkers and mediators 
of systemic diseases. 
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Chapter 4 
Small RNA 
Signature for 
MHO 
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4.1 Introduction 
The association between IR and inflammation is well documented (Lumeng, 2011), 
however the mediators of this association are still under investigation. A caveat to 
uncovering the nature of this association is that it is likely to be different depending on 
various factors, including age, gender, ethnicity and body composition. Thus, the 
mediators of this association may be specific for clinically defined groups of patients or 
even to individuals. This poses a challenge when trying to identity candidates that could 
underpin the association between IR and inflammation. 
4.2 MiR in insulin responsive tissues 
The discovery of circulating miRs has highlighted their potential as both endocrine 
signalling molecules and disease markers. Several candidate miRs that are highly 
expressed in insulin responsive tissues and regulate pathways that lead to IR and 
inflammation have been reported. Some of these are discussed below. 
In the liver, miR-122 is the most abundantly expressed miR and it appears to bind to the 
3 untranslated region of PTP1B (PTPN1) mRNA, which has an important role in insulin 
resistance and in non-alcoholic fatty liver disease (NAFLD); (Elchebly, et al 1999). The 
role of miR-122 in lowering circulating cholesterol has been described by some studies 
(Elmen et al. 2008). Additionally in the liver miR-33a and miR-33b are SREBP gene 
regulators and control cholesterol and lipid homeostasis (Gerin et al. 2010). 
In SMCs, miR-143 and miR-145 are expressed control blood pressure and vascular tone, 
and contribute to vascular remodelling. In addition in these cells miR-21 is induced after 
vascular injury and promotes proliferation and neointima formation. Also erythroid cell 
proliferation and differentiation is mediated by miR-451 (Eric et al. 2011). 
In adipose tissue, several miRs appear to participate in the regulation of adipogenesis 
(Figure 23). For example, miR-27a inhibits adipocyte differentiation by suppressing 
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PPARγ expression. The down-regulation of miR-27a may also be associated with 
adipose tissue dysregulation in obesity, a strong risk factor for osteoarthritis (Kim et 
al.2010). 
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A. Repression, B. Activation. (Moon et al, 2004). 
Figure 26. The role of different miRs in adipogenesis 
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More recently miRs in plasma have also been shown to be related to T2DM and IR. 
Zampetaki et al. reported lower plasma levels of miR-20b, miR-21, miR-24, miR-15a, 
miR-126, miR-191, miR-197, miR-223, miR-320, and miR-486 and an increase in miR- 
28-3p in samples from diabetic patients compared to non-diabetic subjects. Interestingly, 
the expression of miR-15a, miR-28-3p, miR-126, miR-223 and miR-320 was altered 
before the disease was manifested clinically. This was the first demonstration of a unique 
diabetic miR blood signature (Zampetaki et al, 2010). 
Another miR, miR-29a, may target apoptosis through the regulation of several 
components of the mitochondrial outer membrane, including MCL1, PUMA and other 
members of the Bcl2 family of proteins (Guptaet al, 2014). The study also included the 
voltage-dependant anion channels 1 and 2 (VDAC1and VDAC2) as targets of miR-29a 
during apoptosis. MiR-29 may also regulate fibrosis in cardiac tissue (Bargaje et al, 
2012). However, reduction of miR29 expression in several myeloid cancers and its 
ability to cause AML in a mouse model suggests an anti-apoptotic role (Rabinowits et al. 
2009). Reduced expression of miR-29a was also associated with cell death in neuronal 
cells (Kole et al. 2011). 
 
The previous chapter recorded the clinical characterestics of patients with varying levels 
of IR, despite being age and BMI matched. It showed that inflammation and IR were the 
most likely mediators of any future development of T2DM and CVD. In view of the 
reported miRs in other tissues, and the samples generated previously, this chapter 
specifically explored a panel of inflammatory miRs and their relationship with 
biomarkers of IR and inflammation. 
4.3 Specific aims of the study 
1. Explore the differences in inflammatory miRs between the PO and MHO group using 
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an inflammatory pathway specific panel in the blood and adipose tissue. 
2. Validate the miRs identified by the arrays 
3. Validate the expression of miRs seen in the inflammatory pathway specific arrays 
using small RNA sequencing. 
4. Experimental validation of selected miR targets. 
5. Examine the effect of the weight loss on inflammatory miR expression. 
4.4 Methods 
Detailed methodologies have been provided in Chapter 2, sections 2.6, and 2.7. 
Samples used. Blood, whole adipose tissue and collagenase digested tissue (SVF and 
adipocytes). 
Thirty three patients were studied, 24 prior to weight loss and 9 after weight reduction 
surgery.  
The pathway specific arrays were carried out in the blood samples of PO (n=14) and 
MHO (n=10). The effect of weight loss was investigated in PBCs of nine patients. 
In addition SC and OM adipose tissues (n=5) were also used for these analysis. 14 
RNA samples of whole adipose tissue SC and OM (2 MHO, 5 PO) were used to look 
at the variation between the groups in the level of collagen genes, which are miR-29 target 
genes, that was found to be significantly downregulated in the PO group compared to 
the MHO in blood and adipose tissue. Three PBCs samples were used for the small 
RNA sequencing (MHO=1, PO=1 and T2DM=1).  
 
The inflammatory specific pathway array (Qiagen) used was able to assess the 
expression of 84 key miR genes. 
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First method of data analysis (SA Biosciences): Real-time PCR for Miscript Arrays 
was done (chapter 2 section 2.12) to analyze expression of genes in peripheral blood 
samples and adipose tissues (subcutaneous and omenta) from PO and MHO samples. 
Data were presented as fold change (2
-∆∆CT) after normalization, using the Sabioscience 
Software online. These analyses were done at ADLQ. 
 
Second method of data analysis (QCRI): In addition to the Sabioscience software 
analysis, the miR array data analysis was also performed using an R-based in-house tool. 
Raw data, Ct values, was normalized against the housekeeping genes to obtain ΔCt 
values, and the miR expression was calculated as 2^(-ΔCt). Differentially expressed 
microRNAs were selected by ΔΔCt. Fold Change ≥ 2 and their statistical significance 
was determined by Student’s t-Test (p-Value ≤ 0.05). These analyses were done by Dr 
Michele Ceccarelli (QCRI; Qatar Computing Research Institute, Doha, Qatar) and Dr 
Fulvio d’Angelo (Biogem, Italy). 
 
Ingenuity Pathways Analysis (IPA, http://www.ingenuity.com/) was used to perform 
gene enrichment analysis. Gene expression data was mapped into relevant pathways 
based on their functional annotation and known molecular interactions. Statistical 
significance was evaluated with Fisher’s exact test adjusted for multiple comparisons by 
the Benjamini-Hochberg method. 
4.5 Results 
The inflammatory miR array was able to detect 84 different miR associated with targets 
that are in pathways that regulate inflammation. In all the samples at least 40% of the 
miRs in the panel were significantly detectable. 
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4.5.1 Effect of IR on inflammatory miR expression in PBCs (analysed by SA 
Biosciences programme). 
The comparison of the differences in the expression of miRs between the PO group 
(n=14) to the control group MHO (n=10); showed the significant down regulation of 12 
miRs (miR-142, miR-16, miR-185, miR-24, miR-15, miR-28, miR-29b, miR-19b, miR- 
374a, miR-195, miR-130a and miR-144; Figure 24). 
4.5.1.1 Correlation of miR expression and systemic cardiometabolic risk factors 
The correlation between the systemic biomarkers and the inflammatory miRs was 
examined. The heat map (Figure 25) showed that the majority of miRs in this array were 
increased in association with the classic inflammatory markers, MCP-1 and CRP. There 
was also a smaller cohort of the miRs that correlated positively with systemic nsulin 
levels and HOMA, e.g: miR-122, miR-302a, miR-200c. Interestingly, miR-200c which 
is reproted to enhance adipogenesis was upregulated in PO and correlated positively with 
insulin and negatively with leptin. MiR-200c, which decreased after weight loss, was 
related to lower levels of insulin. 
Overall, the correlation studies indicated a unique inflammatory signature that may be 
functional. It was apparent that significant differences in expression of the miRs species 
occur along with changes in metabolic and inflammatory parameters in the two groups 
studied. 
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12 miRs were down regulated in the PO (n=14) compared to the control group (MHO, 
n= 10), normalised to 1. Downregulated miRs: miR-142, miR-16, miR-185, miR-24, 
miR-15, miR-28, miR-29b, miR-19b, miR-374a, miR-195, miR-130a and miR-144. 
Data presented as fold change. (2
-∆∆CT) after normalization using the Sabioscience 
Software. 
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Figure 27. Effect of insulin resistance on miRs expression (SA Biosciences) 
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The positive correlation are in a red color while negative correlations are in blue. 
Three miRs (miR-122, miR-302a, and miR-200c) were positively correlated with 
insulin, glucose and HOMA. 
Figure 28. Correlations between miRs and systemic biomarkers 
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4.5.1.2 Inflammatory array data analysed by R-based in-house programme (QCRI) 
The miR array data generated was analysed separately (QCRI) by a more stringent 
programme using a different algorhythm to that of SA Biosciences programme. 
This generated only 3 miRs that were significantly down regulated in the PO compared 
to MHO: miR-144, miR-29b and miR-374a (Figure 26). However, of note is that these 
three miRs were also present in the SABiosciences analysis. 
 
 
 
 
 
3 miRs were down regulated in the PO (n=14) compared to the control group (MHO, n= 
10). Downregulated miRs: miR-29b, miR-374a and miR-144. The extent of the 
reduction in the PO samples compared to MHO is shown as a percent. 
 
 
 
 
 
 
 
 
hsa-miR-29b-3p 
-26% 
 
 
 
hsa-miR-144-3p 
-50% 
 
hsa-miR-374a-5p 
-24% 
Figure 29. Effect of insulin resistance on miRs expression (QCRI) 
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The miR array data from the abdominal SC and OM adipose tissue samples were then 
analysed using the QCRI programme. 
4.5.2 MiRs gene expression in OM adipose tissue (QCRI) 
Comparison of the expression of miRs in OM adipose tissue of the PO compared to 
MHO samples showed down regulation, to varying degress, of 7 miRs; miRs 101, 42, 
15a, 376c, 424, 27a and 20a (Figure 27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7miRs were reduced in the PO (n=4) compared to MHO (n=1) OM adipose tissue. The 
extent of the reduction in the PO samples compared to MHO is shown as a percent. 
hsa-miR-20a-5p 
-10% 
hsa-miR-101-3p 
-20% 
hsa-miR-27a-3p 
-11% 
hsa-miR-424-5p 
-10% hsa-miR-142-3p 
-15% 
hsa-miR-376c- 
3p 
-25% 
hsa-miR- 
15a-5p 
-9% 
Figure 30. Effect of IR on miR expression in the OM adipose tissue 
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4.5.3 MiRs gene expression in SC adipose tissue (QCRI) 
Only two miRs were downregulated in the SC adipose tissue of the PO compared to the 
MHO, miR-29 and miR-142 (Figure 28). 
 
 
 
 
 
 
2 miRs, 29b and 142, were reduced in the PO (n=4) compared to MHO (n=1) OM 
adipose tissue. The extent of the reduction in the PO samples compared to MHO is 
shown as a percent. 
hsa-miR-29b-3p 
-43% 
 
hsa-miR-142-5p 
-57% 
Figure 31. Effect of IR on miR expression in the SC Adipose tissue 
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4.5.4 MiRs gene expression in Adipocytes (QCRI) 
Three miRs, 126, 194 1nd 376, were downregulated in adipocytes of PO compared to 
MHO (Figure 29). miR-376c was strongly expressed in these cells. 
 
 
 
 
 
 
3 miRs; 126, 376 and 194, were reduced in the PO compared to MHO adipocytes. The 
adipocytes from the OM and SC were analysed together. The extent of the reduction in 
the PO samples compared to MHO is shown as a percent. 
hsa-miR-194-5p
-23%
hsa-miR-376c-3p
-53%
hsa-miR-126-3p
-22%
Figure 32. Effect of IR on miR expression in the adipocytes 
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4.5.5 Validation of the inflammatory miR array 
MiR expression data from the array experiments must be validated because the 
oligonucleotide probes not only bind to the mature miR but also pre-miR, with only the 
mature miR being of biological relevance. 
4.5.5.1 Validation of circulating miRs 
Nine miRs were selected for validation in PBCs: miR-122, miR-29b, miR-124, miR- 
302a, miR-302b, miR-302c, miR-19a, miR-19b and miR-9. Housekeeping genes were 
included for normalization (e.g: SNORD-68, SNORD-96, and RUN-6). The expression 
of miRs were investigated in PO (n=10) and MHO (n=5). 
 
All of the miRs were down-regulated (except for miR-124) in PO compared to MHO. 
Three key miRs that have been implicated in tissue fibrosis and angiogenesis showed 
difference in gene expression between MHO and PO, miR-29b, miR-122 and miR-19b. 
All were down regulated in PO. 
The data confirmed the difference in the expression of selected miRs (miR-122, miR- 
29b, miR-124, miR-302a, miR-302b, miR-302c, miR-19a, miR-19b and miR-9) 
between MHO and PO. 
MiR-302a (p=0.007) showed a significant downregulation that confirmed the differences 
between the two groups. MiR-29 was also downregulated and showed the difference 
clearly between the groups (p=0.06, Figure 30). 
Therefore the qPCR data validated the differences in the expression of the selected miRs 
seen with the pathway specific array in the MHO and PO cross-sectional study. 
4.5.5.2 Validation of miRs in SVF samples 
Selected miRs were used for validation of the miR array data in SVF samples from SC 
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and OM adipose tissue (n=5 patients, 10 samples), specifically: (miR-122, miR-29b, 
miR-124, let7c, let7g, miR-302c, miR-19a, miR-19b and miR-9). There was a non- 
significant upregulation of miR-29 and downregulation of miR-122 and let7c
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MHO was the control and set at 1. All the selected miRs showed downward trends but 
only miR-302a reached statistical significance, while miR-124 was significantly 
upregulated. 
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Figure 33. Validation of the miR array data by q-PCR in PBCs 
140  
4.5.6 Small RNA sequencing of PBCs 
The main aim of sequencing miRs samples was to validate the findings and data outcome 
of the specific miRs found in the blood and the adipose tissue samples using the 
inflammatory pathway specific array. Further it could also help discover some other 
miRs which were not present in the arrays. One of the limitations of microarray 
expression profiling was the requirement of prior sequence information to be used for 
probe design. Until recently, this sequence information has been limited mostly to that 
found in public databases. In contrast, deep sequencing is not dependent on any prior 
sequence information. Instead it provides unbiased information about all RNA species in 
a given sample, thus allowing for discovery of novel miRs or other types of small RNAs. 
Next generation sequencing utilises massively parallel sequencing, generating millions 
of small RNA sequence reads from a sample. 
Three samples were sequenced by PGM (chapter 2); one PO and one T2DM sample 
compared to an MHO sample as control. The results summary is shown in Figure 31 and 
32. 
The data from the T2DM patient was not further analysed as all other measurements 
were only available for the MHO and PO cohorts. 
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A, showed the cluster map to illustrate the variation in gene expression between the 
samples used. 
Figure 34. Summary of miR expression in MHO, PO and T2DM 
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B, showed trends in miR expression in PO and the T2DM compared to MHO. 66 miRs 
in the PO, and 67 miRs in the T2DM, blood samples, were upregulated compared to the 
MHO. 
Also 9 miRs in the PO, and 6 miRs in the T2DM, blood samples, were downregulated 
compared to the MHO. 
Figure 35. Summary of miR expression in MHO, PO and T2DM 
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4.5.6.1 The miRs expression profile in IR using NGS 
Two runs were performed for the same samples PO (n=1) versus MHO (n=1) as explained 
in chapter 2. 
Among these miRs, miR-27b miR-29a, miR-144 and miR-3607 were downregulated in the 
PO by NGS. miR-144 is a direct modulator of IRS1 and a potential therapeutic target of 
IR. MiR-29a targets Akt2 as well as components of the fibrotic pathway. A few novel miRs were 
found to be expressed highly, like miR-27b and miR-3607, which also targets IRS-1 (Figure 
36).  
 
Downregulation of miRs in PO compared to MHO (n=1 each). Shown as fold change. 
miR-144 and miR29 were previously identified in the inflammatory array. 
 
hsa-miR-3607-
5p
-33%
hsa-miR-144-
5p
-3%
hsa-miR-27b-
3p
-51%
hsa-miR-29a-
3p
-7%
hsa-miR-320d
-4%
hsa-miR-194-
5p
-2%
Figure 36. Down regulation of miR by IR - identified by small RNA seq. 
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The NGS data showed the upregulation of three main miRs, which were also highly 
expressed, in the PO: miR-181, miR-29b and miR-30e. Several other species were 
upregulated, but to a lesser extent (Figure 37). 
 
 
 
 
 
 
PO (n=1) versus MHO (n=1). miR-181a, and to a lesser extent, miR 29b and miR 30e were 
upregulated in the PO sample. 
Figure 37 Upregulation of miR by IR - identified by small RNA seq. 
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4.5.7 The predicted target genes of miRs 
Using the data from the inflammatory pathway specific analysis, the qPCR validation 
and NGS the differentially expressed microRNAs, miR-29, miR-144 and miR-374a, 
were investigated further to find their experimentally validated target genes, using various 
databases: Ingenuity Knowledge Base (http://www.ingenuity.com/), miRecords (Xiao 
et al. 2009), TarBase (Vergoulis et al. 2012), and their predicted targets, using 
TargetScan (Lewis 2005). MiR expression and target gene expression results were 
integrated to verify if validated or predicted microRNA-targets were regulated 
coherently. 
 
The data analysis of selected significant differentially expressed genes: 
* PO / MHO absolute log2 Fold Change ≥ 1 
* corrected p-Value (FDR) ≤ 0.05 
 
4.5.7.1 The functional expression of miR-29 target genes 
There were significant effects on the targets of miR-29.e.g: COL1A1, COL1A2 and 
COL3A1, which was highly expressed and control atherosclerosis signalling, and are 
mostly involved in the regulation of fibrosis (Figure 38). In addition other collagen genes 
have also been shown to be involved in hepatic fibrosis like COL6A6 COL5A6 and 
HSPG2. HSPG2 inhibits angiogenesis by TSP1 inhibition of matrix metalloproteases. 
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Data showed significant effects on the targets of miR-29.e.g: COL1A1, COL1A2 and 
COL3A1. COL3A1 is highly expressed and and regulates signalling during 
atherosclerosis; (Madrigal-Matute et al, 2013). 
Figure 38. The functional expression of miR-29 target genes 
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4.5.7.2 The functional expression of miR-144 target genes 
The functional targets for miR-144 also included genes regulating fibrosis such as FBN1, 
COL4A1 and PCDH18, as well as components of the insulin signalling pathway such as  FZD4 
and IGFBP5 (Figure 39). 
 
 
All of the targets were significantly downregulated. PCDH18 (Protocadherin-18) is the 
most highly expressed gene, shown to play a role in the establishment and function of 
specific cell-cell connections in the brain (RefSeq, Jul 2008). 
Figure 39. The functional expression of miR-144 target genes 
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4.5.7.3 The functional expression of miR-374a target genes 
The functional targets for miR-374 included genes that are part of the TGFβ pathway 
which also regulates fibrosis such INHBB (Figure 40). 
 
 
 
 
Around 35 genes were downregulated. INHBB, which is involved in the TGF-β 
signaling pathway, was the most abundant and downregulated target, with a fold change 
of 103 (P09529 - INHBB_HUMAN). 
Figure 40. The functional expression of miR-374a target genes 
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4.5.8 Experimental validation of miR-29 targets 
The results of the inflammatory miRs specific arrays, small RNA sequencing and also 
the predicted target data led to further experimental confirmation of targets of one of the 
miRs in the samples generated in this study. 
 
MiR-29, was consistently shown to be downregulated in the presence of IR (i.e. the PO 
group). Therefore, three collagen genes, COL1A, COL3A and COL6A, which are its 
targets and also shown to be expressed ubiquitously were used for a further investigation 
of potential miR-29 function in the PBCs and SVF samples by qPCR (Tables 12 and 13). 
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 Fold 
Change 
 
95% CI 
 
Comments 
 
P value 
COL1A 0.54 ( 0.00001, 2.63 ) OKAY 0.42 
COL3A 0.32 ( 0.00001, 1.42 ) B 0.89 
COL6A 0.44 ( 0.00001, 2.07 ) OKAY 0.52 
β-actin 1 ( 1.00, 1.00 ) OKAY 0 
 
Table 12. Expression of collagen gene targets of miR-29b in PBCs by qPCR 
The results showed no differences in expression in PBCs between the PO and MHO. 
 
 
 
 
 
Symbol 
Fold 
Change 
 
95% CI 
 
Comments 
 
P value 
COL1A 0.68 ( 0.00001, 1.97 ) OKAY 0.71 
COl3A 0.75 ( 0.00001, 1.65 ) OKAY 0.69 
COL6A 2.07 ( 0.00001, 11.03 ) A 0.60 
-actin 1 ( 1.00, 1.00 ) OKAY 0 
 
Table 13. Expression of collagen gene targets of miR-29b in SVF by qPCR 
The expression of OM SVF (n=5) was compared to SC SVF (n=5). COL6A was 
u p regulated 2 fold in OM SVF compared to SC SVF but this did not reach significance. 
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The targets of miR-29 were also further investigated using specific target arrays. The 
miR-29 target array in the PBCs did not show any significant results. 
 
Further analysis was carried out using SVF samples, where miR-29 targets may play a 
role in regulating fibrosis. Only two genes, SPARC 65 FC and SFPQ of 8 FC, were 
upregulated in the adipose tissue compared to the blood of the PO group. Interestingly 
MCL1 was downregulated when the SVF of OM depots were compared to SC. 
 
The data showed a non-significant upregulation of the majority of miR-29 target genes 
when comparing the whole adipose tissues to their matched PBCs (2 PO blood and 2 
matched tissues of OM and SC). The genes of interest, collagens, were upregulated with 
increased fold change but not significant. 
 
The summary of the findings from the various analysis are shown in Tables 14 & 15. 
152  
 
 
Source MiR 
Blood: Sabioscience miR-142, miR-16, miR-185, miR-24, miR-15, 
miR-28, miR-29b, miR-19b, miR-374a, miR-195, miR- 
130a and miR-144. 
Blood: QCRI miR-29b, miR-144, miR-374a 
 
Adipose tissue: OM 
MiR-27a,miR-376c,  miR-142,  miR-15  and  miR-101, 
miR-424, miR-20a 
Adipose tissue: SC miR-29b, miR-142. 
Adipocytes miR-376c, miR-194, miR-126. 
  
Blood miR NGS: miR-27a, miR-29a, miR-144 and miR-3607 
 
Table 14. The summary of analysis of miR changes from different tissues. 
 
Targets  
Predicted targets: 
miR-29:COL1A1, COL11A, COL3A1↓ 
 miR-144:  PCDH18,  IGFBP5,  CUL5,  FBN1, 
FZD4↓ 
 miR-374a: INHBB: TGFB-signalling. 
 miR-142: IRS1. 
  
PCR arrays targets:  
Adipose tissue versus blood SPARC↑, SFPQ↑ 
OM (PO versus MHO) MCL1↓ 
 
Table 15. Summary of analysis of mRNAs (Targets of miRs) results from different tissues 
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4.5.9 Inflammatory miR profile associated with weight-loss 
4.5.9.1 Effect of weight loss on inflammatory miRs using pathway specific arrays 
The inflammatory specific pathway in the blood was used to see the effect of the weight 
loss on these miRs. The profile of 84 miRs in 9 samples (3MHO and 6 PO) was 
investigated, after the weight loss (Figure 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The inflammatory array was used. Data were normalized to (1) and shown as expression 
before and after weight loss (in n=9 patients). The graph showed that the expression of 
10 miRs: miR-9, miR-200c, miR-141, miR-124, miR-376c, miR-302 (a, b, c), and miR- 
39 were upregulated, and miR-26b was downregulated. 
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Figure 41. Effect of weight loss on expression of systemic miRs 
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4.5.9.2 The validation of selected miRs by qPCR after weight loss 
The same profile of miR expression was seen in the samples obtained before and after 
weight loss. Thus, the results confirmed the upregulation of five miRs after the weight 
loss. These results matched the ones of the inflammatory arrays (Figure 42 and Table 
16). 
 
 
 
 
The expression of all the miRs were upregulated, but only miR-302b was statistically 
significant. 
30 
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Control miR-124 miR-302b miR-19a miR-19b 
Figure 42. The validation of the weight loss effects on miR expression by qPCR 
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Showed the fold change and p-value; miR-302b was highly and significantly expressed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mature ID Fold Change 95% CI P value 
 
 
 
miR-124 
 
 
 
4.5 
 
 
 
( 0.00001, 11.27 ) 
 
 
 
0.006 
 
 
 
miR-302b 
 
 
 
27.4 
 
 
 
( 0.00001, 243.86 ) 
 
 
 
0.005 
 
 
 
miR-19a 
 
 
 
2.1 
 
 
 
( 0.00001, 5.43 ) 
 
 
 
0.03 
 
 
 
miR-19b 
 
 
 
2.1 
 
 
 
( 0.00001, 5.53 ) 
 
 
 
0.03 
 
 
 
miR-9 
 
 
 
40861.9 
 
 
 
( 0.00001, 339677.21 ) 
 
 
 
0.02 
Table 16. Validation of 5 miRs after weight loss 
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4.6 Discussion 
4.6.1 Downregulation of miR expression in PBCs of PO compared to MHO 
In order to look at the differences in miR expression between PO (insulin 
resistant/hyperinsulinaemic) and MHO (insulin sensitive/normoinsulinaemic) subjects, 
two approaches were taken. Firstly, the use of PCR-based inflammatory pathway specific 
arrays in PBCs and adipose tissue components from these patients. These data were then 
analysed using two different software (SA Biosciences and QCRI). Secondly, by small 
RNA sequencing. While the arrays offer a sensitive method for identification of known 
miRNAs, the miRNA profiling via next-generation sequencing technologies can be used 
to identify both novel and known miRNAs. 
The array data showed, in the PBCs, significant differences between MHO and PO in 12 
miRs (miR-142, miR-16, miR-185, miR-24, miR-15, miR-28, miR-29b, miR-19b, miR- 
374a, miR-195, miR-130a and miR-144; SABiosciences). Three of these were confirmed 
by both softwares, miR-29b, miR-144 and miR-374a, which were all downregulated in 
PO, compared to MHO. 
The expression of the majority of these inflammatory miRs was positively correlated 
with the systemic markers of inflammation (MCP-1 and CRP). In addition three miRs 
were also significantly associated with hyperinsulinaemia and HOMA index of IR, miR- 
122, miR-200 and miR-302. 
Overall, miR-29 (either a or b) was the most consistent finding among these miRs and its 
targets were investigated using both predictive software and experimentally. The miR-29 
family consists of three members expressed from two bicistronic miR clusters. MiR-29b- 
1 is coexpressed with miR-29a, whereas the second copy of miR-29b (miR-29b-2) is 
coexpressed with miR-29c. All family members share a conserved seed region and miR- 
29a and miR-29c differ by only one base from the miR-29b sequence. 
157  
Two important pathways that are regulated by miR-29 have a bearing on the pathological 
obesity scenario and may explain the greater susceptibility to disease in these subjects. 
Firstly, miR-29a has negative effects on some of the steps in the insulin-signaling 
pathway. This indicates that abnormal regulation of miR-29a could be part of the etiology 
of T2DM. Some miRs are tissue specific (Lagos-Quintana et al. 2002), however, miR-29 
is present in many different tissues. He et al. were the first to report differences in miR-
29 expression in the liver, skeletal muscle and adipose tissue of patients with T2DM, 
compared to tissues of non-diabetic subjects (He et al. 2007). Up-regulation of miR-
29a, 29b and 29c were observed in adipose tissue and liver, but the difference was most 
profound in the skeletal muscle tissue (He et al. 2007; Figure 43). 
Secondly, several of the collagens, which are miR-29 targets, were shown to be up- 
regulated in the PO samples (in whom miR-29 is down regulated), compared to the 
MHO, suggesting the involvement of fibrosis as part of the pathology. The effect of 
down regulation of miR-29b on fibrosis has been previously reported and appears to 
related to the overexpression of some of the collagen genes, eg COL1A, COL3A and 
FBN (Fibrilin). Therefore, downregulation of miR-29 would increase the gene 
expression of mRNAs of collagens and increase the fibrosis. Conversely upregulation of 
miR-29 is associated with decreased fibrosis. 
Expression of miR-29 has been shown to play a major role in the regulation of cardiac 
fibrosis and may be used as a therapeutic target in the future. TGF-β, a major regulator of 
cardiac fibrosis (Border et al. 1994), can repress miR-29 expression. Because of its role 
in fibrosis, there have been numerous efforts to therapeutically target TGF-β, but the 
problem is that it is involved in mediating other functions, such as the immune response, 
and therefore likely to have major adverse consequences. In addition to miR-29 other 
miRs also regulate fibrogenetic events in various tissues, such as the liver, with 
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expression levels corresponding to those in the circulation (Figure 44). 
In response to obesity-inducd molecular and environmental signals, miRs in adipose 
tissue were strongly dysregulated, for example various miR-29 isoforms were induced in 
the tissue by hyperglycemia and hyperinsulinaemia (Herrera et al. 2010). 
Interestingly, miR-29a and 29b both were lower in PO group and correlated positively 
with insulin (especially miR-29b) and other inflammatory miRs. Their targets were 
confirmed as being the collagen genes and MCL1. 
miR-29 is one of the several miRs associated with inflammatory microvesicles. The up- 
regulation of miR-29a, b and c in non-obese diabetic mice ,caused pancreatic β-cell 
death via suppression of the myeloid cell leukemia-1 (MCL-1) gene, an essential member 
of the pro-survival BCL-2 family genes, and marked the first stage of type 1 DM 
(T1DM) (Roggli et al. 2012). Therefore, the miR-29-MCL-1 axis is a major contributor 
to pancreatic dysfunction in T1DM. Recent studies have highlighted the importance 
of MCL-1, where its deletion leads to cardiomyocyte disorganization, fibrosis, 
inflammation, and lethal heart failure (Wang et al. 2013; Thomas et al. 2013). 
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Adipose tissue, liver and skeletal muscle mediate insulin signalling and glucose 
homeostasis (Rottlers et al, 2012). 
Figure 43. The role of miR-29 in insulin responsive tissues 
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MiRs can be profibrotic (miR-199a/b, miR-19 or miR-34) and antifibrotic (such as miR- 
29, miR-19 and miR-150). (Szabo et al. 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Hepatic fibrosis associated with dysregulation of systemic miRs 
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Another interesting finding was that of miR-374a downregulation in the PO, a miR that 
is known to target 35 genes. The Target Scan Software suggested that miR-374a was the 
most abundant gene and significantly downregulated, with a fold change of 103, INHBB, 
which is involved in the TGF-β signaling pathway (Pan et al. 2006, 2013) and its 
downregulation could inhibit adipogenesis and differentiation in PO. 
MiR-19b was another miR that was downregulated in the PO group. It is reported to play 
a major role in controlling inflammation and release of inflammatory cytokines, such as 
IL-5, IL-8, IL-10 and TNF-α, through its action on NFkB signallng (Gantier et al. 2012; 
Li et al. 2002). TNF-α release from adipocytes may impair pre-adipocyte differentiation 
in obese subjects and hence contribute to lipid deposition in liver and skeletal muscle 
(Gustafson et al. 2009). Release of inflammatory cytokines from adipose tissue also 
attracts macrophages to adipose tissue, while also increasing IR in other peripheral 
tissues (Rosen et al. 2006). 
miR-122, and miR-144 are other miRs that were significantly associated with 
hyperinsulinaemia and down regulated in the PO respectively.They both may function 
through modulating IRS-1. IRS-1 is a protein downstream of insulin receptor that plays a 
significant role in insulin signaling and action, to mediate glucose uptake in fat cells. 
IRS1 is a direct target of miR-144. Thus, the control of miR-144 expression may be a 
potential therapeutic target for T2DM patients, deserving further studies (Karolina et al. 
2011). 
4.6.2 miR expression in AT of  PO compared to MHO 
Using the QCRI analytical tool, compared to MHO, the PO OM adipose tissue showed 
reduction in the expression of 7 miRs, but only miR-15 was also seen in PBCs. In the PO 
SC adipose tissue 2 miRs were down-regulated, miR-29a and miR-142. 
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The miR-29b was expressed and downregulated in the PO subcutaneous adipose tissue, 
compared to that of MHO, similar to the blood. However, it was not expressed in the 
omental. This depot specific difference in the expression of miR-29 may have a role in 
protecting the OM depots from fibrosis. 
In SC adipose tissue both miR-29 and miR-142 were down regulated in PO compared to 
MHO, while in OM adipocytes other miRs (miR-101, miR-15a, miR376c, miR-424, 
miR-27, miR-20a) along with miR-142 were down regulated. Many of these miRs target 
adipogenesis as well as insulin secretion. This is linked to the fact that obesity is 
characterized of both hypertrophy (enlargement of the existing adipocytes) and 
hyperplasia (adipogenesis or adipocyte differentiation). It is also important to point out 
that miRs that were induced during adipogenesis, were repressed during obesity 
development (Xie et al, 2009; Figure 22). The miR-142-5p-regulated gene, BMP-4, is 
involved in adipogenesis regulation of the SC Adipocytes (Gimbleet al, 1995). 
The OM AD in PO has a lower expression of miR-27, miR-376c and miR-15. These 
results were consistent with a previous report showing that miR-27a is a negative 
regulator of adipocyte differentiation via suppressing PPARγ expression (Kim et al. 
2010). Together, these results suggested that miR-27a could suppress adipocyte 
differentiation t h r o u g h  t a r g e t i n g  P P A R γ  ( Kim e t  a l .  2010). Interestingly, 
mature adipocytes of obese mice expressed less miR-27a, compared to lean mice, 
perhasps indicating that miR-27a downregulation may be necessary for adipocyte 
hypertrophy (Kim et al, 2010). Overexpression of miR-27b was found to suppress 
differentiation by targeting a predicted miR-27 binding site on PPARγ mRNA, 
inhibiting expression of PPARγ and downstream factor C/EBPa (Karbiener, et al). 
miR-15a appeared to reduce pre-adipocyte size while promoting adipocyte proliferation. 
In preadipocytes miR-15a had been shown to target Delta homologue 1 (DLK1) at both 
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the mRNA and protein levels. Inhibition of miR-15a in pre-adipocytes resulted in a 
decrease in cell size along with an increase in cell number (Andersen et al. 2010). 
Differentiation and the concomitant reduction of lipid storage capacity may lead to 
ectopic fat deposition in the liver and skeletal muscle with detrimental side-effects, such 
as insulin resistance or steatosis (Rosen et al. 2006). 
All miRs that were downregulated in the OM depots showed their effects on the target of 
genes required for the adipocyte differentiation (miR-27, miR-15), and insulin sensitivity 
(miR-142). 
The validation in PBCs, using qPCR, of 9 selected miRs confirmed the down regulation 
of these miRs in the PO compared to the MHO before and after the weight loss. On the 
other hand the validation was not successful in adipose tissue which could be related to 
RNA degradation in the tissue, accounting for the poor results. The protocol has since 
been revised and improved, but patient numbers have to be boosted again in order to 
validate the findings to the tissue from both patient groups. 
4.6.3 miR NGS results 
The small RNA seq data showed changes in lots of miRs. However, it confirmed the 
downregulation of miR-27b, miR-29a, miR-144 and miR-3607 in the PO, implications of 
which have been discussed above. In addition it also showed upregulation of several miRs 
in the PO compared to the MHO, especially those of miR-181, miR-29b and miR-30e. 
miR-181b serves as a potent regulator of downstream NF-κB signaling in the vascular 
endothelium by targeting importin-α3, a protein that is required for nuclear translocation 
of NF-κB (Sun et al. 2012). Overexpression of miR-181b inhibited importin-α3 
expression and an enriched in a set of NF-κB–responsive genes, such as adhesion 
molecules VCAM-1 and E-selectin in ECs in vitro and in vivo. 
MiR-181a was first recognized as a contributor to hematopoietic lineage commitment and 
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differentiation (Chen et al. 2004). It appears to be an intrinsic modulator of T cell 
sensitivity and selection. Later studies revealed that increased miR-181a activity in 
primary embryonic lymphatic ECs resulted in substantially reduced levels of Prox1 
mRNA and protein and, consequently, regulated vascular development and neo- 
lymphangiogenesis. Altered expression levels of both miR-181a and miR-181b have 
been detected in multiple tumors and leukemia/ lymphoma (Kazenwadel et al. 2008). 
In IGF-1-stimulated PC12 cells it appears to function via CREB1 to inhibite dendritic 
growth of cultured hippocampal neurons (Figure 45). 
 
Interestingly, Pohl et al. reported that upregulation of miR 29b in idiopathic pulmonary 
arterial hypertension (IPAH) might be responsible for the inhibited K+ channel 
expression and function and may therefore provide a new therapeutic target to treat these 
patients. miR-29b expression was elevated in both the to the PO sample (hypertensive) 
and the patients with T2DM, compared to MHO. 
The miR-30 family acts in an anti-inflammatory manner in ECs by regulating the 
expression of the cell-cell adhesion molecules E-selectin, VCAM1 and ICAM1 in an 
Ang2-dependent manner. The up-regulation of the miR-30 family members may 
contribute to the atheroprotective effects of shear stress (Demolli et al. 2013), as well as 
participating in the regulation of insulin signaling and as a useful marker of diabetes 
progression (Karolina et al, 2011). 
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miR-181a targets the mRNA of the IGF-1- regulated CREB1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 45. The role of miR-181a in neural development 
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4.6.4 Changes in miR expression on weight loss 
Gastric bypass surgery is the most commonly performed bariatric surgical procedure and 
an effective approach for achieving sustained weight loss in obese patients, along with 
reducing insulin, leptin levels and other cardiovascular risk factors. The levels of many 
of these cardiovascular risk factors are determined by some of the miRs identified in this 
project. Thus, the miRs that were found to be down regulated in the PO, compared to the 
MHO might be attractive candidates for the study of the regulation of cell fate and 
obesity-related complications.Peripheral blood miRs are useful biomarkers for both the 
diagnosis and prognosis of systemic diseases. A significant modulation of nine 
circulating miRs was shown upon surgery-induced weight loss, as evidenced by the 
marked upregulation of miR-9, miR39, miR302b, miR200c, miR141, miR124, miR376c, 
miR302a, miR302c. Only one showed a down regulation, miR-26b. In the PO group, 
miR-122 especially was significantly downregulated, compared to the MHO and its 
expression was upregulated after weight loss. However, weight loss had no effect on the 
expression of miR-29, suggesting that the changes induced by the miR and its targets 
may be less reversible. 
4.6.5 Conclusions 
The relationship between obesity and diabetes was strongly related to glucose and lipid 
metabolism. miRs have been shown to regulate the activity of key cellular processes, 
including insulin release in pancreatic β cells and differentiation of adipocytes and are 
therefore thought to contribute to these pathologies. A consistent observation in obese 
patients and experimental models of obesity was that the miRs normally induced during 
adipogenesis were downregulated in the obese subjects. (Xie et al 2009). It was apparent 
that significant differences in expression of the miR species occured along with changes 
in metabolic and inflammatory parameters between the groups studied. Elevated 
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production of collagens may be related to excess fibrosis, which causesd a barrier around 
the adipocytes resulting in heterogeneity of adipocyte size and pockets where there is 
adipocyte hypertrophy, leading to higher production of leptin and inflammatory 
cytokines, as well as ROS production. This is a scenario that would lead to progression 
of IR, vascular dysfunction and inflammation. 
There was a positive correlation between the inflammatory miRs and the inflammatory 
biomarkers, such as MCP-1 and CRP. These studies uncovered miR-29, miR-144 and 
miR-374 as important contenders for a pathological obesity (PO) miR signature, along 
with miR122, miR302, miR200, which were associated with hyperinsulinaemia and 
insulin resistance. 
Nonetheless, further investigations using animal models as well as more human samples 
have to be carried out to validate these findings and to further elucidate the mechanisms 
of miR regulatory network. The changes that were found in the PO sample could have 
both diagnostic and therapeutic potential. 
Power calculation: Data on the expression of certain miRs in the PBCs (using the 
statistical analysis provided by QCRI) showed significant down regulation, especially in 
mir-29b. The mean difference in its expression between PO compared to MHO was 0.44 
(SD 0.22). With 10 MHO and 14 PO subjects the study is powered to detect difference at 
the 80% level. Therefore the study using PBCs is sufficiently powered. Despite miR-29 
following a very similar pattern of expression in adipose tissue these studies had much 
lower numbers of samples from the two groups (i.e; MHO, n=1 and PO, n=4). In order to 
be sufficiently powered additional tissue (9 MHO and 6 PO) from both patient groups are 
currently being collected. Small RNA sequencing also needs to be powered adequately, 
currently 1 MHO and 1 PO have been sequenced. 
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Chapter 5 
The Whole 
Transcriptome 
Analysis 
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5.1 Introduction 
The simultaneous assessment of miRNA and mRNA expression profiles provides a 
powerful approach to identify groups of miRNAs whose expression levels are negatively 
coordinated with those of their target mRNAs. Microarrays have been used previously 
for jointly profiling and analysing miRNAs and mRNAs expression in brain cortex from 
Aldziemer’s disease patients and age-matched controls (Nunez-Iglesias et al. 2010). 
These data allowed the study of the relationship between miRNA and mRNA expression 
in normal and affected tissue. The results showed a significant relationship between the 
levels of miRNAs and those of their targets in the brain. Co-expression analysis has also 
been reported elsewhere and recommended as a model for NGS procedures to help 
recognize true targets, confer functionality and identify miR signatures for diseases 
(Zhang et al.2011; Gennarino et al. 2012). 
This approach has not been used previously when considering insulin resistance in 
obesity. Measurement of miRs and mRNA in PBCs and components of adipose tissue 
from normoinsulinaemic and hyperinsulinaemic obese, euglycaemic patients would 
allow for these targets to be elucidated in the different fat depots, as well as in their 
cellular constituents (SVF and adipocytes) and further to relate these to systemic cells 
(PBCs). A recent study reported omental and subcutaneous adipose tissue to have unique 
miR expression profiles (Klöting et al, 2009). Similarly studies reported differences in 
gene expression between subcutaneous and visceral/omental fat depots, accounting for 
increased production of inflammatory cytokines from omental depots (Rosen et  al, 2006), 
which is also less adipogenic and more insulin resistant. Details of the miRs related 
to these various pathways and a limited study of their targets was done (chapter 4), 
specifically uncovering a signature that included miR-29, miR-144, miR-374, miR- 122, 
miR-302, miR-200. Their targets were then validated using NGS platforms. 
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5.2 Aims 
1. Confirm, in the whole transcriptome, targets for the specific miRs. 
2. Validate, in the whole transcriptome, targets for the specific miRs. 
3. Compare expression of target genes in different depots (SVF and AD) and PBCs. 
4. Using the data from whole transcriptome to assign functionality. 
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Methods were provided in Chapter 2. 
5.3 NGS target genes in the blood 
In order to confirm, in the whole transcriptome, targets for the specific miRs, mRNA 
expression was assessed by transcriptome analysis. For the majority of samples the 
Ion Proton platform was used for NGS. In a small subset of PBCs (n=4 patients) 
both microarrays and Ion Proton NGS was carried out. 
5.3.1 Sample selection and data analysis 
Forty three samples (see Table 17) were sequenced using the Ion Proton. Details of 
the methods were described in Chapter 2. 
 
Two MHO and two PO 
patients had an entire complement of samples. 
 
After filtering, dataset description (raw data, FASTQ) was used to analyse 6 MHO 
samples and 12 PO samples matched for age and sex, in addition to BMI. The T2DM 
data was not used for any further analyses. 
To perform differential expression analysis, FASTQ files were processed following these 
steps: 
1. Sequence quality check using FastQC 
2. Two steps alignment of reads to human reference genome (GRCh37/hg19) using both 
TopHat2 and Bowtie2. 
3. Counting of reads for each gene using count Overlaps function of Bioconductor 
package GenomicRanges 
 PBCs OM SVF OM Adips SC SVF SC Adips 
MHO 7 2 2 2 2 
PO 17 2 2 2 2 
T2DM 3 - - - - 
Table 17. Details of the samples used for sequencing studies  
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4. Gene expression analysis using Bioconductor package edgeR. 
In the step 1, quality control for some samples (n=4) resulted in very low coverage 
sequencing and they were excluded from the downstream analysis. 
In the step 2, the short sequence reads contained in FASTQ file were mapped to the 
reference genome using the algorithm TopHat2: the reads were either aligned or un- 
aligned in this process. The un-aligned reads were then mapped with another algorithm 
Bowtie2. The output files (BAM format) from these two alignment processes were then 
merged to generate final aligned BAM for further downstream analysis. 
The output produced in the step 3 is a count table with genes as rows and samples as 
columns, in which each cell is an integer that indicates how many reads in the sample 
overlap with the respective gene. These counts were then normalized for different library 
sizes and to account for sample-specific effects (using edgeR TMM method). The 
resulting normalized-count table was examined (RNAseq_norm.counts.txt). 
In the step 4, differential expression was determined using negative binomial exact test, 
and significant PO vs. MHO differentially expressed genes were selected: 
Absolute log2 (Fold Change) ≥ 1, and corrected p-Value (FDR) ≤ 0.05 
5.4 Results 
5.4.1 NGS of PBCs using Ion Proton platform 
Significant changes in 1448 mRNA were recorded, of which 133 were upregulated and 
1315 down regulated in the PO compared to the MHO samples. 
Keeping in mind the miR signature uncovered for the PO (miR-29, miR-144, miR-374, 
miR-122, miR-302, miR-200) these data were probed for their targets. 
Specifically gene expression in PBCs from PO and MHO revealed significant disparity 
in components of the pathways leading to IR, inflammation and fibrosis (Table 18). 
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Downregulation miR target/ Functions 
Collagens 
COL26A1, 
COL3A1 
miR-29 controled by TGF-β signalling pathway. Alteration of 
Col3A1 gene expression under hyperglycaemic and 
hyperinsulinaemic conditions, leads to fibrosis. 
INHBB MiR-374a plays a physiological role in energy balance or the 
insulin insensitivity associated with obesity. Controled  by TGFβ 
IGFBP5 IGFBP-5 is a direct or indirect target for Stat3 and its upregulation 
is essential to normal involution. 
It is targeted by miR-4731 (Adipose tissue) 
Upregulation miR target/ Functions 
Notch miR-200c blocks Notch signalling (Data showed positive 
correlation between insulin and miR200). Inhibition of Notch 
signaling ameliorates insulin resistance.(Kitamura et al 2007) 
Akt2 miR-29 mediates TGF-β1-induced extracellular matrix synthesis 
through activation of PI3K-AKT pathway. It blocks the glucose 
and insulin signaling pathways. 
DKK2 and 
DKK3 
DKK1 is a direct target of miR-29a, leading to negative regulation 
of Wnt signalling. MiR-376c targets DKK2. 
SMAD2 miR-29 is negatively regulated by TGF-β /Smad signaling in 
fibrosis. 
MCL1 miR-29 regulates MCL-1 protein expression and apoptosis. 
SEC14L1 
Reduce the Choline transport that has been shown to cause a fatty 
liver or muscle damage. Fischer et al 2007. 
CARD8 
Proinflammatory, Dysregulation is associated with a susceptibility 
to rheumatoid arthritis. 
Table 18. PBCs target gene expression, miRs and affected function in PO 
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5.4.2 The dysregulation of the target genes in whole adipose tissues 
In the PO adipose tissue the modulated targets, along with their function and the 
regulatory miR species is shown, compared to MHO (Table 19). 
Similar to results from the PBCs the collagen genes, IRS genes and INHBB were 
downregulated. In addition, upregulation of NOTCH and SMAD, involved in fibrosis 
and vascular dyfunction and IR, were also evident. 
 
 
5.4.3 The dysregulation of the target genes in the SVF and Adipocytes of PO 
In addition to the miRs found previously using the pathway specific approach other miR 
species were found in the SVF and AD, and their main reported targets in the different 
depots (SC and OM; Table 20). 
 
Downregulation miR target/ Functions 
Collagens 
(COL1,COL4,COL5, 
COL6,COL12 
MiR-29 controled by TGF-β signalling pathway. Alteration 
of Collagen gene expression under hyperglycaemic and 
hyperinsulinaemic conditions, leads to fibrosis. 
IRS1and IRS2. IR. 
PCDH18 The target of miR-144 plays a role in the establishment and 
function of specific cell-cell connections in the brain. 
(RefSeq, Jul 2008). 
INHBB The target of miR-374a, controlled by TGF- β 
Upregulation miR target/ Functions 
NOTCH signalling: 
NOTCH2, NOTCH2NL 
miR-200c blocks Notch signalling (Data showed positive 
correlation between insulin and miR-200). Inhibition of 
Notch signaling ameliorates insulin resistance. 
Smad1, smad 6, and 
smad 7 
miR-29 is negatively regulated by TGF-β/Smad signalling in 
fibrosis. 
Table 19. NGS target genes in the AD of PO compared to MHO 
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Further analysis was carried out to look at the blood, AD and SVF from PO samples, as 
well as comparing differences in mRNA expression in SVF of PO compared to MHO 
(Table 21). 
 
Diff  Expr  AD  versus  blood  in 
PO: 
Upregulation: LCP2 target of miR-142. 
Downregulation: COL12A1, FBN1, PPARγ. 
Diff  Expr  SVF versus  blood in 
PO 
Downregulation: COL12A1, FBN1, PPARγ. 
Diff Expr SVF PO versus MHO Downregulation: SLCO5A1; NOTCH2, 
COL11A2, INTS4 (integrator complex subunit 
4), DKK2, WNT7A, and PPRG. 
 
Table 21. mRNA target in the adipose tissue components compared to PBCs 
AD and SVF was compared to PBCs. Also in the SVF, the PO were compared to MHO. 
Downregulation  of  genes  in  the 
SVF of PO SC versus OM 
COL3A1, ASS1P1,ASS1P7and ASS1P11 
 
(Arginine), miR-1245A, miR-663B (it has a 
role in Myocardial infarction, Peng et al 
2014) 
Downregulation of genes in the AD 
of PO SC versus OM 
COL3A1, ASS1P1, ASS1P7 and ASS1P11 
(Arginine) MiR-4731. 
Table 20. Depot specific downregulated genes in PO, SVF and AD 
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5.5 Validation of the NGS samples using the SurePrint G3 Human gene expression 
Microarrays 
Microarrays expression was used to compare between two sets of samples PO (n=2) and 
MHO (n=2), in duplicate. Overall, the results showed that 1567 target genes were 
downregulated and 922 genes were upregulated, in the PO compared to MHO (Figure 46 
and Table 22). 
 
 
Samples 
hybridize
d 
Replicates 
Analysis 
Plan 
Summary of Differentially Regulated 
Genes PO/MHO (n=4, 2 per group) 
MHO-102 Technical 
replicates 
 
 
Control 
Up Down 
MHO-102_R  
 
 
 
 
922 
 
 
 
 
 
1567 
MHO-128 Technical 
replicates MHO-128_R 
PO-122 Technical 
replicates 
 
 
Treated 
PO-122_R 
PO-48 Technical 
replicates PO-48_R 
 
 
Table 22. The summary of differentially regulated genes in PO compared to MHO 
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Figure 46. The cluster map showing variability in gene expression. Samples included PO 
(n=2) and MHO (n=2). The replication was done as a test of technical reprocibility. 
From the cluster map it is apparent that there was greater heterogeneity in the gene 
expression pattern in the MHO (control) samples compared to the PO. 
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5.5.1 The upregulation of pathways in PO 
The Pie chart reveals the participation of the various gene changes in pathways 
upregulated in PO compared to MHO in the blood and their possible contribution to 
elevation in insulin signialling and inflammation, hence reflecting IR of PO phenotypes 
(Figure 47).  
 
 
 
 
 
 
 
Many pathways were involved in different diseases. The pie chart suggested upregulation 
of insulin signalling and inflammation. 
Figure 47. The results showed the up-regulation in PO (n=2) versus MHO (n=2) 
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5.5.2 The upregulated mRNA in specific tissues 
Further analyses were carried out to look at the contribution of the mRNA in different 
tissues. COL12A1, a target of miR-29 is apparent (Figure 48). 
 
 
 
 
 
 
 
 
 
 
 
 
Found in 
collagen I-
containing 
tissues:
Highest levels 
in adipose 
tissue, small 
intestine and 
colon.
15%
B-lymphocytes.
14%
Broadly 
expressed.
14%
Abundantly 
expressed in 
brain and 
pancreatic 
islets.
14%
T-cell and 
macrophage 
specific.
14%
Plasma.
14%
SFRP2
CD37
USP17, 
USP17L2
SPTBN4
CCL5
IGFALS
COL12A1 
Figure 48. Up-regulation of mRNAs implicated and inflammation 
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5.5.3 The role of certain target genes in signalling pathways 
The implication of these gene changes in modulating key signalling pathways was also 
investigated. 
5.5.4. The down regulation of pathways in PO 
These pathways, especially those of Wnt, PPAR and TGFβ, all point to inflammation 
and insulin resistance being important leasions in the PO compared to MHO (Figure 49). 
 
 
 
 
 
Figure 49. Down-regulation of key pathways of IR and inflammation 
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Several of the specific genes in these pathways are shown in Table 23. 
 
 
 
Term P Value Genes 
hsa04620:Toll-like 
receptor signaling 
pathway 
0.109 IRAK4, MAP2K4, TLR1, TLR4, TRAF6, 
TLR6, TAB2, TLR7, CHUK, TLR8, SPP1 
hsa04920:Adipokine 
signaling pathway 
0.25 CD36, SOCS3, PRKAB2, JAK2, 
PRKAA1, CHUK, PTPN11 
P00032:Insulin/IGF 
pathway-mitogen 
activated protein kinase 
kinase/MAP kinase 
cascade 
0.34 RPS6KA3, SOS2, MAP2K4, RPS6KB1, 
MYO19 
P00031:Inflammation 
mediated by chemokine 
and cytokine signaling 
pathway 
0.44 ROCK1, PTGS2, SOCS3, CAMK2G, 
PRKCI, RHOQ, SOCS4, AKAP9, RGS18, 
ITGA4, ARPC5, ITPR1, PRKCB, 
PLA2G4A, ITGA6, CCR3, GNG10, SOS2, 
CCR2, NFAT5, JAK2 
hsa04350:TGF-beta 
signaling pathway 
0.48 EP300, ROCK1, ZFYVE16, RPS6KB1, 
SMAD1, MYC, ACVR1 
hsa04310:Wnt signaling 
pathway 
0.50 EP300, ROCK1, CAMK2G, NFAT5, 
PPP3CB, FRAT1, FZD1, FRAT2, MYC, 
PRKCB, CTNNB1 
 
P00052:TGF-beta 
signaling pathway 
0.75 EP300, RAB28, DCP1A, FOXN2, 
FKBP1A, SMAD1, FOXJ3, RAB10, 
ACVR1 
REACT_498:Signaling 
by Insulin receptor 
0.76 EIF4E, PDE3B, RPS6KB1 
P00057:Wnt 
signaling pathway 
 
 
0.991 
SMARCAD1, PRKCI, FZD1, TLE4, 
SMAD1, ITPR1, PRKCB, CTNNB1, 
EP300, GNG10, PPP3CB, MYC, ACVR1 
hsa03320:PPAR 
signaling pathway 
 
1 
CD36 
REACT_11045:Signaling 
by Wnt 
 
1 
CTNNB1 
 
Table 23. The specific genes involved in diferent downregulated pathways 
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5.5.5. The down regulation of genes in specific tissues 
From the data analyses specific genes that were highly expressed in important insulin 
responsive tissues were revealed (Figure 50). 
Many mRNAs were downregulated in different tissues. 
Figure 50. Tissue specific downregulation of genes 
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5.6 Discussion 
5.6.1 mRNA seq using the Ion Proton platform 
NGS using the Ion Proton platform revealed dysregulation in specific genes like IRS, 
IGF, collagens, MCL1, SMAD and Notch. Notch acts as a major player in angiogenesis, 
whereas collagens (Col3A) MCL1 and SMAD were all involved in fibrosis. In addition 
to IGF and Akt2, IRS1, 2 and IRS4 were all involved in the insulin signaling pathway. 
Similar results were shown when validated by microarrays. 
The miR-29 family targets a cadre of mRNAs that encode proteins involved in fibrosis, 
including multiple collagens, fibrillins, and elastin. Thus, down-regulation of miR-29 
would be predicted to depress the expression of these mRNAs and enhance the fibrotic 
response. Indeed, downregulation of miR-29 with anti-miRs in vitro and in vivo induced 
the expression of collagens, whereas over-expression of miR-29 in fibroblasts reduces 
collagen expression. Furthermore, miR-29-MCL-1 axis is a major contributor to 
pancreatic dysfunction and T1DM. Recent studies have highlighted the importance of 
MCL-1 where the deletion of MCL-1 gene leads to cardiomyocyte disorganization, 
fibrosis, inflammation, and lethal heart failure (Wang et al and Thomas et al, 2013). 
The results here also point to miR-29 as a regulator of fibrosis and a potential therapeutic 
target for tissue fibrosis in general. 
The sequencing results showed a significant mediation of several of the targets of the 
components of the PO miR signature uncovered. 
5.6.2 The validation of Ion Proton mRNA seq by microarrays 
Validation of the NGS by microarrays using four peripheral blood samples, in duplicate, 
showed the difference between the two groups in the gene expression of the mRNAs that 
were down regulated in many pathways. Our focus here was on specific pathways that 
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were involved in the insulin and IGF pathway. IGF1 was initially considered purely as a 
circulating growth factor produced by the liver and mediating the effect of growth 
hormone on body growth. Several studies identified a number of miRs affecting IGF-1. 
Among them, miR-29 was shown to target 3' UTR of IGF-1 mRNA to suppress IGF-1 
expression. (Kwiecinski et al,2012). Our study showed that in addition to Insulin/IGF 
pathway-protein kinase B signaling cascade, IGF-1 was involved in many pathways 
including hypertrophic cardiomyopathy (HCM), Diabetes pathway and cancers. Another 
gene that found downregulated was IRS1. It was reported that, insulin binding to IR 
activates phosphatidylinositol 3-kinase (PI3K)–protein kinase (Akt) pathway and 
disruption of which can lead to diabetes (Bouzakri et al; 2003). 
The data showed that many of the genes that were the targets of the identified miRs 
(Chapter 4) involved in the metabolic pathway leading insulin resistance, inflammation 
and fibrosis were disrupted in the PO. All these processes have a major role in 
developing the pathological disorder in the PO which leads to graeter susceptibility to 
T2DM and CVD.  
Power calculations:  
Targets of mir-29 done by the NGS: The power calculation used the differences in the 
expression of Col3A, based on data from the pilot study using next generation sequencing 
(n=6). In order to reach 80% CI, 4 more MHO samples and 2 more PO samples are 
required. The data analysis was done for 12 POs compared to 6 MHOs in PBCS. However, 
the number of samples from adipose tissues was too small for sufficient statistical power 
(n-2 PO compared to n-2 MHO). Although it was predicative for significant expression of 
the collagen genes this still needs to be confirmed in larger number of adipose tissue 
samples and then expression patterns compared to those in blood.  
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Chapter 6 
Discussion 
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6.1 Introduction 
There is a significant global increase in the prevalence of obesity. Obesity and its 
associated co-morbidities have substantial healthcare and social costs. Prevention, 
especially of the obesity associated pathologies, comes from a better understanding of 
the different mechanisms involved, but it will also be important to help develop 
strategies to treat those already affected. Even relatively modest weight loss of 5-10% 
has been shown to reverse many of the comorbidities associated with obesity and to 
result in significant health gains, both in terms of risk factors and also in the amelioration 
of disease. However, in the face of the global epidemic of this disease, a clear ability to 
stratify obesity groups depending on varying disease risk would help to design and target 
therapy effectively. 
6.2 Clinical Parameters 
Differences in gender, IR, ethnicity and weight loss were considered in an obese Arab 
(Qatari) population to help further group them by disease risk using clinical and systemic 
markers. 
6.2.1 Comparison of cardiometabolic risk factors by gender 
Data showed that when subjects were stratified into two groups based on their gender 
(Chapter 3), as expected and already reported in other studies; females had higher leptin 
and adiponectin levels, probably associated with sex hormones in this relatively young 
cohort, compared to males. Arab men were more hyperinsulinaemic, were IR to a degree 
and had greater elevation in blood pressure, predisposing them to an increased risk for 
developing T2DM and CVD. As the population was young and the prevalence of obesity 
in males and females was not significantly different a factor that could underlie this 
difference may be associated to lifestyle. Smoking, and perhaps alcohol consumption, is 
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more prevalent in males in this population. No further analysis in terms of differences in 
miR signatures by gender was possible because of small numbers of males in the study. 
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6.2.2 Clinical parameters between MHO and PO groups 
The PO group had higher insulin and HOMA-IR, lower adiponectin and, interestingly, 
lower leptin, compared to MHO (Chapter 3). The lower leptin in the PO, despite no 
difference in obesity, may suggest greater SNS activation directly inhibiting adipose 
leptin production. This points to perhaps a stress mediated phenomenon underlying the 
PO phenotype. This may be a consequence of the rapid changes in lifestyle in this 
population (Figure 51). In the PO there was also upregulation of the collagen genes, and 
possibly, generalised tissue fibrosis as a result. Furthermore the vascular dysfunction was 
increased pointing to the high blood pressure (Figure 51). SNS mediated decrease in 
leptin may also predispose them to hyperphagia and therefore obesity. 
Figure 51. Effects of stress in developing IR, Fibrosis and Vascular dysfunction 
 
189  
The clinical differences between the two groups based on IR, the MHO and PO, have 
been highlighted in chapter 3. Further comparison of these phenotypes between two 
different ethnicities was then carried out. In the Arabs, despite being younger, 
hyperinsulinaemia/insulin resistance and inflammation were higher. The longer exposure 
to high levels of insulin in the presence of chronic inflammation, perhaps due to 
early/adolescent onset obesity may account for the greater prevalence of the associated 
diseases, such as T2DM and hypertension, in this population. 
The outcome of the comparison between the two populations showed that MHO 
Caucasians had lower BP (SBP, DBP and MAP) and triglyceride in addition to insulin 
and HOMA compared to PO Caucasians. On the other hand, MHO Arabs had lower 
FBG, insulin and HOMA, in addition to the triglycerides, than PO Arabs. On the other 
hand Arab MHO had a higher systemic leptin level than PO group. 
Obesity in Arab subjects was accompanied by greater degree of hyperinsulinaemia and 
hyperleptinaemia compared to Caucasians, suggesting elevated fat mass contribution to 
the BMI in Arabs. The lower prevalence of MHO in Arabs also reflects the largely 
insulin resistant phenotype of the population. In Caucasians the PO subjects were 
hypertensive and hypertriglyceridaemic compared to the MHO, while these differences 
were not apparent (only TAG showed to be higher in PO) in the Arab MHO and PO 
groups because they were younger. The greater incidence and younger age of onset of 
obesity may warrant more aggressive treatment for obesity amongst the Arab. Therefore 
the prevention of obesity has to start in the younger age groups, and should focus on 
simple measures such as encouraging adoption of a healthy diet and promoting a non- 
sedentary lifestyle, particularly by encouraging physical activity within schools and 
outdoors activities. 
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6.2.3 Effect of weight loss on the clinical parameters 
Three months after surgery, both the PO and MHO groups showed significant reduction 
in BMI associated with reduction in insulin, HOMA and leptin, but no significant changes 
in lipids. After weight loss there was only a slight elevation in systemic adiponectin. The 
difference between the MHO and PO after weight loss was not significant suggesting 
that weight reduction surgery benefits both cohorts equally in this population. 
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6.3 MiR Signature in obesity 
MicroRNA added a further level of regulation. The potential use of blood miRs as 
biomarkers for the obesity, cardiovascular diseases, atherosclerosis, and T2DM, was 
discussed by multiple reports. miRs play a major role as regulators of the different 
pathways like the insulin signalling, TGF-β and the inflammatory signalling pathways. 
The inflammatory pathway has been regulated through different immune cells including 
the B-cells, T-cells and their secreted cytokines. The best example is miR-181 which 
plays a major role in specific developmental stages of T-cell differentiation.(Chen et 
al,2004), Since macrophages and hypertrophied adipocytes are the main sources of AT 
inflammation, the miR mediated interactions (adipocytes-macrophages and larger 
adipocytes-smaller adipocytes) may be novel mechanisms for miRs contributing to 
regulation of AT inflammation (Lumeng et al,2011). 
MiR expression patterns in OM and SC adipose tissue suggest a common developmental 
origin of both fat depots. Differences in miR expression might contribute to differences 
in adipose tissue biology between OM and SC depots. A subset of miRs could be 
packaged into adipocyte-derived microvesicles and delivered into blood or neighboring 
cells, mediating intercellular communication. 
There was a positive correlation between the majority of the inflammatory miRs and the 
biomarkers like MCP-1 and CRP involved in inflammation. Additionally miR-200c, 
miR-302a and miR-122 were correlated positively with high insulin, glucose and HOMA 
The data of the inflammatory pathways arrays and miR NGS showed the role of some 
inflammatory circulating miRs likes: miR-142, miR-16, miR-185, miR-24, miR-15, miR-
28, miR-29b, miR-19b, miR-374a, miR-195, miR-130a and miR-144, which were all 
downregulated in the PO, compared to MHO. 
miR-29b, which was down regulated in the PBCs and SC of the PO, has a major role in 
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fibrosis and acts as a regulator of the collagen genes through the TGF-β signalling 
pathway or through controlling MCL1 that lead to apoptosis, IL-6 and P13K/Akt 
signalling (discussed in chapter 4). MCL1 was upregulated in the PBCs of the PO group 
which could explain the effect of apoptosis during obesity related to hypoxia and 
inflammation.The TGF-β pathway, which plays an important role in obesity, and stress, 
both share MAPKK to activate the same transcription factors. This could explain the 
effect of stress and TGF-β pathway to dysregulate the same genes, perhaps resulting in 
the development of the similar disorders. 
Another miR, miR-142, was involved in IR which targets the IRS1 as shown by NGS 
(Chapter 5). In addition to miR-374a, which targets INHBB, regulated by the TGF-β 
pathway, was shown to be inhibited in PBCs of the PO group. 
NOTCH, targeted by miR-200c, was another key palyer that mediates 
hypoxia/angiogenesis -vascular function. Notch signalling pathway was higher in the PO 
group compared to the MHO. 
Some miRs that were downregulated in the OM depots showed their effects on the 
targets of genes required for the adipocyte differentiation (miR-27 targets PPARγ 
pathway, miR-15 targtes BCL2 for adipocyte diferentiation). Interestingly, INHBB down 
regulation was inhibs adipogenesis and insulin secretion. DLK1 was highly upregulated 
in the PBCs of PO compared to MHO. DLK1 activity was another important gene 
involved in adipocyte differentiation. 
6.4 Effect of weight loss on the miR gene expression 
Interestingly there was a differential effect of weight loss on the expression of some of 
the miRs. All were increased after the weight loss, except one that was downregulated 
(miR-26b). When the insulin level was reduced after the weight loss, the inflammatory 
miRs were upregulated except miR-29b, which did not chang after the weight loss, 
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perhaps suggesting that the effect of this miR on fibrosis was irreversible. 
Surgical weight loss improved metabolic profiles of both cohorts. MiR expression in the 
PO compared to the MHO before weight loss showed significant down regulation of 
those associated with inflammation (miR-19b, miR-9), IR (miR-142, miR-144, miR- 
122), fibrosis (miR-29) and adipogenesis (miR-15, miR-130a, miR-374a). Weight loss 
lead to upregulation of miR expression (miR-302a, b, c, miR-9, miR-200c, miR-141, 
miR-124, miR-376c, and miR-39). 
Therefore some, but not all, of the metabolic and inflammatory lesions that accompany 
obesity and IR are ameliorated by weight loss, along with up-regulation of miRs 
mediating IR and inflammation, but not fibrosis. 
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6.5 The whole transcriptome analysis 
The main aim of this project was to investigate by various approaches (clinical, miR and 
transcriptome) the importance of IR and inflammation as the major difference between 
MHO and PO and the involvement of fibrosis and vascular function in these. The 
transcriptome analysis was used to investigate the miR target genes and also discover 
further involvement of the effected pathways suggested by the studies on the miR.  
Whole transcriptome analysis of mRNA in the blood and adipose tissue samples revealed 
downregution/upregulation of several genes in the metabolic, inflammatory and insulin 
pathways in the PO compared to MHO. Also genes leading to increased fibrosis were 
identified in the PO. 
The data showed a dysregulation in certain target genes by NGS of the PBCS which 
were further validated by HTA. Specifically looking at the targets of the PBCS miRs, 
which have been explored by the inflammatory specific pathway arrays and small RNA 
sequencing like: 
• ↓IRS1 (↓miR-142) controling the insulin signaling pathway, IGF, Akt2, IRS1, 2 
and IRS4 all were involved in insulin signaling pathway 
• ↓Col3A (↓miR-29b), ↑MCL-1 (↓miR-29b), ↑SMAD (↓miR-29b), three of them 
were involved in the dysregulation of TGF-β signaling pathway and lead to 
fibrosis; 
• ↑Notch (miR-200c) affected the vascular pathway. Notch acts as a major player 
in angiogenesis, ASS1B11 was another interesting finding controls the Arginine 
and NOS that are involved in the vascular dysfuction through the regulation of 
TGF-β. 
• ↓INHBB (↓miR-374a, in addition to miR-27 and miR-15) inhibited adipogenesis. 
• Data of NGS showed a new miR, miR-4731 in adipose tissue which targted 
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IGFBP-5 that acts as a direct or indirect target for Stat3. 
 
6.5.1 Two different technologies were used - RNAseq versus HTA 
The NGS data was used for the discovery of the related miR targets that were found 
using the miscript pathways arrays and look at their effects on different pathways. Two 
approaches – one PCR based known as Human Transcriptome array (HTA) and NGS by 
IonProton was done for better understanding and reproducibility. It was very interesring 
to look at the targets of the miRs in the blood samples of the MHO and PO groups from 
different techniques and compare results and data from RNAseq to HTA microarrays. 
The data showed a dysregulation in certain target genes by NGS of the whole 
trqansciptome analysis which were confirmed by HTA microarrays of these specific 
targets. The effects and roles of the four main pathways, IR, fibrosis, pathological 
angiogenesis and inflammation, were all involved in distinguishing between MHO and 
PO (Figure 52). 
It was very useful to run two different techniques (NGS and HTA for mRNA) in parallel 
where we gained the same information about mRNAs targets and their parhways. The 
whole transcriptome was done by the NGS which can be used as a discovery platform for 
the novel targets whereas the HTA can be used for the expansion of samples (increasing 
numbers /reproducibility of the targets). 
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The possible mechanisms and dysregulation involved in developing fibrosis, pathlogical 
angiogenesis, insulin resistance and inflammation in the MHO and PO. 
Figure 52. miR-29 mediated changes in IR and inflammation 
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6.6 Conclusions 
The current study dichotomised a morbidly obese Arab population in to those that were 
euglycemic and normoinsulinaemic (MHO) and the majority that were euglycemic and 
hyperinsulinaemic (PO). The hyperinsulinaemia of pathological obesity was accompanied 
by adipocyte hypertrophy and hyperleptinaimia, along with higher levels of adipokines 
(MCP-1 and CRP), inflammatory miRs and fibrosis. In this group surgical weight loss 
led to a decrease in the systemic insulin levels, HOMA and the proinflammatory 
biomarkers, as well as the expression of specific miR species. Therefore the surgical 
weight loss could be useful in the treatment of obesity and its related metabolic 
disorders in the PO. All results collected from various sources including clinical, miR 
specific inflammatory pathways/small mRNA sequencing and transcriptome were 
support the importance of IR and inflammation as the major difference between MHO 
and PO and the involvement of fibrosis and vascular function in these. 
The cross talk between three main pathways insulin/metabolic pathway, TGF-β 
signalling, and inflammation could help to understand the mechanisms where higher 
insulin level interacts with higher level of FFAs and adipokines in the presence of the 
inflammatory miRs (miR-29, miR-144, miR-374a) and their targets to end up with the 
accumulation of more collagens and increase the fibrosis that along with ROS leading to 
CVD and vascular dysfuction in addition to T2DM (Figure 50). 
Therefore, a better understanding of the function of miRs to distinguish between MHO 
and PO is providing new insights into the molecular basis of human pathologies, as well 
as acting as new biomarkers for disease. 
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Three major pathways involved in the progress of the IR and the development of 
T2DM CVD, and MeS related to the Obesity comorbidities. 
 
 
Obesity 
Figure 53. Schemma of pathways involved in development of disorders in PO 
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6.7 Limitations of the study 
Obviously, the number of subjects was relatively small, RNA degradation in both PBCs 
and adipose tissues on storage was a major culprit, and the described associations between 
anthropometric and metabolic parameters and miR expression for the blood samples, 
and their follow up after weight loss, will require confirmation in larger cohorts. To date 
there is no study on the relationship of microRNA expression in human SC and OM 
adipose tissue and therefore, we believe it was necessary to report our findings that 
may be verified by studies in larger cohorts. In addition, there are some difficulties in 
the interpretation of miR expression data. For example, to investigate biological 
functions of miRs, it is critical to identify miR-directed target genes. Currently available 
computational methods (e.g, miRanda, PicTar, and TargetScan) predict numerous target 
genes that contain many false positives for miR. Also, experimental verification of 
miR-target relationship was complicated by the potential outcome of such an interaction 
being either translational repression or degradation. Furthermore, miRs can target 
multiple genes, and thereby the biological function of a single miR can be diverse. 
Hence, not only to achieve a higher degree of specificity of the prediction, but also to 
comprehensively understand the function of miR, large-scale prediction of targets across 
a whole genome would be required. 
6.8 Long term future direction 
The project was planned to find markers or mediators of the MHO/PO phenotypes in 
morbid obesity. The differences were seen in the peripheral blood cells which was 
possible that the miR were borne in the systemic circulation to affect other insulin- 
sensitive organs and initiated the development of comorbidities associated with insulin 
resistance, such as liver and skeletal muscle dysfunction through adipocyte dysregulation 
and vascular dysfunction. 
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Depending on the results the specific miRs that were found to change uniquely in either 
MHO or PO alone would be further investigated and assigned a function(s) from any 
available data in the literature or through experimental means. Some interesting miRs 
like miR-29b, would be followed by more detailed functionality studies, perhaps 
involving silencing of some miR in whole adipose tissue. It is worth looking at 
theeffects of glucose or insulin as well as the SNS stimulation on the level of miR-29 
gene expression in adipose tissue, liver and skeletal muscle in vivo and in vitro. This 
could help understand the cross talk occurs between these different organs to explain the 
main pathways involved between these different organs. 
miR profiling studies had identified miRs involved in adipogenesis and associated with 
obesity, but the challenge remained to determine how these miRs were regulated in 
adipose tissue. Therefore, it would be worthwhile to investigate if there are parallel 
changes in miR transcription, biogenesis and degradation which can explain the 
dysregulated miRs observed in obesity. Furthermore, the role of other extracellular 
stresses and nutrient availability regulating obesity associated miRs remained unknown. 
From a clinical point of view, with the recent discovery of miRs being secreted into 
extracellular fluids, it allows for the establishment of a circulating miR profile that can 
distinguish healthy obese and pathologic obese subjects. Potentially circulating miR 
profiles could be used by clinicians for obesity management and to track the efficacy of 
miR based therapeutics. Finally, further identification and characterization of miRs 
associated with adipogenesis and obesity could provide a new generation of therapeutic 
targets which will help facilitate the development of new anti-obesity treatments. 
6.9 Future studies 
1. Further comparison between the Caucasian and the Arab population need to be 
carried to distinguish the effect of the ethnicity over the gene expression of miR and their 
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targets in the blood and adipose tissue. 
2. Functional studies including the protein expression and gene silencing. The best 
example for the gene silencing is the miR-29. We plan to treat the adipose tissue with 
anti-miR-29 to see its effects on the collagen genes that are involved in the regulation of 
fibrosis, in addition to MCL1 which has a major role in the apoptosis. miR silencing in 
vivo suggest that anti-miRs are useful tools for validating disease-associated miR targets 
in animal disease models. 
A previous study (Van Rooij et al, 2008) showed the knockout of the miR-29b in vivo 
using cholesterol- modified oligonucleotides.They reported the inhibition of miR-29b 
gene expression in all examined tissues after three days of infusion that induced fibrosis. 
3. In order to understand the difference between the obese groups related to the 
stress. The future plan is to look at the effect of catecholamines, insulin, glucose and 
other inflammatory mediators on miR-29 gene expression and fibrosis in different tissues 
(e.g: AT, cardiac cell lines, muscle and liver). This could be done in vitro and in vivo. 
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Appendix 1 
Extra work was done along with sample collection which needs further completion and 
data analysis for future studies. 50 adipose tissue samples (SC, OM) from Al-Emadi 
hospital were excised and incubated for a day to see the effects of the secretory capacity 
and the cellular make up of the AT. 
 
Adipose organ culture: Secretory capacity of the adipose tissue 
Subcutaneous and omental adipose tissue explants were excised ranging from 0.049g to 
0.052g in size and incubated for 24 hours at 37°C and 5% CO2 in CellGro Complete 
Medium (Mediatech, USA) + 1% Penicillin/Streptomycin solution (Invitrogen, Paisley 
UK) to assess secreted adipokine levels. 
 
Histology samples: to investigate cellular makeup of the AT. 
0.2-0.3g sample from subcutaneous and omental adipose tissue was excised for 
histological purposes and incubated in neutral buffered formalin (VWR International, 
USA) for 24 hours and then transferred to 50% Ethanol and stored at 4°C. 
 
 
Appendix 2 
 
Gene list of miR-29 targets: 
 
 
Position Symbol Description Gene Name 
A01 ACVR2A Activin A receptor, type IIA ACTRII, ACVR2 
A02 ADAM12 ADAM metallopeptidase domain 12 ADAM12-OT1, CAR10, MCMP, 
MCMPMltna, MLTN, MLTNA 
A03 ADAMTS9 ADAM metallopeptidase with 
thrombospondin type 1 motif, 9 
- 
A04 AK3 Adenylate kinase 3 AK3L1, AK6, AKL3L, AKL3L1, FIX 
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A05 BACE1 Beta-site APP-cleaving enzyme 1 ASP2, BACE, HSPC104 
A06 BAK1 BCL2-antagonist/killer 1 BAK, BAK-LIKE, BCL2L7, CDN1 
A07 BBC3 BCL2 binding component 3 JFY-1, JFY1, PUMA 
A08 BCL2 B-cell CLL/lymphoma 2 Bcl-2, PPP1R50 
A09 BCL2L11 BCL2-like 11 (apoptosis facilitator) BAM, BIM, BOD 
A10 BMF Bcl2 modifying factor - 
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A11 NREP Chromosome 5 open reading frame 13 C5orf13, D4S114, P311, PRO1873, 
PTZ17, SEZ17 
A12 CD276 CD276 molecule 4Ig-B7-H3, B7-H3, B7H3, B7RP-2 
B01 CDC42 Cell division cycle 42 (GTP binding protein, 
25kDa) 
CDC42Hs, G25K 
B02 CDK6 Cyclin-dependent kinase 6 PLSTIRE 
B03 COL15A1 Collagen, type XV, alpha 1 - 
B04 COL1A1 Collagen, type I, alpha 1 OI4 
B05 COL1A2 Collagen, type I, alpha 2 OI4 
B06 COL21A1 Collagen, type XXI, alpha 1 COLA1L, dJ682J15.1, dJ708F5.1 
B07 COL2A1 Collagen, type II, alpha 1 ANFH, AOM, COL11A3, SEDC, STL1 
B08 COL3A1 Collagen, type III, alpha 1 EDS4A 
B09 COL4A1 Collagen, type IV, alpha 1 HANAC, ICH, POREN1, arresten 
B10 COL4A2 Collagen, type IV, alpha 2 ICH, POREN2 
B11 COL5A2 Collagen, type V, alpha 2 - 
B12 COL5A3 Collagen, type V, alpha 3 - 
C01 COL7A1 Collagen, type VII, alpha 1 EBD1, EBDCT, EBR1 
C02 CTNNBIP1 Catenin, beta interacting protein 1 ICAT 
C03 DGKD Diacylglycerol kinase, delta 130kDa DGKdelta, dgkd-2 
C04 DICER1 Dicer 1, ribonuclease type III DCR1, Dicer, HERNA, MNG1, RMSE2 
C05 DNAJB11 DnaJ (Hsp40) homolog, subfamily B, 
member 11 
ABBP-2, ABBP2, DJ9, Dj-9, EDJ, 
ERdj3, ERj3, ERj3p, PRO1080, 
UNQ537, hDj-9 
C06 DNMT1 DNA (cytosine-5-)-methyltransferase 1 ADCADN, AIM, CXXC9, DNMT, 
HSN1E, MCMT 
C07 DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha DNMT3A2, M.HsaIIIA 
C08 DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta ICF, ICF1, M.HsaIIIB 
C09 DUSP2 Dual specificity phosphatase 2 PAC-1, PAC1 
C10 ELF2 E74-like factor 2 (ets domain transcription 
factor) 
EU32, NERF, NERF-1A, NERF-1B, 
NERF-1a,b, NERF-2 
C11 ELN Elastin SVAS, WBS, WS 
C12 EOMES Eomesodermin TBR2 
D01 FBN1 Fibrillin 1 ACMICD, ECTOL1, FBN, GPHYSD2, 
MASS, MFS1, OCTD, SGS, SSKS, 
WMS, WMS2 
D02 FEM1B Fem-1 homolog b (C. elegans) F1A-ALPHA, F1AA, FEM1-beta 
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D03 FGA Fibrinogen alpha chain Fib2 
D04 FGB Fibrinogen beta chain HEL-S-78p 
D05 FGG Fibrinogen gamma chain - 
D06 FOXJ2 Forkhead box J2 FHX 
D07 GLUL Glutamate-ammonia ligase GLNS, GS, PIG43, PIG59 
D08 GRN Granulin CLN11, GEP, GP88, PCDGF, PEPI, 
PGRN 
D09 HDAC4 Histone deacetylase 4 AHO3, BDMR, HA6116, HD4, HDAC- 
4, HDAC-A, HDACA 
D10 HRK Harakiri, BCL2 interacting protein (contains 
only BH3 domain) 
DP5, HARAKIRI 
D11 IFI30 Interferon, gamma-inducible protein 30 GILT, IFI-30, IP30 
D12 IREB2 Iron-responsive element binding protein 2 ACO3, IRP2, IRP2AD 
E01 ITGA11 Integrin, alpha 11 HsT18964, RP11-709B3.2 
E02 LAMC1 Laminin, gamma 1 (formerly LAMB2) LAMB2 
E03 LPL Lipoprotein lipase HDLCQ11, LIPD 
E04 MBTD1 Mbt domain containing 1 SA49P01 
E05 MCL1 Myeloid cell leukemia sequence 1 (BCL2- 
related) 
BCL2L3, EAT, MCL1-ES, MCL1L, 
MCL1S, Mcl-1, TM, bcl2-L-3, mcl1, 
EAT 
E06 MMP15 Matrix metallopeptidase 15 (membrane- 
inserted) 
MT2-MMP, MTMMP2, SMCP-2 
E07 MMP24 Matrix metallopeptidase 24 (membrane- 
inserted) 
MMP-24, MMP25, MT-MMP 5, MT- 
MMP5, MT5-MMP, MT5MMP, 
MTMMP5 
E08 MYCN V-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived (avian) 
MODED, MYCNOT, N-myc, NMYC, 
ODED, bHLHe37 
E09 NAV3 Neuron navigator 3 POMFIL1, STEERIN3, unc53H3 
E10 NID1 Nidogen 1 NID 
E11 PCDHA12 Protocadherin alpha 12 PCDH-ALPHA12 
E12 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 
1 (alpha) 
AGM7, GRB1, p85, p85-ALPHA 
F01 PMP22 Peripheral myelin protein 22 CMT1A, CMT1E, DSS, GAS-3, 
HMSNIA, HNPP, Sp110 
F02 PPM1D Protein phosphatase, Mg2+/Mn2+ dependent, 
1D 
PP2C-DELTA, WIP1 
F03 PPP1R13B Protein phosphatase 1, regulatory (inhibitor) 
subunit 13B 
ASPP1, p53BP2-like, p85 
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F04 PTEN Phosphatase and tensin homolog 10q23del, BZS, CWS1, DEC, GLM2, 
MHAM, MMAC1, PTEN1, TEP1 
F05 PXDN Peroxidasin homolog (Drosophila) D2S448, D2S448E, MG50, PRG2, PXN, 
VPO 
F06 RLF Rearranged L-myc fusion ZN-15L, ZNF292L 
F07 S100B S100 calcium binding protein B NEF, S100, S100-B, S100beta 
F08 SERPINB9 Serpin peptidase inhibitor, clade B 
(ovalbumin), member 9 
CAP-3, CAP3, PI-9, PI9 
F09 SESTD1 SEC14 and spectrin domains 1 SOLO 
F10 SFPQ Splicing factor proline/glutamine-rich POMP100, PSF 
F11 SP1 Sp1 transcription factor - 
F12 SPARC Secreted protein, acidic, cysteine-rich 
(osteonectin) 
ON 
G01 SPRY1 Sprouty homolog 1, antagonist of FGF 
signaling (Drosophila) 
hSPRY1 
G02 SRSF10 Serine/arginine-rich splicing factor 10 FUSIP1, FUSIP2, NSSR, SFRS13, 
SFRS13A, SRp38, SRrp40, TASR, 
TASR1, TASR2 
G03 TBX21 T-box 21 T-PET, T-bet, TBET, TBLYM 
G04 TCL1A T-cell leukemia/lymphoma 1A TCL1 
G05 TDG Thymine-DNA glycosylase hTDG 
G06 TET1 Tet oncogene 1 CXXC6, LCX, bA119F7.1 
G07 TFAP2C Transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) 
AP2-GAMMA, ERF1, TFAP2G, hAP-2g 
G08 TGFB3 Transforming growth factor, beta 3 ARVD, ARVD1, RNHF, TGF-beta3 
G09 TNFAIP3 Tumor necrosis factor, alpha-induced protein 
3 
A20, OTUD7C, TNFA1P2 
G10 VEGFA Vascular endothelial growth factor A MVCD1, VEGF, VPF 
G11 ZFP36 Zinc finger protein 36, C3H type, homolog 
(mouse) 
G0S24, GOS24, NUP475, RNF162A, 
TIS11, TTP, zfp-36 
G12 ZFP36L1 Zinc finger protein 36, C3H type-like 1 BRF1, Berg36, ERF-1, ERF1, RNF162B, 
TIS11B, cMG1 
H01 ACTB Actin, beta BRWS1, PS1TP5BP1 
H02 B2M Beta-2-microglobulin - 
H03 GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD, GAPD 
H04 HPRT1 Hypoxanthine phosphoribosyltransferase 1 HGPRT, HPRT 
H05 RPLP0 Ribosomal protein, large, P0 L10E, LP0, P0, PRLP0, RPP0 
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H06 HGDC Human Genomic DNA Contamination HIGX1A 
H07 RTC Reverse Transcription Control RTC 
H08 RTC Reverse Transcription Control RTC 
H09 RTC Reverse Transcription Control RTC 
H10 PPC Positive PCR Control PPC 
H11 PPC Positive PCR Control PPC 
H12 PPC Positive PCR Control PPC 
 
 
Appendix 3 
 
Different concentrations of the enriched miRNA were shown in the figures (App 3.1, 3.2 
and 3.3) for sample 1,2,and 3, the concentration of miRs was between 10-40nt. The 
average size was used in pg/µl. All of them were used in the library preparation for the 
miRNA NGS. 
 
Appendix 4 
 
Different summary reports of the various runs on the Ion Torrent are shown in the figures 
App.4.1, 4.2 and 4.3. 
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App.3.1 
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App.3.2 
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App.3.3 
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App.4.1 The summary report of three different blood samples. 
 
They show the differences of ISP loading, final ISP library % and the number of reads. 
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App.4.2 The run summary report of three adipose tissue samples (AD and SVF). 
Showed the difference of ISP loading, final ISP library % and the reads. 
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App.4.3 The run summary report for the blood sample and matched adipocytes of 
SC and OM.  
Showed the difference of ISP Loading, final ISP library % and the reads. 
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